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1 Introduction  
(based on attachments I and II) 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common cause of senile dementia and about 20 million 
people worldwide currently suffer from this devastating illness, with the number continuing to 
steadily rise due to an aging population [1]. This neurodegenerative disease was firstly described by 
German psychiatrist Alois Alzheimer in 1906. It is characterized by progressive decline of cognitive 
functions and memory caused by the extensive death of neurons, which starts in the entorhinal 
cortex and hippocampus and proceeds to other parts of the brain cortex and subcortical grey 
matter [2]. 
Despite first being identified over a century ago and subject to intensive research, the 
pathogenic mechanisms of AD are still not fully understood and consequently an effective treatment 
is yet to be developed and patient’s death remain a certainty. 
1.1.1 Causes and Risk factors 
A minor part (< 1%) of AD cases is caused by three known genetic mutations, which are all 
connected with increased amyloid-beta peptide (Aβ) production. These mutations involve the gene 
for the amyloid precursor protein (APP) and the genes for the presenilin 1 and presenilin 2 proteins. 
People inheriting any of these genetic mutations are almost certain to develop AD, usually before the 
age of 65, and in such cases we talk about so called familial early-onset form of AD. The exact causes 
of the sporadic late-onset form of AD, which accounts for over 99% of the cases and manifest 
principally after the age of 65, are not yet understood [3]. 
The major risk factor for developing AD is advancing age, although AD is not a normal part of 
aging. Familial history is another important risk, as people who have a parent or a sibling suffering AD 
are more likely to develop the disease. This could be due to the genetic factors and/or the shared 
lifestyle and environment [4, 5]. 
AD is genetically connected to the presence of ε4 form of the gene apolipoprotein E 
(APOE ε4). APOE gene provides the blueprint for a protein that transports cholesterol in the blood 
and can be found in three isoforms (ε2, ε3 and ε4), however, only allele ε4 increases the risk of AD. 
On the contrary, the presence of allele ε2 decreases the risk of developing AD [5, 6]. 
Other risk factors include mild cognitive impairment, depression, head trauma and brain 
injury, low education level, cardiovascular diseases and their risk factors (e.g. high cholesterol, 
obesity, smoking, physical inactivity) and diabetes mellitus type 2 [8, 7, 9–13, 3]. 
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1.1.2 Pathological hallmarks 
The main pathological hallmarks of AD represents extracellular Aβ deposits also termed 
senile plaques, intracellular deposits of phosphorylated τ-protein, termed neurofibrillary tangles, and 
loss of neurons, especially the cholinergic ones [2, 14]. Further AD is connected to loss of synapses, 
mitochondrial dysfunction and inflammation [15–17]. 
1.1.3 Treatment 
Current AD therapy is based on so called cholinergic hypothesis, which asserts that the 
decreased level of acetylcholine in the brain leads to cognitive and memory deficits, and that 
sustaining or recovering cholinergic function should therefore result in amelioration of the symptoms 
[18–20]. Accordingly, inhibitors of enzyme acetylcholinesterase (AChE), which are able to increase 
acetylcholine levels in cholinergic synapses, are used for AD treatment. To date, the number of 
approved drugs is limited to three AChE inhibitors, namely rivastigmine, donepezil, and galantamine, 
and the neuroprotective N-methyl-D-aspartate (NMDA) receptor antagonist memantine (Fig. 1). 
However, none of these drugs can prevent or cure the disease, but afford only symptomatic 
treatment [20, 21]. 
 
Figure 1: Clinically used drugs against AD. 
 
1.1.4 Amyloid cascade hypothesis 
Although the aetiology of AD is still unknown, a build-up of Aβ is considered to play an 
important role in disease progression. Aβ peptide is generated from APP (amyloid precursor protein) 
via its sequential cleavage by β-secretase and γ-secretase (Fig. 2). This action takes place at several 
intracellular sites, including within Golgi apparatus, endoplasmic reticulum (ER), endosomal-
lysosomal systems, and multivesicular bodies. Mutations in either APP or in the presenilin genes have 
been linked to familial, early-onset forms of AD. However, these early onset cases represent only a 
small minority of AD patients, whereas the vast majority of AD cases have developed sporadically 
[22, 23]. The original amyloid cascade hypothesis defined by Hardy et al. in 1992, proposed that 
insoluble extracellular plaques were responsible for the majority of Aβ toxicity. This hypothesis has 
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since been refined, as recent data indicates that soluble intracellular oligomers are now responsible 
for the majority of Aβ induced toxic effects [24–28]. 
 
Figure 2: The structure and processing of APP showing amyloidogenic (on the left) and non-
amyloidogenic (on the right) pathways. Aβ (pink box) constitutes part of the transmembrane domain 
and an adjacent short fragment of the extracellular domain. Reproduced from Haass and Selkoe 
2007, Nature Reviews. Molecular Cell Biology, 8, 101–112 [29]. © Nature Publishing Group. 
 
1.1.5 Mitochondrial dysfunction in AD 
A link between mitochondrial dysfunction and AD has long been suggested to exist. 
Mitochondria are central to many processes including: cellular energetic metabolism, regulation of 
intracellular Ca2+ levels, the regulation of cell death and they are also the main source of reactive 
oxygen species (ROS). All these functions are found to be disturbed in AD, as well as in the presence 
of increased intracellular concentrations of Aβ in different in vitro and in vivo studies. These findings 
are summarized in recent review articles, therefore suggesting that Aβ is responsible for the 




Figure 3: Possible mitotoxic mechanisms induced by Aβ in AD. Reproduced from Tillement et al. 
2011, Mitochondrion, 11, 13–21 [10]. © Elsevier. 
 
Although Aβ is known to be present in mitochondria, its precise location within this 
compartment is a contentious issue. In most studies Aβ was found associated with the inner 
mitochondrial membrane (IMM) and not in the mitochondrial matrix, which is in contrast with 
findings that Aβ interacts with several proteins residing in the mitochondrial matrix. This discrepancy 
can be explained by the rapid Aβ degradation occurring in the matrix by mitochondrial proteases 
(e.g. PreP or IDE) [33–35]. 
Also the origin of mitochondrial Aβ is still a matter of debate. There is experimental evidence 
for both local production (described later in the mitochondrial γ-secretase section of this review) and 
direct import either from ER or from cytosol. The strongest evidence supports the hypothesis that Aβ 
can be transported into the mitochondria from the cytosol via mitochondrial TOM/TIM (translocase 
of the outer membrane/ translocase of the inner membrane) protein-import machinery. In 
accordance with this theory, TOM40 complex was shown to transport Aβ across the outer 
mitochondrial membrane (OMM). However, the mechanistic details of how Aβ gains access to the 
different mitochondrial sub-compartments are currently unestablished, since there are several 
pathways for protein translocation across (TIM23 complex) and into the IMM (TIM23 or TIM22 
complexes). Another theory assumes mitochondria-associated membranes (MAMs) of the ER to be 
responsible for the import of Aβ from this compartment. MAMs are a physical connection between 
the ER membrane and the mitochondrial outer membrane, where lipids and membrane proteins are 




Figure 4: APP and Aβ inside the cell. During protein synthesis, the APP is targeted to the ER and 
transported to the plasma membrane by vesicular transport through the Golgi apparatus. 
Amyloidogenic processing of APP by the β- and γ-secretases at the plasma membrane produces the 
Aβ. This cleavage has also been found to take place prior to exocytosis in the trans-Golgi network (1). 
Aβ can aggregate extracellularly forming extracellular plaques, which are one of the hallmarks of AD 
(2). APP undergoes endocytosis and is normally recycled to the plasma membrane via recycling 
endosomes. Aβ peptides can also enter the cell by endocytosis, but can also be produced from APP 
by β- and γ-secretase cleavage in endosomes (3). Aβ can also compromise the integrity of endosomes 
and secretory vesicles and can be found in the cytosol, probably due to leakage out of these 
compartments (4). Aβ can be imported into the mitochondria via the TOM/TIM mitochondrial import 
machinery. Owing to its chimaeric targeting sequence, APP can also be transported to mitochondria 
where it gets stuck within TOM and TIM proteins, disturbing mitochondrial protein import (5). 
Mitochondrial peptidases PreP and IDE are capable of degrading Aβ in the mitochondrial matrix (6) 




1.1.6 Mitochondrial proteins directly interacting with Aβ 
The particular molecular mechanism, through which Aβ exerts its toxicity in mitochondria, 
has not yet been determined. However, several mitochondrial proteins were ascertained to, or are 
thought to, directly interact with Aβ (Table 1). Such interactions could lead to the disruption of their 
physiological functions and consequential mitochondrial dysfunction finally resulting in the 




Table 1: Aβ-binding proteins, their mitochondrial localization, evidence for the direct interaction with 
Aβ, significance of their role in AD pathophysiology and their potential and suitability as a drug target 
for AD treatment. The number of stars represents the degree of significance with *** being the 
highest score, ** an intermediate score and * the lowest score [36]. 
Protein Localization in mitochondria 
Evidence for direct 
interaction with Aβ 
Significance in AD 
pathophysiology 
Potential as a drug 
target 
ABAD matrix *** *** *** 
CypD matrix, IMM *** *** *** 
ANT IMM ** ** ** 
VDAC OMM ** ** ** 
ETC - Complex I IMM ** ** * 
ETC - Complex IV IMM ** ** * 
ETC - Complex V IMM * ** * 
KGDHC IMM ** * * 
PDHC matrix ** * ** 
CK IMS * * * 
γ-secretase OMM *** *** *** 
NOS IMM ** ** ** 
PAD not specified ** ** ** 
SOD1 IMS, matrix, OMM *** ** * 
Catalase matrix *** ** ** 
Drp-1 OMM ** ** ** 
GAPDH OMM *** *** *** 
HtrA2 IMS *** ** ** 
PreP matrix *** ** ** 
IDE not specified *** *** *** 
Hsps not specified *** ** ** 
HAX-1 not specified * * * 
 
As presented in Table 1, at least five such Aβ-binding partners (druggability score ***) seem 
to be very rational drug targets for AD treatment, namely ABAD, CypD, γ-secretase, GAPDH and IDE. 
These proteins have all been successfully targeted in vivo using neurodegenerative animal models 




1.2 Amyloid beta-binding alcohol dehydrogenase 
Enzyme Aβ  binding alcohol dehydrogenase (ABAD) was first described in 1997 by Yan et al. 
[37] and a year later it was identified as the human analogue of newly discovered bovine 
hydroxyacyl-CoA dehydrogenase type II [38]. Originally it was termed ERAB (endoplasmic reticulum-
associated amyloid-binding protein) as it was initially (and incorrectly) identified within the ER [38], 
however, its actual localization is within the mitochondrial matrix [39]. ABAD has also several 
alternative names derived from different substrates, which it can utilise, namely, 17β-HSD10 
(17β-hydroxysteroid dehydrogenase type 10) [39], SCHAD (human brain short chain L-3-hydroxyacyl-
CoA dehydrogenase) [40], HADH II (human hydroxyacyl-CoA dehydrogenase type II) [41], MHBD 
(2-methyl-3-hydroxybutyryl-CoA dehydrogenase) [42].  
ABAD is an NAD-dependant oxidoreductase belonging to SDR family and catalysing oxidation 
of alcohols and reduction of ketones and aldehydes (Scheme 1) [43]. It has quite low substrate 
specificity as it was experimentally shown to catalyse broad range of structurally diverse substrates. 
Question remains, which of these in vitro identified substrates ABAD actually utilizes under in vivo 
conditions [34]. 
 
Scheme 1: General scheme of ABAD catalysed reaction. 
 
According to its mitochondrial localization, it seems that the main physiological function of 
ABAD is the β-oxidation of fatty acids with short branched sidechain, a process involved in energy 
production and metabolic homoeostasis [44]. Another proposed role of ABAD could be in 
metabolism of hydroxysterioids or steroid modulators of the GABAA receptor. The role in in 
metabolism of sex steroids, especially oestradiol, could explain, why women are more likely to suffer 
from AD [43, 45]. ABAD also takes part in the isoleucine degradation pathway. Nonsense mutations 
of ABAD resulting in catalytically inactive enzyme were connected to loss of mental and motor skills, 
psychomotor retardation and epilepsy, typical symptoms of MHBD deficiency [42]. Further, ABAD 
seems to serve as a structural core for mitochondrial RNAse P, an enzyme essential for production of 
tRNA and consequently synthesis of proteins in mitochondria [46, 47]. The latest proposed function 





1.2.1 Structure and mechanism of function 
ABAD forms a homotetramer with each 27 kDa unit comprising a Rossman fold dinucleotide-binding 
motif and the Ser155, Tyr168, Lys172 catalytic triad typical for SDR family (Fig. 4) [44]. 
Co-factor NAD+/NADH binds to the enzyme in proximity of catalytic triad and forms non-
covalent interaction with its respective amino acids. The substrate binding site includes a region with 
positively charged lysine and histidine residues, which are supposed to interact with negatively 
charged parts of substrates comprising in its structure the CoA group. Therefore, substrates lacking 
the CoA domain are metabolised less effectively. Hydrophobic residues lining the space between the 
catalytic triad and positively charged region is organized favourably for binding the aliphatic side 
chains of fatty acids, which further supports the theory that acyl-CoA is the primary substrate of 
ABAD [44, 49]. 
Proposed mechanism of catalysis can be presented on reduction of a ketone to an alcohol. 
First, Tyr168 interacts with carbonyl group thereby increasing electrophilicity of the carbon atom. 
Ammonium group of Lys172 interacts with Tyr168 to lower its pKa. Co-factor NADH acts as the donor of 
hydride for the reduction. Simultaneously with the hydride transfer to the activated carbonyl 
deprotonation of Tyr168 takes place and the resulting proton is transferred on the newly created 
hydroxyl anion. Negative charge on Tyr168 is stabilized by creating of a hydrogen bond to the Ser155 
[44]. 
Compared to other members of SDR family, ABAD encompasses two extra domains (amino 
acid residues 102-107 and 141-146). Region comprising residues 102-107, which is situated close to 
the active site, is also responsible for Aβ binding to the enzyme [44, 49, 50]. 
 
1.2.2 Interaction with Aβ 
The interaction between ABAD and Aβ was first described in 1997 on an yeast two-hybrid 
screen [37] and this observation was later confirmed using several different techniques, namely 
ELISA [51], crystallography [50], surface plasmon resonance [50, 52], co-immunoprecipitation [37, 50] 
and immunocytochemistry followed by confocal microscopy [50]. 
The region comprising amino acid residues 100–110, also termed loop D, was recognised as 
the binding site for Aβ and point mutations within this region lead to blockage of the interaction 
(Fig. 5) [50]. As already mentioned, ABAD is the only SDR member encompassing this region, which 




Figure 5: Crystal structure of Aβ-bound human ABAD. A) A ribbon diagram with labeled secondary 
structures and the loop D (LD), LE, and LF loops. Helices are shown in green, β strands are shown in 
blue, and loops are shown in pink. Disordered regions are shown by dotted lines. B) Superposition of 
Aβ-bound human ABAD (pink) and rat ABAD in complex with NAD (blue). The LD of 3α-hydroxysteroid 
dehydrogenase is shown in yellow to demonstrate that LD of ABAD contains a unique insertion absent 
in all other SDR family members. NAD+ is shown as a stick model with grey for carbon atoms, red for 
oxygen atoms, blue for nitrogen atoms, and yellow for phosphate atoms. The proposed Aβ-binding 
loop is indicated. C) Superposition of the active sites of Aβ-bound human ABAD (pink) and rat ABAD 
(blue), showing distortion of the NAD+ binding site and the catalytic triad S155, K162, and Y168. Colors 
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are the same as in B). D) A section of the crystal packing interactions, showing the large solvent 
channels. Each ABAD molecule is shown in a different colour. The ordered ends of the LD, residues 94 
and 114, are marked as red and blue balls, respectively, and the hypothetical loops are shown in pink 
as dotted lines. Reproduced from Lustbader et al. 2004, Science, 304, 448–452 [20]. © The American 
Association for the Advancement of Science. 
 
The interaction of Aβ with the enzyme causes conformational changes of the NAD+ binding 
site thereby blocking the binding of the co-factor, which consequently leads to inhibition of enzyme’s 
catalytic activity. Contrary, enzyme with bound co-factor cannot interact with Aβ. The binding of Aβ 
or NAD+ to the ABAD therefore seems exclusive, although they bind to the enzyme at different 
regions [50, 52]. 
Aβ inhibits ABAD enzymatic activity with Ki = 1.2 – 1.6 µM for substrate acetoacetyl-CoA, 
however, the binding of Aβ to the enzyme can be observed at much lower, nanomolar 
concentrations [37, 52]. Possible explanation for this discrepancy is that the enzyme inhibition 
cannot be achieved by Aβ monomers only, but the aggregated oligomeric Aβ species (formed at 
higher Ab concentrations) are required to do the job [34]. 
Experiments on cells showed that Aβ has higher toxicity in cells expressing the wild type 
enzyme compared to cells expressing enzymatically inactive mutant or expressing no enzyme at all. 
Hence it is assumed, that the enhanced Aβ toxicity is not caused by inhibition of ABAD but rather by 
change of its properties (e.g. localization) or a gain of new toxic function to the catalytically active 
enzyme. This is also supported by the finding that Aβ toxicity appears at concentrations sufficient for 
ABAD binding but insufficient for its inhibition [53]. Similar experiments were also performed at an in 
vivo level using transgenic mice and showed similar results concluding that inactivation of the 
enzyme or silencing of its expression ameliorates Aβ toxicity [50]. 
Moreover, ABAD’s expression levels are increased in the brains of AD patients, which further 
supports the connection between ABAD and AD [54, 55]. 
 
1.2.3 Mechanism of ABAD-Aβ complex toxicity 
The mechanism of ABAD mediated Aβ toxicity is yet not known, however, several theories 
exist. One theory assumes that after Aβ binding ABAD takes up the production of toxic aldehydes 
4-hydroxynonenal and malonyldialdehyde, which it under Aβ free conditions catabolizes. This could 
be result of change in enzyme’s function or change in its localization, which could enable ABAD to 
utilise substrates unavailable in its original compartment and vice versa [56, 53, 57]. 
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Other possibility could be that interaction with Aβ leads to excessive degradation of hormone 
oestradiol by ABAD, due to change in its localization or its overexpression [54]. It has been found that 
oestradiol ameliorates Aβ toxicity and its preventive application decreases the risk of developing AD 
[58]. 
Role of ABAD in neurosteroid metabolism, namely in oxidation of positive allosteric 
modulators of GABAA receptors allopregnanolone and allotetrahydrodeoxycorticosterone, and its 
deregulation by Aβ could present another link to development of AD as these neurosteroids are 
important to the maintenance of the neuronal excitability [45]. 
Interaction between ABAD and Aβ also leads to upregulation of protein endophilin I (Ep-I), 
which is known to active JNK (c-Jun N-terminal protein kinase) and consequently the mitochondrial 
apoptotic pathway. The increased activation JNK pathway has been connected to AD 
pathophysiology for some time and Ep-I could therefore present a link between JNK activation and 
Aβ toxicity [59, 60]. 
 
1.2.4 ABAD as a therapeutical target 
 Based on the knowledge of ABAD-Aβ interaction and its consequences two possible 
strategies for AD treatment arise; prevention of ABAD-Aβ interaction or inhibition of ABAD enzymatic 
activity. 
Lustbader et al. established that the ABAD-Aβ interaction is a suitable therapeutical target by 
using the ABAD-decoy peptide (ABAD-DP) [50]. ABAD-DP mimics the binding region of ABAD for Aβ 
(loop D) and has similar binding affinity for Aβ as the native enzyme. In vitro studies found ABAD-DP 
sequestered Aβ making it unable to interact with ABAD. When tested in cell culture experiments, 
ABAD-DP ameliorated the mitochondrial impairment caused by Aβ and its cytotoxicity. Transgenic AD 
mice treated with ABAD-DP displayed improved cognitive function [50, 61, 62]. 
In search for small molecule inhibitors of ABAD-Aβ interaction Xie et al. performed an in vitro 
screening, which lead to identification of frentizole (an FDA approved immunosuppressant; Fig. 5). 
Consequently, a series of frentizole analogues was prepared and in vitro tested for their ability to 
counteract the ABAD-Aβ interaction with compounds 5h and 5l being the best hits (Fig. 6) [51]. 





Figure 6: Structures and IC50 values of ABAD-Aβ interaction inhibitors. 
 
Since ABAD enzymatic activity is necessary for enhancing Aβ toxicity, ABAD inhibitors could 
also be used as therapeutics for AD. However, some side effects may be encountered by the use of 
such treatments as this may potentially cause the inhibition of the enzyme’s physiological functions. 
Currently only limited number of specific small molecule ABAD inhibitors are known (Fig. 7). 
AG18051 is an irreversible inhibitor creating a covalent adduct with the cofactor NAD+ inside the 
active site. It has been shown to decrease Aβ toxicity at the cellular level [49, 63]. The compound 
named RM-532-46 is a reversible ABAD inhibitor with a steroid structure [64]. Recently, 
phosphonate-benzothiazole inhibitor (4b) with moderate activity have been identified and tested in 
vitro for its ability to ameliorate Aβ cytotoxicity with promising results [65]. 
 
Figure 7: Structures and IC50 values of known ABAD inhibitors. 
 
Additionally to AD treatment ABAD inhibition could also be employed in treatment of certain 
types of prostatic cancer, where overexpression of ABAD takes place allowing the cancer cells to 
generate 5α-dihydrotestosterone in the absence of testosterone [45, 66]. 
Eventually, irrespective of their therapeutic applications, inhibitors of the ABAD enzyme are 
likely to be of use in a research setting, as tools to aid our understanding of the cellular role of the 




1.3 Multitarget-directed ligands 
The ‘‘one-target one-compound’’ paradigm was highly successful in the past for many 
common diseases, as their molecular mechanisms were revealed and thus biologists were able to 
define the key target for a particular disease. Once the target was identified, medicinal chemists 
strategically designed a molecule to interact selectively with such a target, with a potential drug as 
the outcome. However, it is apparent that this target-based approach does not always guarantee 
success. Drugs directed to a single target might not always modify complex multifactorial diseases 
such as AD, even if they act in the way they are expected to proceed [67]. It is now widely accepted 
that a more effective therapy could result from the use of multipotent compounds able to intervene 
simultaneously in the different pathological events underlying the aetiology of AD [68, 69]. 
These so called multitarget-directed ligands (MTDLs) include dually acting inhibitors of AChE 
and MAO. Inhibitors of AChE are used for AD treatment for more than 20 years based on the 
cholinergic theory of AD described earlier in the text. 
Monoamine oxidase (MAO; EC 1.4.3.4), an enzyme localised on the cytosolic side of OMM 
[70], is another important target that was considered for the treatment of AD because some 
symptoms of AD are due to alterations in the dopaminergic, serotoninergic and other 
monoaminergic neurotransmitter systems [71, 72]. Moreover, MAO catalysed oxidative deamination 
gives arise to production of hydrogen peroxide and, consequently, reactive oxygen species that have 
also been implicated in the progress of AD [73]. MAO inhibitors (MAOI) should increase 
monoaminergic neurotransmission and reduce reactive oxygen species formation, both effects 
potentially valuable for the treatment of AD [69, 72]. Thus, in this context, multipotent molecules 
able to simultaneously bind both ChEs and MAOs have been investigated [74–77].  
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2 Aim of the work 
1) To summarize current knowledge of AD with regard to Aβ-induced mitochondrial impairment 
and the role of mitochondrial enzyme ABAD in these processes. 
Despite being subject of intensive research, the pathogenic mechanisms of AD are still not fully 
understood and consequently an effective treatment is yet to be developed. Increased levels of 
Aβ and mitochondrial dysfunction are both typical pathological hallmarks of AD and potential 
connection between the two processes has been the topic of several studies. Within these 
studies mitochondrial enzyme ABAD was frequently mentioned as potential target for addressing 
mitochondrial dysfunction in AD. However, a clear summary of current knowledge in the field has 
not been published yet. 
2) To design and synthesize novel compounds, modulators of mitochondrial enzymes, as 
potential AD therapeutics. 
For the potential drug targets identified in the aforementioned literature review the novel small 
molecule modulators with potential to antagonize pathological processes in AD would be 
designed. As a starting point for the design known modulators / binding partners of the 
respective proteins would be used and their structure would be modified in order to get the 
desired activity or to improve their activity. The structural design would consider the physical-
chemical properties of the compounds, which are crucial for the ability to cross biological 
membranes in order to reach target proteins. The consequent series would be designed based on 
the results of biological assessment of the previous series and their SAR studies. If possible, 
compounds of the initial series would be also designed so they can be easily synthesized in good 
yields from cheap and well available precursors. This would form basis for the preparation of 
follow-up series which should become more structurally comprehensive, and which would 
require more synthetic steps with expected lower yields. 
3) To establish structure-activity/toxicity relationship for the prepared compounds. 
The structure-activity/toxicity relationship studies would be performed in order to identify 
chemical moieties and structural motifs responsible for evoking a target biological effect. This 
allows rational modification of the parent compounds in order to improve their activity resp. 
decrease their toxicity. Information on the key structural motifs also enables designing of 
compounds with improved physical-chemical properties or decreased structural complexity 
without negative influence to the biological activity.  
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3 Results and Discussion 
 
3.1 The design, synthesis and evaluation of benzothiazolyl urea analogues 
as inhibitors of the amyloid binding alcohol dehydrogenase 
(based on attachment III) 
Amyloid-beta peptide (Aβ), thought to be the main causative factor for the development of 
Alzheimer’s disease, has been shown to interact with the mitochondrial amyloid beta-binding alcohol 
dehydrogenase (ABAD). In vitro experiments have shown this interaction to be cytotoxic and that 
enzyme activity is necessary for hallmarks of this cytotoxicity to be observed. Thus, the direct 
inhibition of the ABAD may be of therapeutic merit in treating Alzheimer’s disease (AD). 
3.1.1 Design 
The currently known ABAD inhibitors (Fig. 8) have intrinsic properties which will likely render 
them poor drug candidates. Compound AG18051 (1) has been shown to form a covalent adduct to 
NAD+ within the active site of the ABAD enzyme, altering the conformation of the Rossmann fold 
motif and preventing substrate binding [49]. As the Rossmann fold is a common structural feature 
and NAD+ acts as a cofactor for a great many enzyme catalysed reactions, specificity of action is likely 
to be a problem with this inhibitor molecule. Similarly, due to the propensity for many enzymes to 
catalyse the interconversion of such steroidal scaffolds, compound RM-532-46 (2) is likely to also 
suffer from problems related to specificity. Whilst phosphonate derivatives of the benzothiazole core 
(3) have been shown to be capable of directly inhibiting the ABAD enzyme, they do so poorly, with 
the most potent published to date having an IC50 value of 52.7 μM [78]. As such, there is clearly a 
need for new more potent inhibitor molecules, which lack the intrinsic problems associated with the 
previously described compounds. Thus, we have focussed on generating more potent inhibitors 
based around the benzothiazole scaffold.  
However, instead of phosphonate derivatives we decided to start with frentizole (6), resp. to 
replace the phosphonate linker with urea (Fig. 8 and 9). Frentizole analogues (4, 5) were originally 
found to be low micromolar inhibitors of ABAD-Aβ interaction [51] and so we assumed that once 
these compounds have good binding affinity towards the ABAD enzyme, they could serve as a 






Figure 8: Direct inhibitors of the ABAD enzyme (1-3) or ABAD-Aβ interaction (4-5). 
 
Our aim was to produce novel molecules which are able to inhibit the ABAD enzyme via a 
reversible mechanism, are able to penetrate the blood-brain barrier (BBB) (based upon calculated 
physical-chemical properties), and are more potent than the previously described benzothiazole-
phosphonate inhibitors (3). To guide subsequent design strategies, the drug like properties for 
compounds known to either inhibit the ABAD enzyme directly or to perturb the ABAD-Aβ interaction 
were firstly calculated. The most potent compounds from the literature (1–5) were used for this 
purpose (Table 2). Several of the commonly used rules for assessing drug like behaviour were found 
to be violated, predicting poor pharmacokinetics [79–81]. Most notably, poor membrane 
permeability (high tPSA), high plasma binding (ClogD7.4) and high pKa values were predicted for the 
selected compounds (1–5). 
In the first series of novel compounds (7–32, Fig. 9), the 6-halogen substitution on the 
benzothiazole (R1) was retained identical to 4 and 5 and substitutions were made to the phenyl 
moiety (R2-5). Both hydrophilic (hydroxy, carboxy) and hydrophobic moieties (chloro, ethylcarboxy, 
methoxy, methylcarbonyl, methylcarboxamide, phenoxy) were used. In this first series the adherence 
to drug like descriptors was initially relaxed with the aim of generating lead compounds for further 
development. Despite this, compared to the parent compounds (2–4), our novel molecules were 
predicted to have more favourable characteristics including lower MW, lower tPSA, lower 




Figure 9: Design of 1st series of novel ABAD inhibitors. 
 
A second series of novel compounds (33–43) were designed on the basis of the in vitro 
results obtained from the first (Fig. 10; Table 2). The 6-chlorobenzothiazole was retained and the 
phenyl moiety (R2-5) was modified with the functional groups associated with inhibitory activity in the 
first series (chloro, hydroxy). These groups were used in various positions/ratios and further 
combined with other moieties (methoxy, carboxy) to generate a broader structural pool. If compared 
to the parent compounds (2–4), these novel structures were predicted to have similar MW, lower 
tPSA, higher ClogP/ClogD7.4 and in some cases lower solubility (ClogS7.4). 
 




Table 2: Structure and calculated physical-chemical properties (ACDLabs PhysChem Suite v.12) of known and designed ABAD inhibitors. 





tPSA (Å2) ClogP ClogD7.4 ClogS7.4 CpKa 
Optimal properties for CNS penetration [79–81] <450 ˂7 / ˂3 <8 <60-70 1-5 0-3 >(-4.5) 7.5–10.5 
1 (AG18051) --- --- --- --- --- 367.47 6/1 3 96.68 2.43 2.36 -4.22 8.80 
2 (RM-532-46) --- --- --- --- --- 494.71 5/1 5 53.01 4.21 3.86 -3,31 14.67 
3 OMe --- --- OH --- 394.38 7/2 7 128.00 2.75 2.75 -3,54 9.42 
4 F --- COOMe OH --- 361.35 7/3 4 128.79 3.73 3.26 -4.28 7.92 
5 Cl --- COOMe OH --- 377.80 7/3 4 128.79 4.29 3.70 -4.68 7.74 
6 (frentizole) OMe --- --- --- --- 299.35 5/2 3 91.49 3.18 2.50 -3.72 7.02 
1st series 
7 F --- --- OH --- 303.31 5/3 2 102.49 2.80 2.43 -4.17 8.18 
8 Cl --- --- OH --- 319.77 5/3 2 102.49 3.40 2.92 -4.39 8.00 
9 F --- OH --- --- 303.31 5/3 2 102.49 2.90 2.52 -3.73 8.00 
10 Cl --- OH --- --- 319.77 5/3 2 102.49 3.60 3.11 -4.22 7.82 
11 F OH --- --- --- 303.31 5/3 2 102.49 2.91 2.23 -3.41 7.86 
12 Cl OH --- --- --- 319.77 5/3 2 102.49 3.50 2.68 -4.19 7.68 
13 F --- Cl OH --- 337.76 5/3 2 102.49 3.77 3.12 -4.56 7.69 
14 Cl --- Cl OH --- 354.21 5/3 2 102.49 4.33 3.54 -4.92 7.51 
15 F --- COOH OH --- 347.32 7/4 3 139.79 3.39 -0.07 -1.11 3.07 
16 Cl --- COOH OH --- 363.78 7/4 3 139.79 3.90 0.36 -1.6 3.07 
17 F --- --- OMe --- 317.34 5/2 3 91.49 3.21 2.84 -4.79 8.05 
18 Cl --- --- OMe --- 333.79 5/2 3 91.49 3.89 3.42 -4.95 7.87 
19 F --- OMe OMe --- 347.36 6/2 4 100.72 3.08 2.61 -4.5 7.88 
20 Cl --- OMe OMe --- 363.82 6/2 4 100.72 3.71 3.12 -4.58 7.71 
21 F --- COOH OMe --- 361.34 7/3 4 128.79 3.23 -0.05 -1.69 4.01 
22 Cl --- COOH OMe --- 377.80 7/3 4 128.79 3.63 0.26 -1.89 4.01 
23 F --- --- OPh --- 379.41 5/2 4 91.49 4.85 4.46 -5.29 8.01 
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Table 2 continued: Structure and calculated physical-chemical properties (ACDLabs PhysChem Suite v. 12) of known and designed ABAD inhibitors. 
 
  





tPSA (Å2) ClogP ClogD7.4 ClogS7.4 CpKa 
Optimal properties for CNS penetration [79–81] <450 ˂7 / ˂3 <8 <60-70 1-5 0-3 >(-4.5) 7.5–10.5 
24 Cl --- --- OPh --- 395.86 5/2 4 91.49 5.44 4.94 -5.75 7.83 
25 F --- --- COOH --- 331.32 6/3 3 119.56 3.36 0.42 -1.82 4.29 
26 Cl --- --- COOH --- 347.78 6/3 3 119.56 3.93 0.89 -2.35 4.29 
27 F --- --- COOEt --- 359.37 6/2 5 108.56 3.83 3.78 -5.29 7.77 
28 Cl --- --- COOEt --- 375.83 6/2 5 108.56 4.50 4.42 -5.9 7.59 
29 F --- --- COMe --- 329.35 5/2 3 99.33 3.17 3.11 -4.85 7.72 
30 Cl --- --- COMe --- 345.80 5/2 3 99.33 3.80 3.72 -5.73 7.54 
31 F --- --- NHCOMe --- 344.36 6/3 3 111.36 2.45 2.22 -4.34 8.01 
32 Cl --- --- NHCOMe --- 360.82 6/3 3 111.36 3.05 2.74 -4.92 7.84 
2nd series 
33 Cl --- Cl --- --- 338.21 4/2 2 82.26 4.90 4.27 -5.83 7.65 
34 Cl --- --- Cl --- 338.21 4/2 2 82.26 4.67 4.07 -5.79 7.69 
35 Cl --- Cl Cl --- 372.65 4/2 2 82.26 5.40 4.57 -6.27 7.39 
36 Cl Cl --- OH --- 354.20 5/3 2 102.49 4.33 3.50 -3.66 7.44 
37 Cl --- Cl OMe --- 368.23 5/2 3 91.49 4.91 4.30 -5.72 7.67 
38 Cl --- Cl COOH --- 382.22 6/3 3 119.56 4.67 1.15 -2.77 3.09 
39 Cl --- Cl OH Cl 388.65 5/3 2 102.49 5.01 3.71 -5.07 7.17 
40 Cl --- Cl OMe Cl 402.68 5/2 3 91.49 5.59 4.83 -6.59 7.48 
41 Cl --- COOH OH Cl 398.21 7/4 3 139.79 4.97 1.23 -2.09 2.42 
42 Cl --- COOH OMe Cl 412.24 7/3 4 128.79 4.48 0.92 -2.51 3.64 




The aforementioned compounds were prepared in a two-step process. Firstly, the 
corresponding benzothiazol-2-amine was treated with 1,1’-carbonyldiimidazole to form an imidazolyl 
intermediate. The produced imidazolyl intermediate was then treated with the corresponding 
substituted aniline (Scheme 2) [82–85]. In the case of compounds 41 and 42 the corresponding 
aniline derivatives were not commercially available and thus they were prepared in a two or three-
step process. Firstly, 3-chloro-2-methoxybenzoic acid was nitrated [86] in position 5 to give 3-chloro-
2-methoxy-5-nitrobenzoic acid, the nitro group was then reduced [87] to obtain the corresponding 
aniline derivative. In the case of compound 41, demethylation of the methoxy group was performed 
using AlCl3 [88] prior to the reduction step (Scheme 3). The two most active compounds described by 
Xie et al. (compounds 4–5) [51] and frentizole (6) were also synthesized for the purpose of 
comparative biological evaluation. 
 
 
Scheme 2: Synthesis of benzothiazolylurea analogues. Reagents and conditions: (a) CDI, DMF/DCM, 
reflux; (b) substituted aniline, DMF/Et3N, rt. 
 
 
Scheme 3: Synthesis of aniline intermediates. Reagents and conditions: (a) HNO3, H2SO4, 0°C–rt; (b) 
AlCl3, DCM, reflux; (c) H2, Pd/C, EtOAc, rt. 
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3.1.3 Results and Discussion 
The ability of the synthesised compounds to modulate ABAD activity was assessed via a 
spectrophotometric based technique [89]. In brief, during the conversion of substrate to product, 
NADH is converted to NAD+. NADH absorbs light at 340 nm, whilst NAD+ does not; thus ABAD activity 
can be measured via a decrease in absorbance at 340 nm as NADH is oxidised. Varying 
concentrations of compound was added to the reaction mixture to assay any potential inhibitory 
effects. 
An initial compound screen was performed using each compound at 100 μM. For the 
benzothiazolyl standards (4–6) and the first compound series (7–32), an initial screen was performed 
using each compound at 100 μM (Table 3). The compounds previously published as inhibitors of 
ABAD-Aβ interaction (4, 5) [51] and the precursor frentizole molecule (6) were found to be 
ineffective as ABAD inhibitors. Novel compounds 9, 11–14 and 16 were found to be capable of 
markedly decreasing the activity of the ABAD with notably high inhibition by compounds 13, 14. A 
subsequent compound screen was performed at 25 μM in an attempt to isolate the most potent 
inhibitors. At this lower concentration compounds 12–14 showed less marked inhibition, while 
compounds 13, 14 retained a similar level of inhibition as that was seen at 100 μM. In terms of 
structure activity relationships for the first series, various substitutions of the phenyl moiety were 
found to notably affect the potency of the compounds in modulating ABAD activity. At 100 μM the 
compounds with phenolic moiety alone (9, 11, 12) or in combination with electron withdrawing 
group (EWG; 13, 14, 16) at various positions significantly decreased enzyme activity. For halogen 
substitution at position six of the benzothiazole moiety, neither fluorine (13 vs. 14) nor chlorine (11 
vs. 12) gave a consistent alteration in enzyme activity. More interestingly at 25 μM, the inhibitory 
nature was retained with a phenolic moiety in position two (12) or four accompanied by an EWG (13, 
14) consisting of a halogen, but not a carboxyl moiety (16). 
The inhibitory ability of 13, 14 led to the design of second compound series (33–43) retaining 
the 6-chlorobenzothiazolylurea and changing the phenyl scaffold by using chlorine alone, chlorine 
with a methoxy/carboxy moiety, chlorine with a phenolic moiety or a phenolic moiety alone to 
identify further effective leads. At 100 μM, compounds 36, 39, 41 and 43 resulted in inhibition of the 
ABAD enzyme with compound 39 being the most potent from the second series. Similarly at 25 μM, 
compounds 36, 39, 41 and 43 retained some inhibitory ability with compound 39 being the most 
potent. From the structural point of view, the introduction of a chlorine moiety alone (33–35) or 
chlorine with a methoxy/carboxy moiety (37, 38, 40, 42) led to a complete loss of inhibitory activity. 
On the other hand, the combination of chlorine with a phenolic moiety (36, 39, 41) or a phenolic 
moiety alone (43) showed increased potency. The best results were obtained for a four positioned 
phenolic moiety in combination with a chlorine in position two (36) or two chlorines in position three 
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and five (39). Taken together with the first series, the 6-halogen benzothiazolylurea scaffold bearing 
a combination of a four positioned phenolic moiety with one or two chlorines was found the most 
potent for the direct inhibition of the ABAD enzyme. Three compounds (13, 14, 39) were found to 
markedly inhibit ABAD in vitro. 
 
Table 3: Relative ABAD activity in the presence of the synthesised compounds. 
Compound 
100 μM 25 μM  
Compound 
100 μM 25 μM 
(% of Control ± SEM)  (% of Control ± SEM) 
Control 100 ± 3.21 100 ± 1.83  24 102.55 ± 2.30 107.42 ± 1.93 
4 95.47 ± 2.10 97.23 ± 3.84  25 101.97 ± 2.47 107.80 ± 1.75 
5 97.24 ± 1.98 95.62 ±4.49  26 94.25 ± 2.27 105.50 ± 1.68 
6 (frentizole) 105.39 ± 3.04 97.88 ± 3.51  27 104.85 ± 2.53 110.28 ± 1.71 
7 91.02 ± 1.98 94.42 ± 1.13  28 105.39 ± 2.77 108.56 ± 2.21 
8 98.56 ± 4.53 91.93 ± 1.93  29 108.98 ± 1.19 114.67 ± 5.35 
9 83.84 ± 0.76 94.80 ± 0.97  30 95.04 ± 5.15 99.31 ± 3.24 
10 91.20 ± 2.17 93.58 ± 1.87  31 100.00 ± 3.64 94.70 ± 3.27 
11 57.63 ± 1.73 91.46 ± 1.51  32 97.85 ± 1.44 97.88 ± 3.40 
12 40.57 ± 1.14 77.06 ± 0.99  33 99.75 ± 5.16 102.25 ± 2.73 
13 31.06 ± 0.81 39.76 ± 0.48  34 94.78 ± 5.14 100.74 ± 2.41 
14 33.93 ± 0.95 38.61 ± 0.70  35 90.56 ± 6.27 97.42 ± 2.31 
15 92.82 ± 2.94 101.30 ± 1.61  36 41.22 ± 22.11 72.43 ± 5.79 
16 78.64 ± 2.21 100.54 ± 1.05  37 105.70 ± 2.81 97.21 ± 2.47 
17 107.72 ± 2.99 110.95 ± 1.84  38 85.41 ± 3.60 97.70 ± 1.83 
18 106.10 ± 2.11 104.55 ± 1.16  39 31.22 ± 2.05 36.82 ± 1.12 
19 99.10 ± 1.95 103.59 ± 1.91  40 99.28 ± 5.58 96.35 ± 1.76 
20 104.31 ± 4.48 104.36 ± 1.45  41 51.47 ± 1.94 81.34 ± 1.91 
21 102.15 ± 3.75 105.50 ± 1.48  42 87.80 ± 1.77 94.07 ± 1.60 
22 97.31 ± 2.40 107.22 ± 2.54  43 58.39 ± 2.50 86.42 ± 1.45 
23 103.59 ± 2.94 108.75 ± 2.20     
 
To further assess the potency of compounds 13, 14 and 39, ABAD activity was measured in 
the presence of increasing concentrations of each inhibitor and relative IC50 values were calculated. 
Relative IC50 values of 1.89 μM (95% confidence interval 1.52 – 2.35 μM), 1.67 μM (95% confidence 
interval 1.30 – 2.13 μM) and 1.94 μM (95% confidence interval 1.78 – 2.10 μM) were found for 
compounds 13, 14 and 39 respectively (Fig. 11). Compared to previously described benzothiazole 
phosphonates inhibitors (the best of which had IC50 52.7 μM) [78], compounds 13, 14 and 39 were 
found to be more potent with IC50 values of approximately 2 μM, although limited solubility means 
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only relative IC50 values could be generated. Compound 39 was found to have similar potency to 
compounds 13, 14 despite having increased ClogP/ClogD values and decreased solubility. Thus in 




The presented ABAD inhibitors were designed to conform to the attributes associated with 
successful CNS penetration, improving previous benzothiazolyl compounds [79]. For this purpose, the 
physical chemical parameters of novel molecules were first calculated in silico (Table 2). To test the 
validity of the predicted physical chemical data, experimental values of ElogP and ElogD were 
determined for compounds 13, 14 (Table 4). The calculated and experimental values for logP/D were 
found to correlate well, validating the predicted physical chemical properties. 
 
Figure 11: 
Relative IC50 values of compound 13 (A), 
compound 14 (B) and compound 39 (C). 
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Table 4: Correlation of calculated (ACDLabs PhysChem Suite v. 12) and experimental physical 
chemical properties for compounds 13 and 14. 
Compound ClogP ELogP±SD ClogD7.4 ELogD7.4±SD 
13 3.77 3.04 ± 0.35 ‰ 3.12 3.02 ± 1.83 ‰ 
14 4.33 3.81 ± 0.29 ‰ 3.54 3.79 ± 0.92 ‰ 
 
The mechanism of inhibition utilised by compounds 13, 14 was investigated by assessing 
their effect on the kinetic parameters Vmax and Km at two concentrations (1.25 μM and 5 μM). Initial 
experiments utilised a fixed concentration of cofactor, NADH and increasing concentrations of 
substrate, acetoacetyl-CoA. At the lower concentration tested, compound 13 appears to act via a 
pure non-competitive mechanism, whilst at the higher concentration compound 13 appears to act 
via a mixed non-competitive mechanism with respect to substrate, acetoacetyl-CoA (Fig. 12A). At 
both concentrations tested, compound 14 appears to act via a mixed non-competitive mechanism 





Figure 12: Hanes-Woolf plot of initial velocities of enzyme with the indicated concentrations of 
acetoacetyl-CoA both in the presence and absence of compounds 13 (A) or 14 (B). 
 
Subsequent experiments utilised a fixed concentration of acetoactyl-CoA and varied cofactor, 
NADH. At both concentrations tested, compounds 13, 14 appear to act via a pure non-competitive 
mechanism with respect to cofactor, NADH (Figure 13). Thus, there is the potential that these 
compounds are acting outside of the enzyme active site in an allosteric manner, although this 





Figure 13: Hanes-Woolf plot of initial velocities of enzyme with the indicated concentrations of NADH 
both in the presence and absence of compounds 13 (A) or 14 (B). 
 
To assess whether the inhibition of enzyme activity observed with compounds 13, 14 was 
reversible or irreversible in nature, the ABAD enzyme was treated with a saturating dose of each 
molecule and subsequently diluted to yield a non-saturating dose. If reversible in nature, activity 
would be restored upon dilution. In both cases enzyme activity was restored following dilution 





Figure 14: Evaluation of the reversible/irreversible nature of compounds 13 and 14.  
 
The toxicity of compounds 13, 14 was assessed using an LDH assay, providing a measure of 
cell death on the basis of enhanced membrane permeability. Compounds 13, 14 were both found to 





Figure 15: Cytotoxic effects of compounds 13 and 14 on SHSY5Y (A) and HEK293 (B) cells. 
 
3.1.4 Conclusion 
In summary, the novel ABAD inhibitors based on benzothiazolyl urea scaffold were designed 
to fulfil drug-like properties for CNS acting drugs. 37 molecules were prepared and tested in vitro 
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identifying 3 lead structures (13, 14, 39) that were found significantly better to parent benzothiazolyl 
standards. Two lead molecules (13, 14) were further found to possess experimental physical-
chemical properties valuable for pharmacokinetics and CNS penetration. They were also found to 
have non-competitive or mixed non-competitive mechanism of action with respect to the 
substrate/cofactor. The reversibly binding of both lead molecules was confirmed. Both lead 
molecules were also highlighted as non-toxic by in vitro assay after 24 h. Compounds 13 and 14 may 
form the basis for the development of subsequent series of more potent ABAD inhibitor molecules 
for the treatment of Alzheimer’s disease. 
3.1.5 Appendix 
To the 2nd series of compounds presented above logically belong 5 more compounds, which 
have not yet undergone full biological assessment (Table 5). They are all derived from the most 
promising compound within the 1st series (14) and they are supposed to further broaden the SAR 
study of the 2nd series. 
 
Table 5: Analogues of 14 and their preliminary inhibitory data. 
 
Compound R1 R2 R3 
25 µM 
(% of Control ± SEM) 
44 Cl --- --- 38.8 ± 0.39 
45 Cl OH OH 11.8 ± 0.23 
46 Cl OMe OH 26.5 ± 0.43 
47 Cl OH OMe 40.7 ± 0.81 
48 OH Cl OMe nd 
 
Compounds 44–47 were prepared using the general synthetic strategy described in Scheme 
2, only in case of 45 and 46 the intermediate anilines were first prepared from corresponding 
nitrobenzene derivatives by palladium catalysed reduction (similar to Scheme 3, step c) [87]. 
Compound 48 was prepared in three steps (Scheme 4). 3-chloro-4-methoxyaniline was first treated 
with CDI and resulting intermediate was then reacted 2-aminobenzo[d]thiazol-6-ol to give the final 
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product. The 2-aminobenzo[d]thiazol-6-ol was prepared earlier from its precursor by demethylation 
using AlCl3 [88]. 
 
Scheme 4: Synthesis of 48. Reagents and conditions: (a) AlCl3, anh. toluene, reflux; (b) CDI, DMF, 
35°C; (c) DMF, 60 °C. 
 
Preliminary in vitro results support the previous finding that four-positioned phenolic moiety 
is crucial for inhibitory activity and its omission or methylation (44, 47) has negative effect on activity. 
Looking at compound 45, it seems that its hydroxyl substitution in position three further increases 
the inhibitory activity compared to methoxy substitution of 46 or chlorine substitution of parent 14. 
Compound 48 was synthesized to check the effect of relocation of the hydroxyl group from the 
phenyl moiety to the benzothiazole moiety, however, its inhibitory data are not yet available. 
The most promising compounds 13, 14 and 39 were also prepared in form of their salts, 
sodium phenolates, which showed increased solubility in water and thus they are more suitable for 




3.2 Frentizole analogues as inhibitors of ABAD: design, synthesis and in 
vitro evaluation 
In this study, a series of new benzothiazolylurea analogues have been designed, prepared 
and evaluated in vitro for their potency to inhibit ABAD enzymatic activity. The most potent 
compounds have also been tested for their cytotoxic properties and their ability to permeate through 
blood-brain barrier has been predicted based on their physical-chemical properties. 
3.2.1 Design 
Design of novel compounds originates from the previously identified ABAD modulator 
frentizole and its analogues [51, 90, 78]. Our novel compounds consist of three substructural parts 
i.e. a benzothiazole moiety [91], a linker and a phenyl moiety (Fig. 16). The benzothiazole moiety was 
substituted in position 6 with a methoxy group (the same as is found in the parent compound 
frentizole), fluorine or an ethylcarboxyl group to see whether a change in spatial size or lipophilicity 
in this part of the molecule would result in a change of inhibitory ability. Three different linkers 
where used to see difference(s) between a hydrophilic urea (H-bond acceptor; present in parent 
compound frentizole) and guanidine (H-bond donor) linkers and the rather lipophilic thiourea linker. 
The phenyl moiety was either non-substituted (similar to the parent compound frentizole) or 
substituted in position 4 with hydrophilic carboxyl and hydroxyl functional groups (capable of 
creating hydrogen bonds) or rather lipophilic methoxy group. Frentizole was also synthesized as a 
reference compound. 
 
Figure 16: Design of novel frentizole analogues. 
 
3.2.2 Synthesis 
Generally, the synthesis started with activation of the corresponding benzothiazol-2-amine 
using 1,1’-carbonyldiimidazole resp. 1,1’-thiocarbonyldiimidazole. Only the intermediate ethyl 
2-aminobenzothiazole-6-carboxylate was prepared before that in a separate step by treating 
4-aminobenzoate with potassium thiocyanate and bromine in acetic acid [92]. In the next step, the 
reactive imidazolyl intermediate was treated with the corresponding aniline to obtain a non-




Scheme 5: Synthesis of urea and thiourea derivatives. Reagents and conditions: (a) KSCN, Br2, AcOH, 
rt; (b1) CDI, DCM/DMF, reflux; (b2) SCDI, MeCN, reflux; (c) aromatic amine, DMF, 60°C. 
 
Guanidine analogues were prepared by treating corresponding thiourea with mercury oxide 
in methanolic ammonia solution (Scheme 6). Hydrochloride with improved solubility in water 
(suitable for potential in vivo testing) was prepared by stirring guanidine 59 in mixture of diethyl 
ether and THF saturated by gaseous hydrochloric acid. 
 
 
Scheme 6: Synthesis of guanidine analogues. Reagents and conditions: (a) NH3, HgO, MeOH, rt. 
 
3.2.3 Results and discussion 
To assess the ability of the synthesised compounds to modulate ABAD activity, a 
spectrophotometric assay was employed as outlined in Hroch et al. [89]. An initial compound screen 
was performed using each compound at 100 μM concentration. All compounds tested, except of the 
standard frentizole, were found to be capable of markedly decreasing the activity of the ABAD 
enzyme, with nine coumpound (49, 51, 52, 55, 56, 58–61) decreasing the activity by more than 50%. 
A subsequent compound screen was performed at 25 μM in an attempt to isolate the most potent 
inhibitors. At this lower concentration, compounds 49, 52, 56 and 59 were found to retain a similar 
level of inhibition as that seen at 100 μM, whilst the remaining inhibitors showed less marked 
inhibition (Table 6). Establishing of the SAR for the presented set of compounds was, however, a 
difficult task, as there were no clear correlations between the structure of compounds and their 
inhibitory activity. The only trend observed was that the thiourea derivatives showed mostly higher 
potency compared to the ureas and guanidines. Though, the best inhibiton was found for the 
guanidine 59. Different susbstitutions of the benzothiazole and/or phenyl moieties of the parent 
frentizole had their effects on the compounds’ activity, but without logical order. 
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Table 6: Prepared frentizole analogues and their ABAD inhibitory activity. 
 
Compound R1 R2 R3 
100 µM 25 µM 
(% of Control ± SEM) 
control --- --- --- 100.0 ± 0.11 100.0 ± 0.20 
frentizole (6) OMe O --- 102.9 ± 2.98 97.4 ± 0.82 
49 OMe S --- 34.8 ± 1.42 39.8 ± 0.44 
50 OMe NH --- 61.8 ± 5.87 57.9 ± 3.91 
51 F O --- 41.0 ± 0.61 69.2 ± 0.40 
52 F S --- 23.9 ± 0.69 29.0 ± 0.23 
53 F NH --- 81.0 ± 4.78 86.6 ± 1.43 
54 COOEt O --- 64.3 ± 1.56 79.2 ± 1.60 
55 COOEt S --- 36.6 ± 0.33 45.5 ± 0.33 
56 COOEt NH --- 35.6 ± 2.45 32.0 ± 3.00 
57 OMe O OMe 62.2 ± 0.93 69.7 ± 0.42 
58 OMe S OMe 46.9 ± 1.50 60.9 ± 0.74 
59 OMe NH OMe 17.9 ± 0.71 17.0 ± 0.09 
60 OMe O COOH 41.1 ± 0.47 62.4 ± 0.29 
61 OMe S COOH 29.3 ± 0.76 47.0 ± 0.34 
62 OMe NH COOH 86.0 ± 6.23 104.2 ± 4.32 
 
To further assess the potency of the two most active inhibitors, compounds 52 and 59, ABAD 
activity was measured in the presence of increasing concentrations of the two inhibitors and their 
IC50 values calculated using GraphPad Prism. Relative IC50 value of 3.062 μM (95% confidence interval 
2.692 – 3.483) was found for compounds 59 (Fig. 17).  
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Figure 17: IC50 determination for compound 59.  
 
Compound 52 produced an inconclusive dose response curve and a relative IC50 value was 
unable to be calculated for this compound. Further analysis of this compound revealed that the 
inhibition was reversed upon the addition of dithiothreitol (DTT), indicating the inhibition is likely due 
to the formation of a disulphide bond to an active site cysteine residue (Fig. 18). The DMSO control 
and 59 showed little change in ABAD activity with inhibition remaining constant under the addition of 
DTT. However compound 52 showed a reversal in ABAD inhibition upon the addition of DTT with 
activity values nearly returning to the control levels. As many other enzymes exhibit similar 
properties containing active site cysteine residues this could prove difficult to obtain any compound 
specificity for ABAD. From this point of view, the thiourea moiety seems to be unlikely used for 





Figure 18: Relative ABAD activity in the presence of each compound at concentrations of 25 μM and 
100 μM with and without the addition of 5 mM DTT (presented as % of control ± SEM). 
 
The cytotoxicity of the two most potent inhibitors 52 and 59 was assessed using LDH and 
MTT assays. Cytotoxicity assessment revealed that compound 59 is one order of magnitude less toxic 
when compared to 52 using two different assays and that its toxicity is at similar level compared to 
parent frentizole (Table 7). Similar IC50 values obtained for 52 with both methods suggests that the 
compound does not affect the electron transport chain (ETC) of mitochondria. In the case of 59, the 
IC50 value obtained via a MTT assay was lower than when compared to the LDH assay result, which 
could be hypothesized to its influence of ETC. However, only small differences between both assays 
were found that plausibly means only minor influence of mitochondrial ETC and should be further 
explored. 
 
Table 7: Cytotoxicity assessment of frentizole and the most promising inhibitors 52 and 59. 
Compound 
IC50 (µM ± SEM) 
LDH MTT 
frentizole 46 ± 6 38 ± 4.9 
52 3.5 ± 0.2 3.1 ± 0.4 
59 51 ± 11 23 ± 6 
 
The physical-chemical properties were calculated (ACDLabs PhysChemSuite 2014 [93]) 
and/or experimentally measured [94] for the two most potent compounds 52 and 59 and the parent 
compound frentizole (Table 8). The obtained data were compared with optimal properties for CNS 
targeted drugs [79–81]. All compounds complied with the optimal values for molecular weight, H-
bond acceptor/donor numbers, number of rotatable bonds and logP value. LogD7.4 values slightly 
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diverged from the optimal range in case of 52 and 59 and all three compounds showed higher than 
optimal values of total polar surface area (tPSA). Regarding solubility, then only compound 52 did not 
fit the optimal range for the calculated logS7.4. Generally, a good correlation between the 
experimental and calculated logP and loD7.4 values was found. Taken together, these data suggest 
that the compounds could penetrate the blood-brain barrier and so act within the CNS. However, for 
future structure design, it will be advantageous to improve some of the physical-chemical properties, 
especially the tPSA. 
 
Table 8: Physical-chemical properties of frentizole and the most potent inhibitors 52 and 59 




Rot. bonds tPSA (Å2) ClogP ELogP±SD ClogD7.4 ELogD7.4 ± SD ClogS7.4 
optimum  ≤450 ≤7/≤3 <8 ≤(60-70) 1-5 1-5 0-3 0-3 >(-4.5) 
frentizole 299.35 5/2 3 91.49 3.2 nd 2.5 nd -3.7 
52 303.38 3/2 4 97.28 3.5 4.1 ± 0.4‰ 3.5 4.1 ± 1.2‰ -4.6 
59 328.39 6/3 6 107.50 3.3 3.4 ± 0.5‰ 3.2 3.4 ± 0.1‰ -3.6 
 
3.2.4 Conclusion 
In summary, a series of novel ABAD inhibitors, analogues of frentizole, have been designed, 
synthesized and evaluated in vitro. Among the 15 prepared compounds 59 was found the most 
promising hit with good inhibitory activity (IC50 = 3.06 µM) and suitable cytotoxicity profile 
comparable to the parent frentizole. Together with satisfying physical-chemical properties suggesting 
its capability to permeate through BBB, 59 presents a novel lead structure for further development 
and testing. On the other hand, compounds encompassing the thiourea linker in their structure were 
found to be improper leads for further development despite their good inhibitory activity as they 





3.3 Further development of the best hit: Modifications to the structure of 
compound 14 
Based on the previous results we decided to work on with the most promising inhibitor, 
compound 14 (Table 7), and further explore its SAR when making changes to the benzothiazole 
moiety and to the urea linker connecting the two aromatic moieties. However, compounds 
presented in this chapter have been currently undergoing the in vitro evaluation and thus no 
inhibition data are yet available. 
19 compounds within this chapter (namely 63, 67–76, 79, 82–87 and 91) have been prepared 
by the pregraduate student Vendula Králová participating on this project. Detailed synthetic 
procedure and characterization of these compounds are not mentioned in this work as they are 
going to be presented in her thesis. 
 
3.3.1 Different positioning of chloro-substitution on the benzothiazole moiety 
3.3.1.1 Design 
Compound 14 possess chlorine substitution in position 6 of the benzothiazole moiety, 
therefore, we decided to prepare 4, 5 and 7 chloro-substituted analogues to compare their inhibitory 
activity (Table 9). 
 











Additionally, the 6-chlorobenzothiazole (66) was prepared to find whether the sole 
benzothiazole moiety is capable of ABAD inhibition (Fig. 19). 
 
 
Figure 19: Structure of compound 66. 
 
3.3.1.2 Synthesis 
7-Chlorobenzo[d]thiazol-2-amine was prepared from 7-chlorobenzo[d]thiazole-2-thiol in two 
steps (scheme 7). First, the five membered ring was cleaved by heating in hydrazine hydrate to give 
corresponding 2-aminobenzenethiol which was then treated with di(1H-imidazol-1-yl)methanimine 
to give the desired product [95]. The di(1H-imidazol-1-yl)methanimine was prepared beforehand 
according to the literature [96]. 5-Chlorobenzo[d]thiazol-2-amine was prepared from corresponding 
2-aminobenzenethiol in reaction with BrCN (Scheme 7). 
 
Scheme 7: Synthesis of benzothiazoles with chloro-substitution in different positions of the benzene 
ring. Reagents and conditions: (a) hydrazine hydrate, 110°C; (b1) BrCN, water/MeOH, rt; (b2) di(1H-
imidazol-1-yl)methanimine, dioxane, reflux. 
 
Further, the synthesis of 63–65 proceeded according to the general procedure using CDI as 
described in previous chapters. Compound 66 was prepared from 6-chlorobenzo[d]thiazol-2-amine in 
reaction with amylnitrite [97]. 
 
3.3.2 Different substitutions at position 6 of the benzothiazole moiety 
3.3.2.1 Design 
In next series, a broad range of different substitutions was introduced mainly to the position 
6 of the benzothiazole moiety (Table 10) in order to find promising hits plausibly better than the 
original 6-chloro-substitution of compound 14.  
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Table 10: Analogues of 14 with different substitution in position 6 of the benzothiazole moiety and 
their preliminary inhibitory data. 
 
Compound R 
25 µM  
Compound R 
25 µM 
(% of Control ± SEM)  (% of Control ± SEM) 
67 --- 20.0 ± 0.61  77 NH2 nd 
68 5-Br 9.8 ± 0.18  78 OH nd 
69 Br 13.6 ± 0.25  79 i-Pr 36.5 ± 0.54 
70 Me 25.6 ± 0.47  80 t-butyl 34.0 ± 2.44 
71 CF3 9.7 ± 0.41  81 I 76.7 ± 3.76 
72 OMe 10.0 ± 0.39  82 OEt 28.7 ± 0.38 
73 COMe 48.3 ± 0.63  83 SCF3 50.5 ± 1.25 
74 COOMe 18.1 ± 0.59  84 SCN 37.8 ± 0.35 
75 CN 10.7 ± 0.25  85 SO2Me 21.6 ± 0.21 
76 NO2 23.0 ± 0.37  86 SO2CF3 29.1 ± 0.32 
 
3.3.2.2 Synthesis 
If necessary, the 6-substituted benzothiazoles were prepared from the corresponding 
4-substituted anilines in reaction with potassium isocyanate and bromine or potassium isocyanate 
and tetramethylammonium dichloroiodate (Scheme 8). Method using bromine as the oxidant was 
generally employed as bromine is significantly cheaper. Tetramethylammonium dichloroiodate was 
used when high yields were required and in case of 6-iodobenzo[d]thiazol-2-amine preparation, 
which in the bromine setup gave 6-isothiocyanate instead of the desired 6-iodo substitution (Scheme 







Scheme 8: Synthesis of 6-substituted benzothiazoles. Reagents and conditions: (a1) KSCN, Br2, acetic 
acid, 10°C–rt; (a2) KSCN, tetramethylammonium dichloroiodate, DMSO/water, rt–70°C. 
 
Compound 77 was prepared from the corresponding 6-nitro substituted compound (76) by 
reduction with iron powder and ammonium chloride (Scheme 9). Compound 78 was prepared from 
compound 48 by demethylation of its methoxy group using AlCl3 (reaction conditions similar to 
Scheme 4, step a). 
 
 
Scheme 9: Synthesis of compound 77. Reagents and conditions: (a) Fe, NH4Cl, THF/MeOH/water, 
50°C. 
 
Preliminary data for this series of compounds indicate that the type of substitution in the 
position 6 has only limited influence on the inhibitory activity. Thus, for the following series we used 
mainly 6-methoxy substitution, which showed improved inhibitory potency compared to parent 
compound 14 and for which the synthetic precursors were easier to obtain. However, the original 
6-chloro substitution was also employed in some cases as well as the unsubstituted benzothiazole as 




3.3.3 Alternatives to the benzothiazole heterocycle 
3.3.3.1 Design 
The benzothiazole heterocycle itself was also subject of modifications as indicated in the 
Table 11 beneath. The sulphur atom in the thiazole ring was replaced to obtain the benzoxazole (89, 
90) or benzimidazole (87, 88) analogues, the benzene ring was replaced with saturated cycloxane 
(94), estranged (95) or removed at all (93), the thiazole ring was replaced with aliphatic cyclopentane 
(96) or reduced to an ethylene bridge (97). Moreover, the symmetric derivative 98 was prepared to 
see, whether the dimerized phenyl moiety alone is sufficient for ABAD inhibition. 
 
Table 11: Analogues of 14 with modified benzothiazole moiety. 
 



























Both, 2-aminobenzoxazoles and 2-aminobenzimidazoles were prepared in reaction with BrCN 





Scheme 10: Synthesis of benzoxazole and benzimidazole intermediates. Reagents and conditions: 
(a1=benzoxazoles) BrCN, THF, rt; (a2=benzimidazoles) BrCN, MeOH/H2O, rt. 
 
The next reaction step using CDI followed the general procedure described earlier in the text 
only in the case of compounds comprising the 2-aminothiazole core. In case of compounds 92, 96 
and 97 the procedure had to be updated due to increased solubility of imidazolecarboxamide 
intermediates, which did not allow their simple isolation by filtration in satisfactory yields. Therefore, 
after the activation of starting compound with CDI was finished, 4-amino-2-chlorophenol was added 
directly to the current reaction mixture (Scheme 11). 
 
 
Scheme 11: One-pot synthesis of phenylureas 92, 96 and 97. 
 
The symmetric 1,3-bis(3-chloro-4-hydroxyphenyl)urea (98) was prepared in two steps 
(Scheme 12). First 3-chloro-4-methoxyaniline was treated with CDI to give 1,3-bis(3-chloro-4-
methoxyphenyl)urea, which was then demethylated in reaction with AlCl3. 
 
 
Scheme 12: Synthesis of symmetric urea derivative 98. Reagents and conditions: (a) CDI, DMF, 60°C; 
(b) AlCl3, toluene, reflux. 
 
3.3.4 Modifications of the urea linker 
3.3.4.1 Design 
The original urea linker became a subject of modification, too (Table 12). It was replaced with 
analogous thiourea (99) and guanidine (100) linkers, the shorter amide (in both possible orientations; 
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compounds 102, 103) and secondary amine (101) linkers or it was also prolonged by one methylene 
group on the phenyl side of the molecule (104, 105). Finally, methylation of the either one (106–108) 
or both nitrogen atoms (109) of the urea linker was conducted with aim of constraining the 
conjugation between the two aromatic moieties. 
 
Table 12: Analogues of 14 with alternative linkers connecting the two aromatic moieties. 
 







































     
 
3.3.4.2 Synthesis 
Thiourea analogue 99 was prepared in similar manner to the parent 14 just instead of CDI 
was for the reaction used thiocarbonyldiimidazole (SCDI) and the procedure was slightly updated 
(already described in Scheme 5). Consequently guanidine analogue 100 was prepared from thiurea 
99 in reaction with ammonia and mercury oxide as described previously (Scheme 6). Compounds 104 
and 105 were prepared using the general procedure with CDI. In case of compound 104 synthesis, 
the corresponding benzylamine intermediate was prepared from its methoxy analogue by 
demethylation using AlCl3 (reaction conditions similar to Scheme 4, step a). Compound 101 with 
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linker consisting of secondary amine group was prepared by mean of simple alkylation and amides 
102 and 103 were prepared in reaction of corresponding carboxylic acid with CDI and corresponding 
amine (Scheme 13). 
 
 
Scheme 13: Synthesis of compounds 101–103. Reagents and conditions: (a) NMP, 160°C; (b) CDI, 
anh. DMF, rt; (c) AlCl3, DCM, reflux. 
 
Compound 106 was prepared in 4 steps (Scheme 14). The benzothiazole moiety was 
prepared from 2-iodoaniline in reaction with methylisothiocynate and  tetrabutylammonium 
bromide catalysed by copper (I) chloride [98]. 3-chloro-4-methoxyaniline was treated with 
triphosgene to give the isocyanate intermediate, which was then reacted with the benzothiazole 





Scheme 14: Synthesis of compound 106. Reagents and conditions: (a) MeNCS, TBABr, CuCl, DMSO, 
60–80°C; (b) triphosgene, Et3N, DCM, 0°C–reflux; (c) THF, rt; (d) AlCl3, toluene, reflux. 
 
The first step in the synthesis of compounds 107–109 was preparation of corresponding 
methylated phenyl moieties in one (N-methylation with methyl iodide) resp. two steps (O-
demethylation using AlCl3) as shown in Scheme 15. 
 
 
Scheme 15: Synthesis of N-methylated aniline derivatives. Reagents and conditions: (a) CH3I, NaH, 
THF, 0°C–rt; (b) AlCl3, toluene, reflux. 
 
2-chloro-4-(methylamino)phenol was used for synthesis of 107 and 108 according to the 
general procedure employing CDI. Synthesis of compound 109 started with preparation of 
3-(benzo[d]thiazol-2-yl)-1-(3-chloro-4-methoxyphenyl)-1-methylurea from 2-aminobeznothiazole and 
previously prepared 3-chloro-4-methoxy-N-methylaniline according to the general CDI procedure. 
The product was then treated with methyl iodide to methylate the second nitrogen of the urea 





Scheme 16: Synthesis of compound 109. Reagents and conditions: (a) NMP, 160°C; (b) AlCl3, toluene, 
reflux. 
 
3.4 Conclusion for the ABAD inhibitors development section 
Taken together 103 (plus 3 standards) potential ABAD inhibitors have been designed and 
synthesized (including 19 compounds prepared by pregraduate student). Although the biological 
assessment of these compounds is still ongoing, several promising hits have already been identified, 
namely compounds 13, 14 and 39, which all showed IC50 values around 2 µM (Fig. 20). Common 
structural features of the novel inhibitors are two aromatic moieties connected through the urea 
linker. The best inhibition ability was observed for the benzothiazol-2-yl moiety with fluorine or 
chlorine substitution in position 6 plus the phenyl moiety with hydroxyl substitution in position 4 and 
chlorine substitution in position 3 resp. 3 and 5. Especially the 4-positionned hydroxyl group seems to 
be crucial for retaining inhibitory activity as omission of this substitution or substitution in position 4 
with other group lead to drop-off in activity. Possible explanation for this observation could be that 
the hydroxyl group creates a crucial hydrogen bond with the enzyme, which significantly contributes 
to the overall affinity of the respective inhibitors. Also compound 59 showed promising inhibitory 
activity, with IC50 value 3 µM (Fig. 20). Interestingly, this compound does not follow the 




Figure 20: Development of novel ABAD inhibitors based on the structure of parent frentizole (6) and 
other inhibitors of ABAD-Aβ interaction (4, 5). 
 
The priority now is to finish the biological assessment. Consequently, the best compounds 
with highest inhibitory activity, plausible cytotoxicity and potential to cross the BBB (PAMPA assay) 
will undergone more detailed evaluation including in vivo testing on mouse model of AD. Moreover, 
such a wide set of compounds with its biological data could be used for pharmacophore modelling 
and 3D-QSAR studies in order to further rationalize the future design of ABAD inhibitors. It would be 
also of merit to find out, whether the novel compounds retained the inhibitory activity towards 
ABAD-Aβ interaction (Fig. 20). Such activity would further increase their therapeutical potential to 





3.5 Design, synthesis and in vitro evaluation of indolotacrine analogues as 
multi-target-directed ligands for the treatment of Alzheimer’s disease 
(based on attachement IV) 
The aim of this study was to develop novel multi-target-directed ligands (MTDLs) acting 
primarily as MAO and cholinesterase inhibitors. For this purpose we chose structural motifs 
contained in previously described MAO and/or ChEIs and incorporate them into the scaffold of the 
novel compounds. Two distinct series of molecules have been designed. The first series containing 
2-aminoindole-3-carbonitrile structural scaffold (further referred as “indole” series; compounds 110–
112 and 113) employs an indole ring, that is a structural core in several MAOIs or dual-acting 
compounds targeting both MAO and ChEs, such MBA236 (Fig. 21) [99, 100], and the β-aminonitrile 
motif found in some previously identified MAOI [101]. Compounds 111, 112 also contains the 
propargylamine moiety, which is an essential part of many neuroprotective, irreversible MAOIs (Fig. 
21) [102]. Originally, only compounds 110, 111 had been designed, however, during the synthesis of 
111 a side-product 112 was isolated. Because of the low yield obtained, 112 was tested only for its 
inhibitory activity against MAO. Compound 113 was synthesized later on to explore, whether the 
N-allyl or N-propargyl substitution on the amino group in position two is important for MAO 
inhibition and also to validate the importance of the phenolic group for the antioxidant activity of 
other compounds in the series (discussed later in the text). 
 
 
Figure 21: Design of indole series. 
 
The second series was then designed employing the 2,3,4,6-tetrahydro-1H-indolo[2,3-
b]quinolin-11-amine structural scaffold (described hereafter as the “indolotacrine” series; 
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compounds 114, 115 and 116) to improve the unsatisfactory anti-ChE activity of the indole series. For 
this purpose the 2-aminoindole-3-carbonitrile scaffold of the indole series was fused with the 
structure of potent ChEI tacrine or 7-methoxytacrine (7-MEOTA). Moreover, the resulting 
indolotacrines also resemble β-carboline alkaloids (e.g. harmine), which are known MAOI (Fig. 22) 
[103, 104]. Since compound 112 with N-propargyl substitution in position 1 was found the most 
potent MAOI within the indole series, it was decided to preserve this potentially favourable motif 
when designing compound 116 with benzyl substitution analogous to former N-propargyl moiety. 
 
 
Figure 22: Design of indolotacrine series. 
 
5-Hydroxy-1H-indole-3-carbonitrile derivatives 110–112 were prepared in three steps 
(Scheme 17). At first malononitrile was treated with ethanol in diethyl ether saturated with HCl (g) to 
obtain 3-amino-3-ethoxyacrylonitrile. In next step the 3-amino-3-ethoxyacrylonitrile was treated 
with the corresponding alkylamine to give N-alkylated 3,3-diaminoacrylonitriles. Lastly, 
diaminoacrylonitriles were treated with p-benzoquinone to give 2-(alkylamino)-5-hydroxy-1H-indole-
3-carbonitriles 110, 111 [105]. Moreover, a by-product, whose structure was assigned as the 






Scheme 17: Synthesis of indole series (110–112). Reagents and conditions: (a) HCl, EtOH, Et2O, 0˚C–
rt; (b) alkylamine, EtOH, rt; (c) p-benzoquinone, EtOH, rt. 
 
Indole 113 and indolotacrines 114, 115 were prepared in two to four steps using a similar 
synthetic approach (Scheme 18). The synthesis of compound 115 started from commercial 2-iodo-4-
methoxy-1-nitrobenzene, which was reduced using Fe powder and ammonium chloride to the 
corresponding aniline derivative. The other two aniline intermediates were obtained as commercial 
chemicals. Further, the synthesis proceeded identically for three compounds. Corresponding 
2-iodoaniline derivatives were treated with trifluoroacetic anhydride to give the trifluoracetamides, 
which were then used for the copper iodide catalysed cyclization with malononitrile to obtain 
corresponding indole derivatives including the end product, compound 113 [106]. Finally, 
indolotacrines 114 and 115 were prepared using microwave-assisted Friedländer reaction [107] of 
corresponding indole derivatives with cyclohexanone. 
 
 
Scheme 18: Synthesis of indolotacrines 114–116 and indole 113. Reagents and conditions: (a) Fe, 
NH4Cl, MeOH/H2O (3:1), 50˚C; (b) trifluoroacetic anhydride, Et3N, THF, -7˚C–rt; (c) malononitrile, 
L-proline, K2CO3, CuI, DMSO/H2O (1:1), 60˚C; (d) cyclohexanone, AlCl3, 1,2-dichloroethane, microwave 
irradiation, 95˚C; (e) benzaldehyde, MeOH, rt; (f) NaBH3CN, AcOH/MeOH, 0˚C–rt; (g) malononitrile, 




Indolotacrine 116 was prepared by a slightly different synthetic procedure in four steps 
(Scheme 2). Firstly, 2-iodoaniline was treated with benzaldehyde to give N-(2-iodophenyl)-1-
phenylmethanimine, which was then reduced to corresponding amine using NaBH3CN. In next step 
cyclization of this amine with malononitrile gave 2-amino-1-benzyl-1H-indole-3-carbonitrile [108], 
which in the Friedländer reaction [107] with cyklohexanone gave indolotacrine 116. 
For the biological evaluation, all final products (Fig. 23) were transformed into better water-
soluble hydrochlorides by stirring them in diethyl ether saturated with HCl (g). 
 
Figure 23: Indole (A) and indolotacrine (B) analogues prepared in this study. 
 
Both series were assayed in vitro for their inhibitory activity against membrane-bound MAO 
A and MAO B (Table 13). All the indoles were potent and unselective MAOIs, with 112 being the best 
inhibitor of both isoenzymes in the series. Indoles 110–112 were evaluated for irreversible inhibition 
and, unexpectedly, none of compounds showed significantly lower IC50 value after 30 min pre-
incubation with enzyme, despite compounds 111, 112 have the N-propargylamine moiety, which is 
present in many known irreversible MAOIs (e.g. deprenyl, clorgyline or rasagiline). This could be due 
to the change in the electron density on the triple bond of the N-propargyl motif, as its connecting 
nitrogen atom is here part of the aromatic system, in contrast to the known irreversible inhibitors 
where the N-propargylamine moiety is separated from the aromatic system usually by an alkyl linker. 
Alternatively, steric hindrance from the carbonitrile substituent could prevent the generation of the 
reactive intermediate or its modification of the enzyme. Based on this finding, we decided to 
investigate whether the N-allyl or N-propargyl substitution is necessary for MAO inhibition and so we 
synthesized compound 113. Evaluation revealed that indole 113 devoid of any N-alkyl substitution on 
the amino group at position 2 retained the inhibitory activity at level similar to other indoles, 
showing that the propargyl moiety does not contribute to the binding. 
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Indolotacrine 115 retained the inhibitory activity for both MAO isoenzymes, however, 114 
inhibited only MAO A and 116 with an extra N-benzyl substitution showed no inhibition of either 
MAO isoenzyme. It could be assumed that the extended spatial size of 116 would prevent entry into 
the active site of MAO enzymes [109]. In addition, compound 114 was used for inactivation studies 
with MAO A and showed the expected reversible mode of inhibition. Unlike the unselective indole 
analogues, indolotacrines 114, 115 both exerted some selectivity towards MAO A inhibition with 115 
being the most potent MAO A inhibitor among all the compounds tested (IC50 = 0.49 µM). Standards 
tacrine and 7-MEOTA showed only moderate activity being worse inhibitors of both MAO isoenzymes 
compared to the indolotacrine 115. 
 
Table 13: Inhibition of MAO A and MAO B. 
Compound 
MAO A 
IC50 ± SD (µM) 
MAO B 
IC50 ± SD (µM) 
SI[b] 
MAO A 30’[c] 
IC50 ± SE (µM) 
MAO B 30’[c] 
IC50 ± SE (µM) 
110 2.32 ± 0.26 2.02 ± 0.56 0.9 1.78 ± 0.33 10.86 ± 0.78 
111 1.32 ± 0.12 1.70 ± 0.40 1.3 1.80 ± 0.56 2.48 ± 0.32 
112 0.68 ± 0.08 1.62 ± 0.35 2.4 0.45 ± 0.03 0.87 ± 0.10 
113 2.80 ± 0.40 3.89 ± 0.02 1.4 - - 
114 11.40 ± 1.10 > 100 8.8 30.0 ± 1.9 - 
115 0.49 ± 0.05 53.90 ± 10.70 110.0 - - 
116 > 100 > 100 - - - 
tacrine 14.07 ± 1.47 317.2 ± 201.0 22.5 - - 
7-MEOTA 7.10 ± 0.03 98.61 ± 14.63 13.9 - - 
[a] IC50 and SD/SE values were obtained as a mean of 2 independent measurements 
[b] selectivity index = IC50 MAO B / IC50 MAO A 
[c] IC50 values after 30 min pre-incubation of enzyme with inhibitor 
 
All final compounds with the exception of 112 (which was a by-product of synthesis and, due 
to low yield, was tested only for MAO inhibition) and 113 (prepared subsequently to enhance SAR on 
MAO inhibition and antioxidant activity) were assayed in vitro for their inhibitory activity against 
human recombinant acetylcholinesterase (AChE) and human plasma butyrylcholinesterase (BChE) 
(Table 14). 
As preceded earlier in the text, no significant inhibitory activity against AChE or BChE was 
detected for indoles 110, 111. Both compounds exerted only poor inhibition of AChE in high 
micromolar range and were found inactive against BChE at the highest concentration tested. Possible 
explanation for this observation is that compounds 110, 111 lack the structural complexity of other 
indoles or indanes, which are capable of ChEs inhibition (e.g. extra N-benzylpiperidine moiety 
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present in donepezil, ASS234 and MBA236 or carbamate moiety of ladostigil) [100]. Conversely, 
indolotacrines 114, 115 were found potent unselective inhibitors of both enzymes with IC50 values in 
low micromolar range. Compound 116 was found to be a selective BChEI. None of the compounds 
were found superior compared to tacrine; however, compound 115 was found better inhibitor of 
both ChEs compared to 7-MEOTA. IC50 values obtained for standard inhibitors tacrine and 7-MEOTA 
were found in good correlation with previously published results [110]. 
 
Table 14: Inhibition of AChE and BChE. 
Compound 
AChE 
IC50 ± SEM (µM) 
BChE 
IC50 ± SEM (µM) 
SI[b] 
110 319.2 ± 15.9 > 1000 3.1 
111 101.9 ± 5.4 > 1000 9.8 
114 11.6 ± 0.6 4.7 ± 0.1 0.4 
115 1.5 ± 0.1 2.4 ± 0.1 1.6 
116 > 1000 1.09 ± 0.07 0.001 
tacrine 0.32 ± 0.01 0.088 ± 0.001 0.3 
7-MEOTA 10.0 ± 1.0 17.6 ± 0.8 1.8 
[a] IC50 and SEM values were obtained as a mean of 3 independent measurements 
[b] selectivity index = IC50 BChE / IC50 AChE 
 
Additionally, as ROS are likely to play a part in the development and progression of AD [111], 
the compounds were evaluated for their antioxidant activity using DPPH assay (Table 15). Indoles 
110, 111 showed promising antioxidant properties, similar to standard N-acetylcysteine and only 
slightly weaker than trolox. We hypothesized that this could be due to the presence of phenolic 
group, which is a key structural motif common of many antioxidants [112]. To prove this assumption 
we synthesized compound 113, where the phenolic group was replaced with chlorine. Evaluation 
showed, in good correlation with our hypothesis, that indole 113 exerts more than 20 times weaker 
antioxidant activity compared to phenolic compounds 110 and 111. Neither the indolotacrines nor 
tacrine or 7-MEOTA showed any significant antioxidant activity, which is not surprising, as they all 
lack the phenolic group responsible for this activity as demonstrated for the indoles. Introduction of 





Table 15: Antioxidant activity and cytotoxicity of prepared compounds. 
Compound 
Antioxidant activity 
EC50 ± SEM (µM) 
Cytotoxicity 
IC50 ± SEM (µM) 
110 37.86 ± 5.01 > 1000 
111 25.82 ± 1.35 > 1000 
113 731.70 ± 27.17 113 ± 29 
114 ˃ 5000 13.0 ± 1.4 
115 ˃ 5000 5.5 ± 0.4 
116 3827.0 ± 227.1 7.0 ± 0.7 
tacrine ˃ 5000 248 ± 11 
7-MEOTA ˃ 5000 63 ± 4 
N-acetylcystein 27.91 ± 1.82 - 
trolox 16.20 ± 0.42 - 
[a] EC50/IC50 and SEM values were obtained as a mean of 3 independent measurements 
 
Next, the cytotoxicity of the compounds was evaluated using the MTT assay on the CHO-K1 
cell line (Table 5). Indoles were found to possess very low toxicity with IC50 values above the 
measurable range (>1000 µM) in case of 110, 111 and at high microlomolar range for 113. All 
indolotacrines exerted similar level of cytotoxicity with IC50 values around 10 µM. Standards 
7-MEOTA and tacrine were both found to be less toxic, with tacrine being the least toxic compound 
among the series in vitro. This could be considered quite a surprising result as it is known that in vivo 
tacrine is more toxic than 7-MEOTA [113]. 
Assuming the fact that the principal target of tacrine toxicity in vivo is liver, we decided to 
evaluate tacrine and 7-MEOTA together with the most promising indolotacrine 115 for their 
hepatotoxicity on the HepG2 cell line using the MTT assay (Table 16) [114]. Compound 115 was 
found slightly more hepatotoxic compared to 7-MEOTA and tacrine. As in cytotoxicity evaluation, 
tacrine showed lower in vitro hepatotoxicity compared to 7-MEOTA, which is at odds with the in vivo 
results [113]. A possible explanation for this peculiarity is that the hepatoxicity is not caused by 
tacrine itself but by its metabolites, products of cytochrome P450 oxidation [115]. Therefore it is 
hard to conclude about the compounds’ toxicity in vivo (e.g. 115) based on the results of in vitro 





Table 16: Hepatotoxicity evaluation. 
Compound 
Hepatotoxicity 
IC50 ± SEM (µM) 
115 1.22 ± 0.11 
tacrine 17.28 ± 0.76 
7-MEOTA 11.50 ± 0.77 
[a] IC50 and SEM values were obtained as a mean of 3 independent measurements 
 
Penetration across the blood-brain barrier (BBB) is an essential property for compounds 
targeting the CNS and should always be considered during the drug development. In order to predict 
passive BBB penetration, modification of the parallel artificial membrane permeation assay (PAMPA) 
has been used based on reported protocol [116]. As summarized in Table 17, it is obvious that 
compound 115 has a high potential to be available in the CNS. Data obtained for the new compound 
were correlated to standard drugs, where CNS availability is known and also reported using the 
PAMPA assay [116]. Our data show high resemblance with previously reported penetrations as well 
as with a general knowledge about the availability in the CNS of such standard drugs. 
 
Table 17: Prediction of blood-brain barrier penetration of 115 and reference compounds. 
Compound 
BBB penetration estimation 
Pe ± SEM (10-6 cm s-1) CNS (+/-)[b] 
115 6.6 ± 0.65 (+) 
donepezil 7.3 ± 0.9 (+) 
rivastigmine 6.6 ± 0.5 (+) 
tacrine 5.3 ± 0.19 (+) 
testosterone 11.3 ± 1.6 (+) 
chlorpromazine 5.6 ± 0.6 (+) 
hydrocortisone 2.85 ± 0.1 (+/-) 
piroxicam 2.2 ± 0.15 (+/-) 
theophyline 1.07 ± 0.18 (-) 
atenolol 1.02 ± 0.37 (-) 
[a] Pe and SEM values were obtained as a mean of 4 independent measurements          
[b]   (+) (high BBB permeation predicted) Pe (10-6 cm s-1) > 4.0 
  (-) (low BBB permeation predicted) Pe (10-6 cm s-1) < 2.0 




In summary, in this chapter we have reported design, synthesis and in vitro evaluation of 
series of indoles and series of indolotacrine hybrid analogues as potential drugs for the treatment of 
AD. The novel compounds were designed as MTDLs targeting primarily ChEs and MAOs. In addition 
to ChE and MAO inhibition, the biological evaluation also involved determination of antioxidant, 
cytotoxic and hepatotoxic properties and permeability prediction (PAMPA assay). The most 
promising compound, indolotacrine 115 (Fig. 24), was found to be a potent inhibitor of AChE (IC50 = 
1.5 µM), BChE (IC50 = 2.4 µM) and MAO A (IC50 = 0.49 µM) and weak inhibitor of MAO B (IC50 = 53.9 
µM). The inhibitory activity of 115 against ChEs and MAOs therefore seems quite well balanced, 
which should enable the desired simultaneous multi-target directed action in vivo, however, the 
optimal inhibitory ability against the single targets and their balance in AD is still not known [117]. 
Although, the cytotoxic and hepatotoxic profile of 115 are slightly worse compared to standards 
tacrine and 7-MEOTA the overall improvement in the enzymatic inhibitory activities and potential to 
cross BBB make indolotacrine 115 a promising lead compound for further development and 
investigation. 
 





4 Experimental part 
4.1 Chemical preparation 
4.1.1 General chemistry 
Solvents and reagents were purchased from Fluka and Sigma-Aldrich (Czech Republic) and 
used without further purification. Reactions were monitored by thin layer chromatography (TLC) 
performed on aluminium sheets pre-coated with silica gel 60 F254 (Merck, Czech Republic) and 
detected under 254 nm UV light. Column chromatography was performed on silica gel 60 (230 
mesh). Melting points were measured on Stuart SMP30 melting point apparatus (Bibby Scientific 
Limited, Staffordshire, UK) and are uncorrected. 
NMR spectra were generally recorded at Varian Gemini 300 (1H 300 MHz, 13C 75 MHz, Palo 
Alto CA, USA) or Varian S500 (1H 500 MHz, 13C 126 MHz, Palo Alto CA, USA). In all cases, the chemical 
shift values for 1H spectra are reported in ppm (δ) relative to residual CHD2SO2CD3 (δ 2.50) or CDCl3 (δ 
7.27), shift values for 13C spectra are reported in ppm (δ) relative to solvent peak dimethylsulfoxide-
d6 (δ 39.52) or CDCl3 (δ 77.2). The assignment of chemical shifts was based on standard NMR 
experiments (1H, 13C, 1H–1H COSY, 1H–13C HSQC, HMBC). The measurments were performed at 
Faculty of Pharmacy in Hradec Králové by assoc. prof. Jiří Kuneš and his group. 
Mass spectra (MS, respectively, multiple stage MS) were recorded on a LTQ XL linear ion trap 
mass spectrometer and evaluated using Xcalibur v 2.5.0 software (both Thermo Fisher Scientific, San 
Jose, CA, USA). The samples were dissolved in methanol (HPLC grade; Sigma-Aldrich, Prague, Czech 
Republic) and injected continuously (10 µL/min) using a Hamilton syringe into the electrospray ion 
source. The parameters of the electrospray were set up as follows: sheath gas flow rate 20 arbitrary 
units, aux gas flow rate 10 arbitrary units, sweep gas flow rate 0 arbitrary units, spray voltage 4.5 kV, 
capillary temperature 275 °C, capillary voltage 13 V, tube lens 100 V. The measurments were 
performed at Faculty of Military Healt Sciences in Hradec Králové by assoc. prof. Daniel Jun and his 
group. 
For HRMS determination, a Dionex UltiMate 3000 analytical LC-MS system coupled with a Q 
Exactive Plus hybrid quadrupole-orbitrap spectrometer (both produced by ThermoFisher Scientific, 
Bremen, Germany) was used. The LC-MS system consisted of a binary pump HPG-3400RS connected 
to a vacuum degasser, a heated column compartment TCC-3000, an autosampler WTS-3000 
equipped with a 25 μL loop and a VWD-3000 ultraviolet detector. A Waters Atlantis dC18 100Å (2.1 x 
100mm/3µm) column was used as the stationary phase. The analytical column was protected against 
mechanical particles by an in-line filter (Vici Jour) with a frit of 0.5 µm pores. Water (MFA) and 
acetonitrile (MFB) used in the analyses were acidified with 0.1% (v/v) of formic acid. Ions for mass 
spectrometry (MS) were generated by heated electro-spray ionization source (HESI) working in 
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positive mode, with the following settings: sheath gas flow rate 40, aux gas flow rate 10, sweep gas 
flow rate 2, spray voltage 3.2 kV, capillary temperature 350 °C, aux gas temperature 300 °C, S-lens RF 
level 50, microscans 1, maximal injection time 35 ms, resolution 140 000. The full-scan MS analyses 
monitored ions within m/z range 100 – 1500. The studied compounds were dissolved in methanol 
and 1 µL of the solution was injected into the LC-MS system. For elution, following ramp-gradient 
program was used: 0 – 1 min: 10% MFB, 1 – 4 min: 10% – 100% MFB, 4 – 5 min: 100% MFB, 5 – 7.5 
min: 10% MFB. The flow-rate in the gradient elution was set to 0.4 mL/min. To increase the accuracy 
of HRMS, internal lock-mass calibration was employed using polysiloxane traces of m/z = 445.12003 
([M+H]+, [C2H6SiO]6) present in the mobile phases. The chromatograms and mass spectra were 
processed in Chromeleon 6.80 and Xcalibur 3.0.63 software, respectively. The measurments were 
performed at University Hospital in Hradec Králové by dr. Rafael Doležal and his group. 
Elemental analysis (EA) was measured at Perkin-Elmer CHN Analyser 2400 Series II apparatus. 
The measurments were performed at Faculty of Pharmacy in Hradec Králové by prof. Martin Doležal 
and his group. 
 
4.1.2 Detailed description of synthetic procedures 
General procedure for synthesis of N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carboxamides  
Corresponding benzo[d]thiazol-2-amine (1 eq.) was dissolved in a mixture of 
dichloromethane (DCM) and dimethylformamide (DMF) (6:1; 12 mL/mmol). 1,1’-carbonyldiimidazole 
(CDI; 1.2 eq.) was added and the reaction mixture was vigorously stirred at reflux overnight. The 
resulting precipitate was collected by filtration, washed with DCM and dried under reduced pressure 
to obtain corresponding N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carboxamide in good to excellent 
yield (80-95%). 
 
General procedure for synthesis of N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carbothioamides  
Corresponding benzo[d]thiazol-2-amine (1 eq.) was dissolved in acetonitrile (MeCN; 
5 mL/mmol), then 1,1’-thiocarbonyldiimidazole (SCDI; 1.2 eq.) was added and the reaction mixture 
was stirred at reflux overnight. The resulting precipitate was collected by filtration, washed with DCM 
and dried under reduced pressure to obtain corresponding N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-




General procedure for synthesis of 1-(benzo[d]thiazol-2-yl)-3-phenylureas, -3-benzylureas and -3-
phenylthioureas (4–47, 49, 51, 52, 54, 55, 57, 58, 60, 61, 64, 65, 80, 81, 88–91, 93–95, 99, 104, 105, 
107, 108) 
Corresponding N-(benzo[d]thiazol-2-yl)-1H-imidazole-1-carboxamide resp. N-
(benzo[d]thiazol-2-yl)-1H-imidazole-1-carbothioamide (1 eq.) was dissolved in DMF (8 mL/mmol), the 
corresponding aniline / fenylmethanamine derivative (1.1 eq.) was added and the reaction mixture 
was stirred at 60 °C overnight. 
When the corresponding fenylmethanamine was available in the form of hydrochloride, it 
was first converted to a free amine by stirring with trimethylamine in DMF at 60°C for 2h, before the 
activated benzothiazol was added to the reaction mixture. 
After the reaction was completed (monitored by TLC), 1M aq. HCl was poured to the reaction 
mixture. The resulting precipitate was collected by filtration, washed with water, MeCN and dried to 
obtain corresponding 1-(benzo[d]thiazol-2-yl)-3-phenylurea or 1-(benzo[d]thiazol-2-yl)-3-
phenylthiourea. In cases, where further purification was required, the procedure is described 
together with the respective compound’s characterization. 
 
3-chloro-2-methoxy-5-nitrobenzoic acid 
3-chloro-2-methoxybenzoic acid (1 eq.) was dissolved in 96% sulphuric acid (3.1 mL/mmol). 
The solution was cooled in an ice bath and 69% nitric acid (3.2 eq.) was added dropwise. The reaction 
mixture was warmed to rt and stirred for 3 h. After the reaction was completed (monitored by TLC), 
reaction mixture was slowly poured into ice cold water and the mixture was stirred for 30 mins. The 
resulting precipitate was collected by filtration, dried under reduced pressure and used for the next 
step without further purification. 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 8.51 (dd, J = 2.9, 0.6 Hz, 1H), 8.41 (dd, J = 2.8, 0.7 Hz, 1H), 3.94 
(d, J = 0.5 Hz, 3H). 
 
3-chloro-2-hydroxy-5-nitrobenzoic acid 
3-chloro-2-methoxy-5-nitrobenzoic acid (1 eq.) was dissolved in anhydrous DCM (9 
mL/mmol), aluminium chloride (3.5 eq.) was added and the reaction mixture was stirred at reflux 
overnight. After the reaction was completed (monitored by TLC), 1M aq. HCl was slowly poured in 
and reaction mixture was stirred for another 15 mins and then the product was extracted to DCM. 
Organic layer was washed with brine, dried with anhydrous Na2SO4 and concentrated under reduced 
pressure to obtain in 3-chloro-2-hydroxy-5-nitrobenzoic acid quantitative yield. 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.66 (br s, 2H), 8.48 (dd, J = 2.5, 0.9 Hz, 1H), 8.41 (dd, J = 2.9, 




General procedure for synthesis of anilines by palladium catalysed reduction of nitrobenzenes 
Corresponding nitrobenzene derivative (1 eq.) was dissolved in EtOAc (10 mL/mmol), 10% Pd 
on carbon (0.01 eq.) was added and the reaction mixture was stirred at rt under hydrogen 
atmosphere overnight. After the reaction was completed (monitored by TLC), reaction mixture was 
filtered over Celite, filter was washed sufficiently with suitable solvent (usually EtOAc, MeOH or THF) 
and filtrate was concentrated under reduced pressure to obtain the crude product, which was either 
further purified (described separately for respective compounds) or used as such. 
5-amino-3-chloro-2-methoxybenzoic acid (100%) 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 6.83 (d, J = 2.8 Hz, 1H), 6.78 (d, J = 2.8 Hz, 1H), 3.67 (s, 3H). 
5-amino-3-chloro-2-hydroxybenzoic acid 
The crude product was recrystallized from Et2O to obtain 5-amino-3-chloro-2-hydroxybenzoic 
acid in 58% yield. 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 7.19 (d, J = 2.8 Hz, 1H), 7.05 (d, J = 2.8 Hz, 1H). 
4-amino-2-methoxyphenol (100%) 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 7.79 (br s, 1H), 6.46 (d, J = 8.3 Hz, 1H), 6.23 (d, J = 2.5 Hz, 1H), 
5.98 (dd, J = 8.3, 2.4 Hz, 1H), 4.44 (br s, 2H), 3.66 (s, 3H). 
4-aminobenzene-1,2-diol (100%) 
2-aminobenzo[d]thiazol-6-ol 
2-aminobenzo[d]thiazol-6-ol was prepared according to the generel procedure for 
demethylation of methoxy group using aluminium chloride (AlCl3). 
Corresponding phenylmethylether (1 eq.) was dissolved/dispersed in anhydrous toluene (12 
mL/mmol), aluminium chloride (3.5 eq.) was added and the reaction mixture was stirred at reflux 
overnight. After the reaction was completed (monitored by TLC), water was slowly poured in and the 
reaction mixture was stirred for another 15 mins. Then the product was extracted to EtOAc, organic 
layer was washed with brine, dried with anhydrous Na2SO4 and evaporated. The crude product was 
either further purified (described separately for respective compounds) or used as such. 
The crude product was recrystallized from Et2O to obtain 2-aminobenzo[d]thiazol-6-ol in 80% 
yield. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.09 (br s, 1H), 7.13 (d, J = 8.6 Hz, 1H), 7.09 (br s, 2H), 7.03 (d, 





3-chloro-4-methoxyaniline (1 eq.) was dissolved in DMF  (3 mL/mmol), CDI (1.1 eq.) was 
added and the reaction mixture was stirred at 35 °C for 6 h. Then 2-aminobenzo[d]thiazol-6-ol (1.1 
eq.) was added and the reaction was stirred at 60 °C overnight. After the reaction was completed 
(monitored by TLC), 1M aq. HCl was added to the reaction mixture and resulting precipitate was 
collected by filtration. The crude product was purified using column chromatography to obtain the 
product 48 in 31% yield. 
 
General procedure for synthesis of guanidines from thioureas using mercury oxide (50, 53, 56, 59, 62, 
100) 
The corresponding thiourea (1 eq.) was dissolved in 7N methanolic ammonia solution 
(12 mL/mmol), mercury oxide (3 eq.) was added and the reaction mixture was stirred at room 
temperature overnight. After the reaction was completed (monitored by TLC), the reaction mixture 
was filtered over Celite and washed with either THF or MeOH (40 mL/mmol). Evaporation of the 
filtrate gave corresponding guanidine in poor to good yield (10–79 %). In cases, where further 




Ethyl 4-aminobenzoate (1 eq.) and KSCN (4 eq.) were dissolved in acetic acid (4 mL/mmol) 
and stirred at rt for 20 mins. Then the reaction mixture was cooled to 10 °C and bromine (2 eq.) 
dissolved in small amount of acetic acid was added dropwise. Afterwards the reaction mixture was 
left to warm up to rt and stirred overnight. After the reaction was completed (monitored by TLC), 
reaction mixture was added dropwise into the sat. aq. NH3 solution (15 mL/mmol) while cooling in an 
ice bath. The product was extracted to EtOAc and the organic layer was washed with Na2S2O3, sat. 
aq. NaHCO3 and brine, dried using anhydrous Na2SO4 and concentrated under reduced pressure. The 
crude product was either recrystallized from diethylether to obtain ethyl 2-aminobenzo[d]thiazole-6-
carboxylate in 69% yield. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.27 (d, J = 1.8 Hz, 1H), 7.88 (s, 2H), 7.81 (dd, J = 8.4, 1.8 Hz, 
1H), 7.36 (d, J = 8.4 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H). 
 
5-chlorobenzo[d]thiazol-2-amine 
BrCN (1.5 eq.) was dissolved in mixture MeOH/H2O of (2:1; 4 mL/mmol), then 2-amino-4-
chlorobenzenethiol (1 eq.) dissolved in MeOH was added dropwise and the reaction mixture was 
stirred at rt overnight. The next day another 0.3 eq. of BrCN was added and reaction was stirred for 3 
68 
 
more days. After the reaction was completed (monitored by TLC), EtOAc was poured into the 
reaction and extracted with sat. aq. NaHCO3 and brine, dried using anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by column chromatography to 
obtain 5-chlorobenzo[d]thiazol-2-amine in 31% yield. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.68 (br s, 2H), 7.66 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 2.0 Hz, 1H), 
7.02 (dd, J = 8.3, 2.0 Hz, 1H). 
 
di(1H-imidazol-1-yl)methanimine 
Imidazole (3 eq.) and BrCN (1 eq.) were dissolved DCM (5 mL/mmol) and stirred at reflux for 
30 mins. Then the reaction mixture was cooled to rt and filtered. Filtrate was concentrated under 
reduced pressure to 1/10 of its original volume and left to crystallize in freezer overnight. Resulting 
precipitate was collected by filtration to obtain the di(1H-imidazol-1-yl)methanimine in 76% yield. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.20 (br s, 1H), 8.08 (d, J = 26.0 Hz, 2H), 7.56 (d, J = 36.6 Hz, 
2H), 7.12 (d, J = 7.8 Hz, 2H). 
 
2-amino-6-chlorobenzenethiol 
7-chlorobenzo[d]thiazole-2-thiol (1 eq.) was dissolved in 50% aq. hydrazine solution (2 
mL/mmol) and stirred at 110 °C overnight. After the reaction was completed (monitored by TLC), 
water was poured into the reaction, pH was adjusted to 7 using 1M HCl and the product was 
extracted to Et2O. Organic layer was washed brine, dried using anhydrous Na2SO4 and concentrated 
under reduced pressure. The crude product was purified by column chromatography to obtain 2-
amino-6-chlorobenzenethiol in 65% yield. 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 7.02 (t, J = 8.0 Hz, 1H), 6.64 (dd, J = 8.3, 1.3 Hz, 1H), 6.57 (dd, J 
= 7.7, 1.2 Hz, 1H), 5.78 (br s, 2H). 
 
7-chlorobenzo[d]thiazol-2-amine 
2-amino-6-chlorobenzenethiol (1 eq.) and di(1H-imidazol-1-yl)methanimine (1.1 eq.) were 
dissolved in 1,4-dioxane (4 mL/mmol) and the reaction mixture was stirred at reflux for 3 days. Then 
water was added to quench the reaction and product was extracted to EtOAc. Organic layer was 
washed with brine, dried with anhydrous Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by column chromatography to obtain 7-chlorobenzo[d]thiazol-2-amine in 
17% yield. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.73 (br s, 2H), 7.28 (dd, J = 8.0, 1.0 Hz, 1H), 7.23 (t, J = 7.9 Hz, 





6-chlorobenzo[d]thiazol-2-amine (1 eq.) was dissolved in THF (2.5 mL/mmol), amylnitrite (2.2 
eq.) was added dropwise and the reaction mixture was stirred at reflux for 30 mins. After the 
reaction was completed (monitored by TLC), the solvent was evaporated and the residue was 
partitioned between EtOAc and water. The organic layer was washed with 15% citric acid and brine, 
dried with anhydrous Na2SO4 and evaporated. The crude product was purified by column 
chromatography to obtain 6-chlorobenzo[d]thiazole in 82% yield. 
 
1-(6-aminobenzo[d]thiazol-2-yl)-3-(3-chloro-4-hydroxyphenyl)urea (77) 
1-(3-chloro-4-hydroxyphenyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (1 eq.) was dissolved in 
mixture of THF/ MeOH /water (2:1:1; 12 mL/mmol), iron powder (10 eq.) and ammonium chloride (4 
eq.) were added and the reaction mixture was stirred at 50 °C overnight. After the reaction was 
completed (monitored by TLC), the reaction mixture was filtered over Celite, washed with THF and 
concentrated. The product was precipitated from the residual liquid by addition of water, filtered 
and dried under reduced pressure. Recrystallization from Et2O gave 1-(6-aminobenzo[d]thiazol-2-yl)-
3-(3-chloro-4-hydroxyphenyl)urea in 77% yield. 
 
1-(3-chloro-4-hydroxyphenyl)-3-(6-hydroxybenzo[d]thiazol-2-yl)urea (78) 
1-(3-chloro-4-hydroxyphenyl)-3-(6-hydroxybenzo[d]thiazol-2-yl)urea was prepared from 1-(3-
chloro-4-methoxyphenyl)-3-(6-hydroxybenzo[d]thiazol-2-yl)urea (48) according to the General 
demethylation procedure using AlCl3 described above (see 2-aminobenzo[d]thiazol-6-ol synthesis). 
The crude product was purified using column chromatography (85%). 
 
General procedure for synthesis of benzo[d]thiazol-2-amines substituted in position 6 using 
tetramethylammonium dichloroiodate 
Corresponding 6-substituted aniline (1 eq.) and KSCN (7 eq.) were dissolved in mixture of 
DMSO/H2O (9:1; 10 mL/mmol). Tetramethylammonium dichloroiodate (3 eq.) was added and the 
reaction mixture stirred at rt for 5 mins and then at 70 °C overnight. After the reaction was 
completed (monitored by TLC), water was poured into the reaction and the product extracted to 
EtOAc. The organic layer was washed with Na2S2O3, sat. aq. NaHCO3 and brine, dried using anhydrous 
Na2SO4 and concentrated under reduced pressure. The crude product was used without further 
purification or purified by column chromatography. 
6-(tert-butyl)benzo[d]thiazol-2-amine 
The crude product was used for the next step without further purification (98%). 
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1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.65 (m, 1H), 7.33 (br s, 2H), 7.25 – 7.22 (m, 2H), 1.28 (s, 9H). 
6-iodobenzo[d]thiazol-2-amine 
The crude product was purified using column chromatography (36%). 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.00 (d, J = 1.8 Hz, 1H), 7.58 (br s, 2H), 7.48 (dd, J = 8.4, 1.9 Hz, 
1H), 7.12 (d, J = 8.4 Hz, 1H). 
 
6-chloro-1H-benzo[d]imidazol-2-amine 
BrCN (1.1 eq.) was dissolved in mixture MeCN/H2O of (1:10; 3 mL/mmol), then 4-
chlorobenzene-1,2-diamine (1 eq.) dissolved in MeOH was added dropwise and the reaction mixture 
was stirred at rt for 2 h. After the reaction was completed (monitored by TLC), EtOAc was poured 
into the reaction and extracted with sat. aq. NaHCO3 and brine, dried using anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by column chromatography to 
obtain 6-chloro-1H-benzo[d]imidazol-2-amine in 71% yield. 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.75 (br s, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 
6.84 (dd, J = 8.3, 2.1 Hz, 1H), 6.33 (br s, 2H). 
 
General procedure for synthesis of benzo[d]oxazol-2-amines from 2-aminophenols using cyanic 
bromide 
Corresponding 2-aminophenol (1 eq.) was dissolved in THF (4 mL/mmol), cyanic bromide (1.8 
eq.; BrCN) was added and the reaction mixture was stirred at rt overnight. The next day another 0.35 
eq of BrCN was added and reaction was stirred for 3 more days. After the reaction was completed 
(monitored by TLC), EtOAc was poured into the reaction and extracted with sat. aq. NaHCO3 and 
brine, dried using anhydrous Na2SO4 and concentrated under reduced pressure. The crude product 
was purified by column chromatography to obtain the corresponding benzo[d]oxazol-2-amine. 
benzo[d]oxazol-2-amine (87%) 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 7.37 (br s, 2H), 7.30 (d, J = 7.7 Hz, 1H), 7.19 (d, J = 7.0 Hz, 1H), 
7.08 (td, J = 7.6, 1.2 Hz, 1H), 6.95 (td, J = 7.7, 1.3 Hz, 1H). 
6-chlorobenzo[d]oxazol-2-amine (73%) 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.53 (s, 2H), 7.47 (d, J = 1.9 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 
7.12 (dd, J = 8.3, 1.9 Hz, 1H). 
 
1-(benzo[d]thiazol-6-yl)-3-(3-chloro-4-hydroxyphenyl)urea (92) 
Benzo[d]thiazol-6-amine was dissolved in a mixture of DCM and DMF (6:1; 12 mL/mmol). CDI 
(1.1 eq.) was added and the reaction mixture was stirred at reflux overnight. The resulting precipitate 
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was collected by filtration and removed. Filtrate was concentrated, dissolved in MeCN 
(10 mL/mmol), 4-amino-2-chlorophenol (1.1 eq.) was added and the reaction was stirred at reflux 
overnight. After the reaction was completed (monitored by TLC), 1M aq. HCl was added to the 
reaction mixture and resulting precipitate was collected by filtration. The crude product was purified 
using column chromatography to obtain 1-(benzo[d]thiazol-6-yl)-3-(3-chloro-4-hydroxyphenyl)urea in 
25% yield. 
 
1-(3-chloro-4-hydroxyphenyl)-3-(2,3-dihydro-1H-inden-2-yl)urea (96)  
2,3-dihydro-1H-inden-2-amine (1 eq.) was dissolved in DMF  (3 mL/mmol), CDI (1.1 eq.) was 
added and the reaction mixture was stirred at 50 °C for 6 h. Then 4-amino-2-chlorophenol (1.1 eq.) 
was added and the reaction was stirred at 70 °C overnight. After the reaction was completed 
(monitored by TLC), 1M aq. HCl was added to the reaction mixture and resulting precipitate was 
collected by filtration. The crude product was purified using column chromatography to obtain N-(3-
chloro-4-hydroxyphenyl)-6-methoxybenzo[d]thiazole-2-carboxamide in 21% yield. 
 
1-(3-chloro-4-hydroxyphenyl)-3-(4-methoxyphenethyl)urea (97) 
2-(4-methoxyphenyl)ethan-1-amine (1 eq.) was dissolved in DMF (7 mL/mmol), CDI (1.1 eq.) 
was added and the reaction mixture was stirred at 45 °C for 6 h. Then 4-amino-2-chlorophenol (1.1 
eq.) was added and the reaction was stirred at 70 °C overnight. After the reaction was completed 
(monitored by TLC), 1M aq. HCl was added to the reaction mixture and resulting precipitate was 
collected by filtration. The crude product was purified using column chromatography to obtain 1-(3-
chloro-4-hydroxyphenyl)-3-(4-methoxyphenethyl)urea in 21% yield. 
 
1,3-bis(3-chloro-4-methoxyphenyl)urea 
3-chloro-4-methoxyaniline (2 eq.) was dissolved in DMF (3 mL/mmol), CDI (1 eq.) was added 
and the reaction mixture was stirred at 60°C overnight. After the reaction was completed (monitored 
by TLC), 1M aq. HCl was added to the reaction mixture and resulting precipitate was collected by 
filtration, washed with water and dried to give 1,3-bis(3-chloro-4-methoxyphenyl)urea in 90% yield. 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 8.62 (br s, 2H), 7.64 (d, J = 2.2 Hz, 2H), 7.25 (dd, J = 
8.9, 2.2 Hz, 2H), 7.07 (d, J = 8.9 Hz, 2H), 3.80 (s, 6H). 
 
1,3-bis(3-chloro-4-hydroxyphenyl)urea (98) 
1,3-bis(3-chloro-4-hydroxyphenyl)urea was prepared from 1,3-bis(3-chloro-4-
methoxyphenyl)urea according to the General demethylation procedure using AlCl3 described above 
(see 2-aminobenzo[d]thiazol-6-ol synthesis). 
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The crude product was recrystallized from Et2O to obtain compound 98 in 94% yield. 
 
2-chloro-4-((6-chlorobenzo[d]thiazol-2-yl)amino)phenol (101) 
2,6-dichlorobenzo[d]thiazole (1 eq.) and 4-amino-2-chlorophenol (1.05 eq.) were dissolved in 
N-methyl-2-pyrrolidone (NMP; 3mL/mmol) and the reaction mixture was stirred at 160°C overnight. 
After the reaction was completed (monitored by TLC), 1M aq. HCl was added to the reaction mixture 
and the water layer was extracted with EtOAc. The water layer was adjusted to pH=7 and extracted 
with EtOAc. The organic layer was evaporated and the crude residue was purified using column 
chromatography to obtain the product in 30% yield. 
 
3-chloro-4-methoxy-N-(6-methoxybenzo[d]thiazol-2-yl)benzamide 
3-chloro-4-methoxybenzoic acid (1 eq.) was dissolved in anhydrous DMF (7 mL/mmol), CDI 
(1.1 eq.) was added and the reaction mixture was stirred at rt for 2 h. Then 6-
methoxybenzo[d]thiazol-2-amine (1.1 eq.) was added and the reaction was stirred at rt overnight. 
After the reaction was completed (monitored by TLC), 1M aq. HCl was added to the reaction mixture 
and the resulting precipitate was collected by filtration and dried. The crude product was purified by 
column chromatography to obtain 3-chloro-4-methoxy-N-(6-methoxybenzo[d]thiazol-2-yl)benzamide 
in 34% yield. 
 
3-Chloro-4-hydroxy-N-(6-methoxybenzo[d]thiazol-2-yl)benzamide (102) 
3-chloro-4-hydroxy-N-(6-methoxybenzo[d]thiazol-2-yl)benzamide was prepared from 3-
chloro-4-methoxy-N-(6-methoxybenzo[d]thiazol-2-yl)benzamide according to the General 
demethylation procedure using AlCl3 described above (see 2-aminobenzo[d]thiazol-6-ol synthesis). 




6-methoxybenzo[d]thiazole-2-carboxylic acid (1 eq.) was dissolved in anhydrous DMF 
(7 mL/mmol), CDI (1.1 eq.) was added and the reaction mixture was stirred at rt for 1 h. Then 4-
amino-2-chlorophenol (1.1 eq.) was added and the reaction was stirred at rt overnight. After the 
reaction was completed (monitored by TLC), 1M aq. HCl was added to the reaction mixture, resulting 
precipitate was collected by filtration and recryctallized from MeCN to obtain N-(3-chloro-4-





4-(aminomethyl)-2-chlorophenol was prepared from (3-chloro-4-
methoxyphenyl)methanaminium chloride according to the General demethylation procedure using 
AlCl3 described above (see 2-aminobenzo[d]thiazol-6-ol synthesis). 
After the reaction was completed (monitored by TLC), water was slowly poured in and the 
reaction mixture was stirred for another 15 mins. The organic layer was removed and the water layer 
was filtered and the filtrate evaporated. The solid residue was dispersed in acetone using the 
ultrasound bath and filtered. Filtrate was evaporated to give 4-(aminomethyl)-2-chlorophenol (92%), 
which was used for the next step without further purification. 
 
N-methylbenzo[d]thiazol-2-amine 
2-iodoaniline (1 eq.), methylisothiocyanate (1 eq.), tetrabutylammonium bromide (1 eq.) and 
copper (I) chloride (0.01 eq.) were dissolved in DMSO (7 mL/mmol) and the reaction mixture was 
stirred at 80°C overnight. After the reaction was completed (monitored by TLC), water was added to 
the reaction mixture and the product was extracted to Et2O. Organic layer was washed with brine, 
dried using anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was 
purified by column chromatography to obtain N-methylbenzo[d]thiazol-2-amine in 40% yield. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.91 (d, J = 4.4 Hz, 1H), 7.65 (dd, J = 7.8, 0.9 Hz, 1H), 




Triphosgene (1 eq.) was dissolved in anh. DCM (3.5 mL/mmol) at 0 °C and 3-chloro-4-
methoxyaniline (1 eq.), dissolved in anh. DCM, was added dropwise. Consequently, Et3N (0.3 
mL/mmol) was added dropwise and the reaction mixture was stirred at reflux for 1 h. Then the 
reaction was cooled to the room temperature, Et2O was added, the mixture was filtered and washed 
with Et2O. The filtrate was concentrated under reduced pressure to obtain the crude product (100%), 
which was used without further purification for the next step. 
 
1-(benzo[d]thiazol-2-yl)-3-(3-chloro-4-methoxyphenyl)-1-methylurea 
N-methylbenzo[d]thiazol-2-amine (1 eq.) was dissolved in anh. THF (6 mL/mmol), 2-chloro-4-
isocyanato-1-methoxybenzene (0.95 eq.), dissolved in anh. THF, was added dropwise and the 
reaction mixture was stirred at reflux overnight. After the reaction was completed (monitored by 
TLC), 1M aq. HCl (1 mL/mmol) was added dropwise and the reaction mixture was evaporated to 
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dryness under reduced pressure. The crude residue was dispersed in MeOH in the ultrasound bath, 
filtered and washed with MeOH to give the product in 67% yield. 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.54 (s, 1H), 7.91 (dd, J = 7.8, 0.6 Hz, 1H), 7.75 (d, J = 8.0 Hz, 
1H), 7.69 (d, J = 2.6 Hz, 1H), 7.49 (dd, J = 8.9, 2.6 Hz, 1H), 7.44 – 7.37 (m, 1H), 7.30 – 7.23 (m, 1H), 
7.16 (d, J = 9.0 Hz, 1H), 3.85 (s, 3H), 3.76 (s, 3H). 
 
1-(benzo[d]thiazol-2-yl)-3-(3-chloro-4-hydroxyphenyl)-1-methylurea (106) 
Compound 106 was prepared from 1-(benzo[d]thiazol-2-yl)-3-(3-chloro-4-methoxyphenyl)-1-
methylurea according to the General demethylation procedure using AlCl3 described above (see 2-
aminobenzo[d]thiazol-6-ol synthesis). 




3-chloro-4-methoxyaniline (1 eq.) was dissolved in anh. THF (4 mL/mmol), sodium hydride 
(1.5 eq.) was added at 0°C and the reaction mixture was stirred for 30 mins. Then methyl iodide (1.1 
eq.) was added and the reaction was allowed to warm up to rt and stirred overnight. After the 
reaction was completed (monitored by TLC), water was slowly added into the reaction and product 
was extracted to EtOAc. The organic layer was washed with brine, dried using anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by column chromatography to 
obtain 3-chloro-4-methoxy-N-methylaniline in 28% yield. 
1H NMR (500 MHz, CDCl3): δ (ppm) 6.82 (d, J = 8.8 Hz, 1H), 6.68 (d, J = 2.7 Hz, 1H), 6.50 (dd, J = 8.8, 
2.7 Hz, 1H), 3.82 (s, 3H), 2.79 (s, 3H). 
 
2-chloro-4-(methylamino)phenol 
2-chloro-4-(methylamino)phenol  was prepared from 3-chloro-4-methoxy-N-methylaniline 
according to the General demethylation procedure using AlCl3 described above (see 2-
aminobenzo[d]thiazol-6-ol synthesis). 
The crude product was purified by column chromatography to obtain the product in 74% 
yield. 
1H NMR (500 MHz, CDCl3): δ (ppm) 6.86 (d, J = 8.7 Hz, 1H), 6.59 (d, J = 2.8 Hz, 1H), 6.48 (dd, J = 8.7, 





3-(benzo[d]thiazol-2-yl)-1-(3-chloro-4-methoxyphenyl)-1-methylurea was prepared from 
benzo[d]thiazol-2-amine and 3-chloro-4-methoxy-N-methylaniline in two steps according to the 
general procedure for synthesis of urea derivatives employing CDI (described earlier in this chapter). 
 
1-(benzo[d]thiazol-2-yl)-3-(3-chloro-4-methoxyphenyl)-1,3-dimethylurea 
3-(benzo[d]thiazol-2-yl)-1-(3-chloro-4-methoxyphenyl)-1-methylurea (1 eq.) was dissolved in 
anh. DMF (10 mL/mmol), sodium hydride (1.2 eq.) was added at 0°C and the reaction mixture was 
stirred for 30 mins. Then methyl iodide (2.2 eq.) was added and the reaction was allowed to warm up 
to rt and stirred overnight. After the reaction was completed (monitored by TLC), water was slowly 
added and product was extracted to EtOAc. The organic layer was washed with brine, dried using 
anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was recrystallized 
from MeOH to obtain the product in 77% yield.  
1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.76 (d, J = 7.7 Hz, 1H), 7.49 (d, J = 2.6 Hz, 1H), 7.48 – 7.39 (m, 
2H), 7.31 (dd, J = 8.8, 2.5 Hz, 1H), 7.25 (t, J = 8.0 Hz, 1H), 7.13 (d, J = 8.9 Hz, 1H), 3.87 (s, 3H). 
 
1-(benzo[d]thiazol-2-yl)-3-(3-chloro-4-hydroxyphenyl)-1,3-dimethylurea (109) 
1-(benzo[d]thiazol-2-yl)-3-(3-chloro-4-hydroxyphenyl)-1,3-dimethylurea was prepared from 
1-(benzo[d]thiazol-2-yl)-3-(3-chloro-4-methoxyphenyl)-1,3-dimethylurea according to the General 
demethylation procedure using AlCl3 described above (see 2-aminobenzo[d]thiazol-6-ol synthesis). 
The crude product was purified by column chromatography to obtain compound 109 in 65% 
yield. 
 
Detailed synthesis of indole analogues 110 – 112 (respective steps according to Scheme 17 in the 
manuscript). 
a) Malononitrile (1 eq) and EtOH (1.1 eq) were dissolved in Et2O saturated with HCl gas (0.8 
mL/mmol) at 0˚C under argon atmosphere. Reaction mixture was allowed to warm to RT and stirred 
for 4 h. Precipitate was filtered off and washed extensively with Et2O. Free base was obtained by 
addition of K2CO3 saturated aq. solution and extraction into Et2O. Organic layer was then dried with 
brine and Na2SO4 and evaporated to obtain 3-amino-3-ethoxyacrylonitrile as white solid (18%), which 
was used for the next step without further purification. 
b) 3-amino-3-ethoxyacrylonitrile (1 eq) was dissolved in EtOH (1 mL/mmol) under argon 
atmosphere, corresponding amine (1.2 eq) was added and reaction mixture stirred at RT overnight. 
Solvent was evaporated and product isolated by flash chromatography (hex/EtOAc) to obtain 
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product 3-(allylamino)-3-aminoacrylonitrile (Rf = 0.30, EtOAc) as yellow oil (61%) or 3-amino-3-(prop-
2-yn-1-ylamino)acrylonitrile (Rf = 0.30, EtOAc) as orange oil (77%). 
3-(allylamino)-3-aminoacrylonitrile 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 6.12 (t, J = 5.2 Hz, 1H), 5.89 – 5.70 (m, 1H), 5.53 (s, 2H), 5.24 – 
5.13 (m, 1H), 5.13 – 5.07 (m, 1H), 3.53 (t, J = 5.5 Hz, 2H), 2.85 (s, 1H). 
3-amino-3-(prop-2-yn-1-ylamino)acrylonitrile 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 6.25 (t, J = 5.7 Hz, 1H), 5.62 (s, 2H), 3.74 (dd, J = 5.8, 2.5 Hz, 
2H), 3.20 (t, J = 2.5 Hz, 1H), 2.93 (s, 1H). 
c) Corresponding N-substituted 3,3-diaminoacrylonitrile (3) (1 eq) was dissolved in EtOH (4 
mL/mmol) under argon atmosphere, p-benzoquinone (1.2 eq) was added and reaction mixture 
stirred at RT for 1 h. Solvent was evaporated and product (4) isolated by flash  chromatography 
(hex/EtOAc). 2-(allylamino)-5-hydroxy-1H-indole-3-carbonitrile (4a) (Rf = 0.40, hex/EtOAc, 40%) was 
obtained as brown solid (22%). Recrystallization from EtOAc/hex gave beige crystals. Mixture of 5-
hydroxy-2-(prop-2-yn-1-ylamino)-1H-indole-3-carbonitrile (4b) and 2-amino-5-hydroxy-1-(prop-2-yn-
1-yl)-1H-indole-3-carbonitrile (4c) was obtained as brown oil. Repeated flash chromatography 
DCM/MeOH with SiO2 neutralized by washing with Et3N resulted in isolation of the products as 
brown oils. Recrystallization from EtOAc/hexane gave 4b (Rf = 0.10, DCM/MeOH, 5%) as white 
crystals (10%) and 4c (Rf = 0.15, DCM/MeOH, 5%) as off-white crystals (14%). 
 
Detailed synthesis of indolotacrine analogues (114 – 116) and indole analogue 113 (respective steps 
according to Scheme 18 in the manuscript). 
a) 2-iodo-4-methoxy-1-nitrobenzene (1 eq), Fe powder (10 eq) and NH4Cl (4 eq) were 
dissolved/dispersed in MeOH/H2O (3:1; 14 mL/mmol) and stirred at 50˚C for 2 h. The mixture was 
filtered and washed extensively with MeOH. The filtrate was concentrated under vacuum, resulting 
liquid diluted with water and extracted with EtOAc. Organic layer was washed with brine, dried over 
Na2SO4 and evaporated. 2-iodo-4-methoxyaniline (Rf = 0.25, hex/DCM, 5%) was isolated by flash 
chromatography (hex/DCM) as light orange oil (79%). Compounds 2-iodoaniline and 4-chloro-2-
iodoaniline were purchased commercially. 
2-iodo-4-methoxyaniline 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.21 (d, J = 2.7 Hz, 1H), 6.77 (dd, J = 8.7, 2.7 Hz, 1H), 6.70 (d, J = 




b) Corresponding 2-iodoaniline derivative (1 eq) was dissolved in dry THF (2.5 mL/mmol), 
Et3N (1.2 eq) was added and resulting solution cooled down to -7˚C. Trifluroacetic anhydride (1.2 eq) 
dissolved in dry THF was added dropwise within 20 min and then the reaction was allowed to warm 
up to RT and was stirred overnight. After completion the reaction was diluted with water and the 
product extracted to EtOAc. Organic layer was washed with brine, dried over Na2SO4 and evaporated 
to obtain 2,2,2-trifluoro-N-(2-iodophenyl)acetamide (Rf = 0.40, hept/EtOAc, 25%) as light pink solid 
(99%), 2,2,2-trifluoro-N-(2-iodo-4-methoxyphenyl)acetamide (Rf = 0.30, hex/DCM, 50%) as off-white 
crystals (97%) or 2,2,2-trifluoro-N-(2-iodo-4-chlorophenyl)acetamide (Rf = 0.50, hept/EtOAc, 25%) as 
pink solid (98%). Products were used for the next step without further purification. 
c) Corresponding 2,2,2-trifluoro-N-(2-iodophenyl)acetamide derivative (1 eq), malononitrile 
(1.2 eq), K2CO3 (2 eq) and L-proline (0.2 eq) were dispersed in DMSO/H2O (1:1; 2 mL/mmol) and 
stirred for 15 min at RT. Then CuI (0.1 eq) was added and the reaction mixture stirred at 60˚C 
overnight. After completion the reaction mixture was filtrated and filter washed extensively with 
MeOH. The filtrate was concentrated and resulting liquid diluted with water and extracted with Et2O. 
Organic layer was washed with brine, dried over Na2SO4 and evaporated to obtain 2-amino-5-
methoxy-1H-indole-3-carbonitrile (Rf = 0.25, hex/EtOAc, 50%) as beige solid (90%). In case of 2-
amino-1H-indole-3-carbonitrile and 2-amino-5-chloro-1H-indole-3-carbonitrile (113) the crude 
product was purified by flash chromatography (hex/EtOAc) to afford (Rf = 0.30, hex/EtOAc, 50%) as 
beige solid (56%) and 113 (Rf = 0.35, hex/EtOAc, 50%) as brown solid (48%). 
2-amino-1H-indole-3-carbonitrile 
1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.68 (br s, 1H), 7.13 (d, J = 8.6 Hz, 2H), 6.96 (t, J = 7.5 Hz, 1H), 
6.90 (t, J = 7.5 Hz, 1H), 6.71 (s, 2H). 
2-amino-5-methoxy-1H-indole-3-carbonitrile 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.49 (br s, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.65 (d, J = 2.0 Hz, 3H), 
6.49 (dd, J = 8.5, 2.5 Hz, 1H), 3.72 (s, 3H). 
d) AlCl3 (1.5 eq) and corresponding 2-amino-1H-indole-3-carbonitrile derivative (1 eq) were 
loaded into a 10 mL microwave glass tube under argon atmosphere and dispersed in dry 1,2-
dichloroethane (7 mL). Cyclohexanone (1.5 eq) was added and reaction exposed to microwave 
irradiation at 95˚C for 2 h. Reaction was quenched by adding THF/H20 (2:1; 15 mL) dropwise at RT. An 
aqueous solution of NaOH (10%) was added dropwise to adjust pH 8-9. After stirring for 30 min, the 
mixture was extracted with DCM. The organic layer was washed with brine, dried over Na2SO4 and 
concentrated. The crude product was purified by flash chromatography (DCM/MeOH) to afford the 
2,3,4,6-tetrahydro-1H-indolo[2,3-b]quinolin-11-amine (114) (Rf = 0.20, DCM/MeOH, 10%) as beige 
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solid (25%), 9-methoxy-2,3,4,6-tetrahydro-1H-indolo[2,3-b]quinolin-11-amine (115) (Rf = 0.20, 
DCM/MeOH, 10%) as beige solid (16%) or 6-benzyl-2,3,4,6-tetrahydro-1H-indolo[2,3-b]quinolin-11-
amine (116) (Rf = 0.60, DCM/MeOH, 10%) as beige solid (54%). Recrystallization from EtOH gave 
beige crystals in all cases. 
e) 2-iodoaniline (1 eq) and benzaldehyde (1 eq) were dissolved in MeOH (2 mL/mmol) and 
stirred at RT overnight. Evaporation of solvent gave crude product (E)-N-(2-iodophenyl)-1-
phenylmethanimine (Rf = 0.70, hex/EtOAc, 25%) as brown oil (97%). The crude product was used for 
the next step without further purification. 
(E)-N-(2-iodophenyl)-1-phenylmethanimine 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 8.48 (s, 1H), 8.10 – 7.96 (m, 2H), 7.91 (d, J = 7.9 Hz, 1H), 7.64 – 
7.51 (m, 3H), 7.45 (t, J = 7.6 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H). 
f) (E)-N-(2-iodophenyl)-1-phenylmethanimine (1 eq) was dissolved in MeOH (15 mL/mmol), 
resulting solution was acidified with acetic acid (2 drops/mmol) and cooled to 0˚C. NaBH3CN (1.1 eq) 
was added at 0 ˚C and the reaction was allowed to warm up to RT and stirred overnight. After 
completion the reaction was quenched with few drops of 1 M NaOH aq. solution (pH 8) and the 
product N-benzyl-2-iodoaniline (Rf = 0.65, hex/EtOAc, 20%) isolated by flash chromatography 
(hex/EtOAc) as light yellow oil (75%). 
N-benzyl-2-iodoaniline 
1H NMR (300 MHz, CDCl3): δ (ppm) 7.68 (dd, J = 7.8, 1.5 Hz, 1H), 7.43 – 7.27 (m, 5H), 7.20 – 
7.11 (m, 1H), 6.54 (dd, J = 8.2, 1.3 Hz, 1H), 6.48 – 6.42 (m, 1H), 4.63 (br s, 1H), 4.41 (d, J = 4.2 Hz, 2H). 
g) Malononitrile (1.2 eq), picolinic acid (0.2 eq), K2CO3 (3 eq) and CuI (0.1 eq) were charged 
into microwave vessel under argon atmosphere. N-benzyl-2-iodoaniline (1 eq) dissolved in dry DMSO 
was added and the reaction mixture was exposed to microwave irradiation at 90˚C for 12 h. After 
completion the reaction mixture was diluted with water and the product extracted to Et2O. Organic 
layer was washed with brine, dried over Na2SO4 and evaporated. 2-amino-1-benzyl-1H-indole-3-
carbonitrile (Rf = 0.60, hex/EtOAc, 50%) was isolated by flash chromatography (hex/EtOAc) as yellow-
brown solid (26%). 
2-amino-1-benzyl-1H-indole-3-carbonitrile 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 7.38 – 7.06 (m, 9H), 7.05 – 6.96 (m, 1H), 6.94 – 6.86 (m, 1H), 




Hydrochlorides of final products were prepared by dissolving the compounds in a minimal 
volume of EtOAc and adding dropwise a saturated solution of HCl (g) in diethyl ether. A white solid 





4.2 Final products and their characterization 
Yields are given for the last step of synthesis resp. last 2 steps in case that the synthesis 
followed the general procedure employing CDI for preparation of urea derivatives. 
 
Compound 4 (standard 5h)[51] 
methyl 5-(3-(6-fluorobenzo[d]thiazol-2-yl)ureido)-2-hydroxybenzoate 
M.p. 277–279 °C. Yield 81 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.28 (br s, 1H), 9.09 (br s, 1H), 
8.04 (d, J = 2.6 Hz, 1H), 7.82 (dd, J = 8.7, 2.6 Hz, 1H), 7.68 – 7.60 (m, 1H), 7.55 (dd, J = 8.9, 2.7 Hz, 1H), 
7.23 (td, J = 9.1, 2.7 Hz, 1H), 6.98 (d, J = 9.0 Hz, 1H), 3.92 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ 
(ppm) 168.94, 159.54, 158.29 (d, J = 239.0 Hz), 155.98, 152.11, 132.43, 130.19, 127.59, 120.38, 
120.13, 117.80, 113.80 (d, J = 24.4 Hz), 112.71, 108.09 (d, J = 26.9 Hz), 52.55. ESI-MS: m/z 362 [M+H+] 
(calc. for C16H12FN3O4S: 361.05). EA: calc. C 53.18; H 3.35; N 11.63; S 8.87. Found: C 52.90; H 2.96; N 
11.28; S 9.15. 
 
Compound 5 (standard 5l)[51] 
methyl 5-(3-(6-chlorobenzo[d]thiazol-2-yl)ureido)-2-hydroxybenzoate 
M.p. 278–280 °C. Yield 80 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.29 (br s, 1H), 9.11 (br s, 1H), 
8.08 – 8.00 (m, 2H), 7.62 (d, J = 9.0 Hz, 1H), 7.55 (dd, J = 9.6, 2.3 Hz, 1H), 7.39 (dd, J = 9.0, 2.1 Hz, 1H), 
6.98 (d, J = 9.7 Hz, 1H), 3.92 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 168.94, 160.46, 156.00, 
152.24, 147.04, 132.88, 130.15, 127.59, 126.89, 126.20, 121.21, 120.13, 117.80, 112.69, 52.55. ESI-
MS: m/z 378 [M+H+] (calc. for C16H12ClN3O4S: 377.02). EA: calc. C 50.87; H 3.20; N 11.12; S 8.49. 
Found: C 50.57; H 3.47; N 10.88; S, 8.52. 
 
Compound 6 (frentizole) 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylurea 
M.p. 328–330 °C. Yield 91 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.68 (br s, 1H), 9.13 (br s, 1H), 
7.56 (d, J = 8.8 Hz, 1H), 7.54 – 7.47 (m, 3H), 7.33 (t, J = 7.9 Hz, 2H), 7.05 (t, J = 7.3 Hz, 1H), 6.98 (dd, J = 
8.8, 2.6 Hz, 1H), 3.79 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 157.68, 155.87, 152.01, 142.82, 
138.66, 132.61, 129.10, 123.08, 120.29, 118.95, 114.55, 105.12, 55.78. ESI-MS: m/z 300 [M+H]+ (calc. 
for C15H13N3O2S: 399.07). EA: calc. C, 60.19; H, 4.38; N, 14.04; S, 10.71. Found: C, 60.31; H, 4.20; N, 






M.p. 250 °C decomp. Yield 90 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.85 (br s, 1H), 7.81 (dd, J = 
8.7, 2.7 Hz, 1H), 7.67 – 7.60 (m, 1H), 7.30 – 7.25 (m, 2H), 7.21 (td, J = 9.1, 2.7 Hz, 1H), 6.76 – 6.71 (m, 
2H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.64, 158.26 (d, J = 238.9 Hz), 153.51, 151.97, 145.48, 
132.62 (d, J = 11.0 Hz), 129.65, 121.22, 120.52, 115.37, 113.72 (d, J = 24.3 Hz), 108.03 (d, J = 26.9 Hz). 
ESI-MS: m/z 304 [M+H+] (calc. for C14H10FN3O2S: 303.05). EA: calc. C 55.44; H 3.32; N 13.85; S 10.57. 




M.p. 285 °C decomp. Yield 58 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.25 (br s, 1H), 8.83 (br s, 1H), 
8.03 (d, J = 2.1 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.39 (dd, J = 8.6, 2.2 Hz, 1H), 7.33 – 7.22 (m, 2H), 6.80 
– 6.68 (m, 2H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.33, 153.55, 151.77, 147.74, 133.15, 129.57, 
126.81, 126.16, 121.21, 120.81, 115.37. ESI-MS: m/z 320 [M+H+] (calc. for C14H10ClN3O2S: 319.02). EA: 




M.p. 298–300 °C. Yield 49 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.45 (br s, 1H), 9.02 (br s, 1H), 
7.83 (dd, J = 8.7, 2.5 Hz, 1H), 7.71 – 7.60 (m, 1H), 7.23 (td, J = 9.1, 2.7 Hz, 1H), 7.14 – 7.06 (m, 2H), 
6.84 (d, J = 8.0 Hz, 1H), 6.47 (dd, J = 8.1, 1.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 158.29 
(d, J = 239.0 Hz), 157.85, 151.41, 145.58, 139.33, 132.60, 129.66, 120.80, 113.80 (d, J = 24.3 Hz), 
110.19, 109.45, 108.06 (d, J = 26.9 Hz), 105.80. ESI-MS: m/z 304 [M+H+] (calc. for C14H10FN3O2S: 




M.p. 294–296 °C. Yield 36 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.47 (br s, 1H), 9.05 (br s, 1H), 
8.05 (d, J = 2.1 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.40 (dd, J = 8.7, 2.2 Hz, 1H), 7.18 – 7.03 (m, 2H), 6.85 
(d, J = 8.4 Hz, 1H), 6.47 (dd, J = 8.0, 1.9 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.21, 157.89, 
151.59, 139.33, 133.09, 129.72, 126.93, 126.24, 121.26, 120.81, 110.26, 109.48, 105.82. ESI-MS: m/z 
320 [M+H+] (calc. for C14H10ClN3O2S: 319.02). EA: calc. C 52.59; H 3.15; N 13.14; S 10.03. Found: C 






M.p. 228–230 °C. Yield 80 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.82 (br s, 1H), 8.04 (d, J = 8.0 Hz, 
1H), 7.83 (dd, J = 8.7, 2.4 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.23 (td, J = 9.0, 2.4 Hz, 1H), 6.88 (d, J = 4.3 Hz, 
2H), 6.83 – 6.77 (m, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.12, 158.28 (d, J = 238.9 Hz), 
151.41, 146.17, 145.81, 132.74 (d, J = 11.1 Hz), 126.47, 123.11, 120.83, 119.21, 119.05, 114.63, 
113.76 (d, J = 24.3 Hz), 108.04 (d, J = 27.0 Hz). ESI-MS: m/z 304 [M+H+] (calc. for C14H10FN3O2S: 




M.p. 216–218 °C. Yield 42 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.30 (br s, 1H), 10.12 (br s, 1H), 
8.84 (br s, 1H), 8.04 (d, J = 1.8 Hz, 1H), 7.99 (d, J = 6.5 Hz, 1H), 7.64 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 
2.1 Hz, 1H), 6.93 – 6.88 (m, 2H), 6.85 – 6.77 (m, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.77, 
152.24, 148.09, 146.47, 133.35, 126.67, 126.54, 125.97, 123.13, 121.01, 120.77, 119.28, 119.06, 
114.91. ESI-MS: m/z 320 [M+H+] (calc. for C14H10ClN3O2S: 319.02). EA: calc. C 52.59; H, 3.15; N 13.14; 




M.p. 298–299.5 °C. Yield 74 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.94 (br s, 1H), 8.98 (br s, 1H), 
7.82 (dd, J = 8.6, 2.6 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.59 (d, J = 2.5 Hz, 1H), 7.22 (td, J = 9.1, 2.7 Hz, 1H), 
7.18 (dd, J = 8.7, 2.5 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.42, 
158.29 (d, J = 239.1 Hz), 151.83, 149.05, 145.57, 132.52, 130.60, 120.92, 120.57, 119.59, 119.36, 
116.67, 113.80 (d, J = 24.4 Hz), 108.11 (d, J = 27.0 Hz). ESI-MS: m/z 338 [M+H+] (calc. for 





M.p. 283.5–285 °C. Yield 30 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.95 (br s, 1H), 9.01 (br s, 1H), 
8.04 (d, J = 2.1 Hz, 1H), 7.70 – 7.56 (m, 2H), 7.40 (dd, J = 8.6, 2.2 Hz, 1H), 7.19 (dd, J = 8.8, 2.5 Hz, 1H), 
6.94 (d, J = 8.7 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.40, 151.93, 149.07, 132.94, 130.55, 
126.88, 126.20, 121.24, 120.93, 119.60, 119.34, 116.66. ESI-MS: m/z 354 [M+H+] (calc. for 







M.p. 304–305 °C. Yield 70 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.13 (br s, 1H), 8.01 (d, J = 2.7 Hz, 
1H), 7.82 (dd, J = 8.7, 2.7 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.58 (dd, J = 8.8, 2.7 Hz, 1H), 7.22 (td, J = 9.1, 
2.7 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 171.60, 159.58, 158.29 (d, 
J = 239.1 Hz), 157.09, 152.26, 144.93, 132.45 (d, J = 11.3 Hz), 129.97, 127.69, 120.52, 120.42, 117.45, 
113.79 (d, J = 24.2 Hz), 112.65, 108.09 (d, J = 26.9 Hz). ESI-MS: m/z 348 [M+H+] (calc. for 





M.p. 285–287 °C. Yield 61 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.10 (br s, 1H), 8.05 (d, J = 2.1 Hz, 
1H), 8.01 (d, J = 2.7 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.57 (dd, J = 8.8, 2.5 Hz, 1H), 7.40 (ddd, J = 8.6, 
2.2, 0.7 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 189.75, 171.62, 160.45, 
157.14, 152.28, 147.04 132.94, 129.93, 127.74, 126.90, 126.22, 121.24, 120.58, 117.47, 112.66. ESI-
MS: m/z 364 [M+H+] (calc. for C15H10ClN3O4S: 363.01). EA: calc. C 49.53; H 2.77; N 11.55; S 8.81. 




M.p. 331–333 °C. Yield 70 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.95 (br s, 1H), 7.82 (dd, J = 8.6, 
2.4 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.22 (td, J = 9.1, 2.7 Hz, 1H), 6.91 (d, J = 9.0 
Hz, 2H), 3.73 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.44, 158.26 (d, J = 239.0 Hz), 155.30, 
151.85, 145.47, 132.62, 131.22, 120.82, 120.70, 114.11, 113.75 (d, J = 24.3 Hz), 108.05 (d, J = 26.8 
Hz), 55.21. ESI-MS: m/z 318 [M+H+] (calc. for C15H12FN3O2S: 317.06). EA: calc. C 56.77; H 3.81; N 




M.p. 280–282 °C. Yield 92 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 8.96 (br s, 1H), 8.04 (d, J = 2.1 Hz, 
1H), 7.63 (d, J = 8.6 Hz, 1H), 7.45 – 7.36 (m, 3H), 6.95 – 6.88 (m, 2H), 3.73 (s, 3H). 13C NMR (75 MHz, 
DMSO-d6): δ (ppm) 160.31, 155.33, 151.83, 147.59, 133.08, 131.18, 126.83, 126.16, 121.19, 120.83, 
114.11, 55.21. ESI-MS: m/z 334 [M+H+] (calc. for C15H12ClN3O2S: 333.03). EA: calc. C 53.97; H 3.62; N 






M.p. 280–282 °C. Yield 84 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 8.97 (br s, 1H), 7.82 (dd, J = 8.7, 
2.7 Hz, 1H), 7.73 – 7.59 (m, 1H), 7.28 – 7.17 (m, 2H), 6.97 (dd, J = 8.6, 2.3 Hz, 1H), 6.91 (d, J = 8.7 Hz, 
1H), 3.76 (s, 3H), 3.73 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 159.47, 158.29 (d, J = 239.0 Hz), 
148.81, 144.91, 132.53, 131.72, 120.54, 113.79 (d, J = 24.3 Hz), 112.28, 111.11, 108.07 (d, J = 26.9 
Hz), 104.46, 55.78, 55.47. ESI-MS: m/z 348 [M+H+] (calc. for C16H14FN3O3S: 347.07). EA: calc. C 55.32; 




M.p. 280–282 °C. Yield 87 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.98 (br s, 1H), 8.03 (d, J = 2.1 Hz, 
1H), 7.64 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 2.2 Hz, 1H), 7.20 (d, J = 2.1 Hz, 1H), 6.97 (dd, J = 8.6, 2.3 
Hz, 1H), 6.91 (d, J = 8.7 Hz, 1H), 3.76 (s, 3H), 3.73 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 
160.27, 151.78, 148.80, 147.81, 144.94, 133.06, 131.66, 126.85, 126.18, 121.19, 120.76, 112.28, 
111.12, 104.47, 55.78, 55.47. ESI-MS: m/z 364 [M+H+] (calc. for C16H14ClN3O3S: 363.04). EA: calc. C 




M.p. 278–279 °C. Yield 47 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.13 (br s, 1H), 7.85 – 7.80 (m, 
2H), 7.68 – 7.62 (m, 1H), 7.60 (dd, J = 8.9, 2.8 Hz, 1H), 7.23 (td, J = 9.1, 2.7 Hz, 1H), 7.11 (d, J = 9.0 Hz, 
1H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.97, 159.56, 158.30 (d, J = 239.0 Hz), 
154.11, 152.22, 144.87, 132.44 (d, J = 12.1 Hz), 130.95, 124.02, 121.71, 121.27, 120.41, 113.80 (d, J = 
24.3 Hz), 113.17, 108.10 (d, J = 26.9 Hz), 56.05. ESI-MS: m/z 362 [M+H+] (calc. for C16H12FN3O4S: 




M.p. 268.5–270.5 °C. Yield 56 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.12 (br s, 1H), 8.05 (d, J = 1.9 
Hz, 1H), 7.82 (d, J = 2.7 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.60 (dd, J = 9.0, 2.7 Hz, 1H), 7.40 (dd, J = 8.6, 
2.1 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.95, 
160.44, 154.13, 152.22, 132.92, 130.89, 126.89, 126.20, 124.04, 121.74, 121.26, 121.23, 120.49, 
85 
 
113.16, 56.05. ESI-MS: m/z 378 [M+H+] (calc. for C16H12ClN3O4S: 377.02). EA: calc. C 50.87; H 3.20; N 




M.p. 305–307 °C. Yield 83 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.15 (br s, 1H), 7.82 (dd, J = 8.6, 
2.2 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.37 (t, J = 7.8 Hz, 2H), 7.23 (td, J = 9.1, 2.5 
Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H). 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 158.29 (d, J = 238.4 Hz), 151.74, 134.16, 132.54, 129.96, 122.99, 120.79, 120.67, 
119.67, 117.87, 113.80 (d, J = 24.3 Hz), 108.09 (d, J = 27.1 Hz). ESI-MS: m/z 380 [M+H+] (calc. for 





M.p. 295–297 °C. Yield 88 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.15 (br s, 1H), 8.05 (d, J = 2.0 Hz, 
1H), 7.64 (d, J = 8.9 Hz, 1H), 7.53 (d, J = 9.2 Hz, 2H), 7.41 (dd, J = 8.6, 2.2 Hz, 1H), 7.40 – 7.35 (m, 2H), 
7.11 (t, J = 7.4 Hz, 1H), 7.03 (d, J = 8.9 Hz, 2H), 6.98 (d, J = 7.7 Hz, 2H). 13C NMR (126 MHz, DMSO-d6): 
δ (ppm) 160.31, 157.66, 157.33, 151.78, 150.59, 135.75, 134.12, 133.01, 129.97, 126.90, 126.21, 
123.01, 122.73, 121.24, 120.81, 119.92, 119.79, 119.66, 117.89, 117.57. ESI-MS: m/z 396 [M+H+] 
(calc. for C20H14ClN3O2S: 395.05). EA: calc. C 60.68; H 3.56; N 10.61; S 8.10. Found: C 60.33; H 3.94; N 




M.p. 300 °C decomp. Yield 67 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.38 (br s, 1H), 7.91 (d, J = 
8.7 Hz, 2H), 7.84 (dd, J = 8.7, 2.6 Hz, 1H), 7.69 – 7.65 (m, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.24 (td, J = 9.1, 
2.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.92, 162.31, 159.07, 158.36 (d, J = 239.1 Hz), 
152.10, 144.90, 142.80, 132.50 (d, J = 11.0 Hz), 130.63, 120.57 (d, J = 9.0 Hz), 117.68, 113.89 (d, J = 
24.2 Hz), 108.12 (d, J = 27.0 Hz). ESI-MS: m/z 332 [M+H+] (calc. for C15H10FN3O3S: 331.04). EA: calc. C 






M.p. 300 °C decomp. Yield 35 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.76 (br s, 1H), 8.06 (d, J = 2.0 
Hz, 1H), 7.92 (d, J = 8.6 Hz, 2H), 7.70 – 7.59 (m, 3H), 7.41 (dd, J = 8.6, 2.1 Hz, 1H). 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 166.90, 160.24, 152.21, 142.67, 132.81, 130.59, 127.04, 126.30, 124.82, 121.31, 
120.48, 117.90. ESI-MS: m/z 348 [M+H+] (calc. for C15H10ClN3O3S: 347.01). EA: calc. C 51.80; H 2.90; N 




M.p. 333–335 °C. Yield 32 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.53 (br s, 1H), 7.99 – 7.79 (m, 
3H), 7.72 – 7.56 (m, 3H), 7.29 – 7.20 (m, 1H), 4.33 – 4.25 (m, 2H), 1.31 (t, J = 6.5 Hz, 3H). 13C NMR 
(126 MHz, DMSO-d6): δ (ppm) 165.30, 158.36 (d, J = 237.5 Hz), 142.93, 130.39, 123.85, 118.02, 
117.49, 113.94 (d, J = 23.6 Hz), 108.21 (d, J = 26.9 Hz), 60.44, 14.24. ESI-MS: m/z 360 [M+H+] (calc. for 





M.p. 326–328 °C. Yield 45 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.19 (br s, 1H), 8.08 (s, 1H), 7.97 – 
7.86 (m, 2H), 7.72 – 7.55 (m, 3H), 7.48 – 7.39 (m, 1H), 4.34 – 4.25 (m, 2H), 1.32 (t, J = 6.9 Hz, 3H). 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 165.27, 160.41, 151.78, 142.91, 132.73, 130.37, 127.04, 126.31, 
123.86, 121.33, 118.03, 117.45, 60.45, 14.24.ESI-MS: m/z 376 [M+H+] (calc. for C17H14ClN3O3S: 




M.p. 308–310 °C. Yield 48 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.53 (br s, 1H), 8.00 – 7.80 (m, 
3H), 7.71 – 7.55 (m, 3H), 7.25 (t, J = 7.8 Hz, 1H), 2.53 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 
196.41, 158.37 (d, J = 235.7 Hz), 151.85, 143.91, 143.02, 132.24, 131.36, 129.67, 120.45, 117.89, 
117.38, 113.96 (d, J = 23.8 Hz), 108.26 (d, J = 27.9 Hz), 26.45. ESI-MS: m/z 330 [M+H+] (calc. for 







M.p. 288–290 °C. Yield 38 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.62 (br s, 1H), 8.20 – 7.80 (m, 
3H), 7.66 (d, J = 13.9 Hz, 3H), 7.42 (d, J = 13.3 Hz, 1H), 2.53 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ 
(ppm) 196.40, 160.77, 152.56, 143.05, 132.72, 131.37, 129.63, 126.99, 126.29, 121.32, 120.32, 
117.93, 117.38, 26.43. ESI-MS: m/z 346 [M+H+] (calc. for C16H12ClN3O2S: 345.03). EA: calc. C 55.57; H 




M.p. 335–337 °C. Yield 85 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.88 (br s, 1H), 9.03 (br s, 1H), 
7.82 (dd, J = 8.6, 2.5 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.54 (d, J = 8.9 Hz, 2H), 7.42 (d, J = 8.9 Hz, 2H), 7.23 
(td, J = 9.1, 2.7 Hz, 1H), 2.03 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 167.94, 158.27 (d, J = 
239.0 Hz), 151.64, 145.50, 134.84, 133.37, 132.52, 120.66, 119.60, 119.41, 118.52, 113.76 (d, J = 24.2 
Hz), 108.05 (d, J = 26.8 Hz), 23.88. ESI-MS: m/z 345 [M+H+] (calc. for C16H13FN4O2S: 344.07). EA: calc. C 




M.p. 335–337 °C. Yield 89 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.89 (br s, 1H), 9.06 (br s, 1H), 
8.04 (d, J = 1.9 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.54 (d, J = 9.2 Hz, 2H), 7.45 – 7.36 (m, 3H), 2.03 (s, 
3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 167.98, 160.25, 151.69, 134.89, 133.34, 126.87, 126.19, 
121.21, 120.80, 119.60, 119.46, 23.90. ESI-MS: m/z 361 [M+H+] (calc. for C16H13ClN4O2S: 360.04). EA: 




M.p. 351–353 °C. Yield 83 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.07 (br s, 1H), 9.36 (br s, 1H), 
8.04 (s, 1H), 7.73 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.47 – 7.27 (m, 3H), 7.10 (d, J = 7.3 Hz, 1H). 13C NMR 
(126 MHz, DMSO-d6): δ (ppm) 160.42, 152.17, 146.76, 139.99, 133.28, 132.77, 130.54, 127.04, 
126.30, 122.69, 121.32, 120.54, 118.29, 117.40. ESI-MS: m/z 338 [M+H+] (calc. for C14H9Cl2N3OS: 




M.p. 335–337 °C. Yield 86 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.98 (br s, 1H), 9.29 (br s, 1H), 
8.04 (s, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 8.6 Hz, 2H), 7.47 – 7.27 (m, 3H). 13C NMR (126 MHz, 
88 
 
DMSO-d6): δ (ppm) 160.24, 152.01, 147.33, 137.40, 132.83, 128.79, 126.99, 126.68, 126.26, 121.28, 
120.48. ESI-MS: m/z 338 [M+H+] (calc. for C14H9Cl2N3OS: 336.98). EA: calc. C 49.72; H 2.68; N 12.42; S 




M.p. 334–336 °C. Yield 85 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.25 (br s, 1H), 9.47 (br s, 1H), 
8.03 (s, 1H), 7.90 (s, 1H), 7.77 – 7.19 (m, 4H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.70, 152.89, 
145.92, 138.79, 132.47, 131.13, 130.66, 127.05, 126.31, 124.36, 121.35, 120.01, 119.01. ESI-MS: m/z 
372 [M+H+] (calc. for C14H8Cl3N3OS: 370.95). EA: calc. C 45.12; H 2.16; N 11.28; S 8.60. Found: C 44.91; 




M.p. 283–285 °C. Yield 71 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.29 (br s, 1H), 9.77 (br s, 1H), 
8.74 (br s, 1H), 8.05 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 8.9 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 
2.4 Hz, 1H), 6.90 (d, J = 2.6 Hz, 1H), 6.77 (dd, J = 8.9, 2.5 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ 
(ppm) 160.16, 154.72, 151.80, 147.81, 133.14, 126.94, 126.19, 125.94, 125.42, 125.04, 121.19, 
121.00, 115.61, 114.65. ESI-MS: m/z 354 [M+H+] (calc. for C14H9Cl2N3O2S: 352.98). EA: calc. C 47.47; H 




M.p. 307–309 °C. Yield 93 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.00 (br s, 1H), 9.12 (br s, 1H), 
8.03 (d, J = 2.2 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.39 (dd, J = 8.6, 2.2 Hz, 1H), 
7.36 (dd, J = 8.9, 2.3 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 3.83 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ 
(ppm) 160.39, 152.14, 150.50, 147.12, 132.84, 131.96, 126.90, 126.20, 121.23, 120.86, 120.82, 
119.16, 113.04, 56.20. ESI-MS: m/z 368 [M+H+] (calc. for C15H11Cl2N3O2S: 366.99). EA: calc. C 48.93; H 




M.p. 324–326 °C. Yield 83 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.27 (br s, 1H), 9.69 (br s, 1H), 
8.05 (d, J = 1.9 Hz, 1H), 7.92 – 7.77 (m, 2H), 7.62 (d, J = 8.6 Hz, 1H), 7.50 (dd, J = 8.6, 1.6 Hz, 1H), 7.41 
(dd, J = 8.6, 2.0 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 166.00, 160.99, 152.98, 145.64, 
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142.54, 133.30, 132.53, 132.40, 127.13, 126.40, 124.12, 121.43, 119.90, 119.74, 116.74. ESI-MS: m/z 
382 [M+H+] (calc. for C15H9Cl2N3O3S: 380.97). EA: calc. C 47.14; H 2.37; N 10.99; S 8.39. Found: C 




M.p. 300 °C decomp. Yield 69 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.61 (br s, 1H), 9.19 (br s, 
1H), 8.03 (d, J = 2.1 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.55 (s, 2H), 7.39 (dd, J = 8.6, 2.2 Hz, 1H). 13C NMR 
(75 MHz, DMSO-d6): δ (ppm) 160.83, 152.82, 146.07, 144.82, 132.58, 131.55, 126.97, 126.28, 122.42, 
121.33, 120.06, 119.41. ESI-MS: m/z 388 [M+H+] (calc. for C14H8Cl3N3O2S: 386.94). EA: calc. C 43.27; H 




M.p. 290 °C decomp. Yield 90 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.26 (br s, 1H), 9.39 (br s, 
1H), 8.02 (d, J = 2.0 Hz, 1H), 7.65 (s, 2H), 7.60 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.7, 2.0 Hz, 1H), 3.79 (s, 
3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 146.74, 135.97, 132.25, 128.14, 127.03, 126.31, 121.36, 
119.07, 60.64. ESI-MS: m/z 402 [M+H+] (calc. for C15H10Cl3N3O2S: 400.96). EA: calc. C 44.74; H 2.50; N 




M.p. 268–270 °C. Yield 68 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.34 (br s, 1H), 9.23 (br s, 1H), 
8.03 (d, J = 2.1 Hz, 1H), 7.93 (d, J = 2.6 Hz, 1H), 7.87 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.39 
(dd, J = 8.6, 2.2 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 171.37, 160.76, 152.64, 146.45, 
132.67, 130.24, 126.97, 126.73, 126.28, 121.30, 120.47, 119.53, 114.20. ESI-MS: m/z 398 [M+H+] 
(calc. for C15H9Cl2N3O4S: 396.97). EA: calc. C 45.24; H 2.28; N 10.55; S 8.05. Found: C 44.83; H 2.69; N 




M.p. 263.6–265 °C. Yield 60 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.10 (br s, 1H), 9.41 (br s, 1H), 
8.04 (d, J = 2.1 Hz, 1H), 7.89 (d, J = 2.7 Hz, 1H), 7.79 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.40 
(dd, J = 8.6, 2.2 Hz, 1H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.11, 160.84, 152.95, 
149.82, 145.83, 135.06, 132.50, 128.18, 128.02, 127.04, 126.31, 123.23, 121.34, 119.79, 61.67. ESI-
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MS: m/z 412 [M+H+] (calc. for C16H11Cl2N3O4S: 410.98). EA: calc. C 46.62; H 2.69; N 10.19; S 7.78. 




M.p. 241–243 °C. Yield 81 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.60 (br s, 1H), 8.03 (d, J = 2.1 Hz, 
1H), 7.72 – 7.53 (m, 2H), 7.38 (dd, J = 8.6, 2.1 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 6.21 (dd, J = 8.7, 2.5 Hz, 
1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.33, 153.99, 151.53, 148.23, 147.76, 133.19, 126.78, 
126.16, 121.37, 121.15, 120.81, 117.75, 105.63, 102.57. ESI-MS: m/z 336 [M+H+] (calc. for 





M.p. 360–362 °C. Yield 71 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.87 (br s, 1H), 9.14 (br s, 1H), 
8.05 (d, J = 1.9 Hz, 1H), 7.64 (d, J = 10.0 Hz, 1H), 7.51 (d, J = 9.9 Hz, 2H), 7.40 (dd, J = 10.0, 2.0 Hz, 1H), 
7.34 (m, 2H), 7.06 (t, J = 7.1 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.13, 151.70, 147.51, 
138.27, 133.02, 128.95, 126.91, 126.20, 123.09, 121.22, 120.83, 118.89; ESI-MS: m/z 304 [M+H+] 
(calc. for C14H10ClN3OS: 303.02). EA: calc. C 55.36; H 3.32; N 13.83; S 10.55. Found: C 54.91; H 3.56; N 




M.p. 257–259 °C. Yield 27%. 1H NMR (500 MHz DMSO-d6): δ (ppm) 9.18 (s, 1H), 8.03 (d, J = 2.2 Hz, 
1H), 7.63 (d, J = 8.6 Hz, 1H), 7.38 (ddd, J = 8.6, 2.2, 0.5 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 6.73 – 6.64 (m, 
2H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.17, 151.60, 147.56, 145.29, 141.39, 133.14, 130.10, 
126.75, 126.13, 121.13, 120.70, 115.58, 110.12, 107.69. ESI-HRMS: m/z 336.02020 [M+H]+ (calc. for 




M.p. 257–259 °C. Yield 90%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.42 (s, 1H), 8.03 (d, J = 2.2 Hz, 
1H), 7.63 (d, J = 8.6 Hz, 1H), 7.39 (dd, J = 8.6, 2.2 Hz, 1H), 7.17 (d, J = 2.4 Hz, 1H), 6.82 (dd, J = 8.5, 2.4 
Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 3.77 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.19, 151.85, 
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147.51, 147.47, 142.61, 133.11, 130.21, 126.78, 126.16, 121.15, 120.68, 115.45, 111.74, 104.76, 




M.p. 281–283 °C. Yield 75%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.77 (s, 1H), 9.12 (s, 1H), 8.88 (s, 
1H), 8.04 (d, J = 2.1 Hz, 1H), 7.63 (d, J = 8.7 Hz, 1H), 7.39 (dd, J = 8.7, 2.2 Hz, 1H), 7.07 (d, J = 2.4 Hz, 
1H), 6.86 (d, J = 8.8 Hz, 1H), 6.82 (dd, J = 8.7, 2.4 Hz, 1H), 3.73 (s, 3H). 13C NMR (126 MHz, DMSO-d6): 
δ (ppm) 160.23, 151.67, 147.38, 146.73, 143.85, 133.06, 131.68, 126.81, 126.15, 121.16, 120.65, 





M.p. 290–292 °C. Yield 31%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.68 (s, 1H), 9.43 (s, 1H), 9.09 (s, 
1H), 7.69 (d, J = 2.6 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.35 (dd, J = 8.9, 2.5 Hz, 1H), 7.22 (d, J = 2.4 Hz, 
1H), 7.11 (d, J = 9.0 Hz, 1H), 6.84 (dd, J = 8.6, 2.4 Hz, 1H), 3.83 (s, 3H). 13C NMR (126 MHz, DMSO-d6): 
δ (ppm) 157.00, 153.67, 152.21, 150.31, 141.07, 132.26, 120.82, 120.67, 119.86, 118.95, 114.74, 




M.p. 198–200 °C. Yield 88 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.51 (br s, 1H), 10.80 (br s, 1H), 
7.70 (d, J = 7.9 Hz, 2H), 7.49 (m, 2H), 7.35 (t, J = 7.4 Hz, 2H), 7.14 (s, 1H), 7.02 (dd, J = 8.8, 2.3 Hz, 1H), 
3.79 (s, 3H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 181.42, 156.09, 139.38, 128.44, 124.17, 122.87, 
114.74, 105.93, 55.68; ESI-MS: m/z 316 [M+H]+ (calc. for C15H13N3OS2: 315.05); EA: calc. C, 57.12; H, 
4.15; N, 13.32; S, 20.33. Found: C, 57.28; H, 4.17; N, 13.61; S, 20.73. 
 
Compound 50 
The crude product was recrystallized from petroleum ether. 
1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylguanidine 
M.p. 129.5–131 °C. Yield 79 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.04 (br s, 1H), 7.96 (br s, 2H), 
7.48 (dd, J = 8.5, 0.9 Hz, 2H), 7.46 (d, J = 8.8 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.08 
– 7.01 (m, 1H), 6.90 (dd, J = 8.8, 2.7 Hz, 1H), 3.77 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 
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171.47, 155.27, 153.69, 145.64, 138.93, 131.80, 128.82, 122.83, 120.68, 119.53, 113.54, 104.94, 




M.p. 362.5–364.4 °C. Yield 76 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.77 (br s, 1H), 9.06 (br s, 
1H), 7.79 (dd, J = 8.7, 2.6 Hz, 1H), 7.71 – 7.61 (m, 1H), 7.51 (d, J = 7.8 Hz, 2H), 7.34 (t, J = 7.9 Hz, 2H), 
7.21 (td, J = 9.2, 2.7 Hz, 1H), 7.07 (t, J = 7.4 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.20, 
158.14 (d, J = 239.3 Hz), 151.64, 144.93, 138.10, 132.39, 128.63 (d, J = 15.5 Hz), 122.84 (d, J = 8.3 Hz), 
120.28, 118.79 (d, J = 16.6 Hz), 113.48 (dd, J = 24.3, 14.2 Hz), 107.70 (dd, J = 26.9, 13.5 Hz). ESI-MS: 
m/z 288 [M+H]+ (calc. for C14H10FN3OS: 287.05). EA: calc. C, 58.53; H, 3.51; N, 14.63; S, 11.16. Found: 




M.p. 302 °C decomp. Yield 84 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.52 (br s, 1H), 10.81 (br s, 
1H), 7.81 (dd, J = 9.0, 2.1 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.55 (s, 1H), 7.36 (t, J = 7.9 Hz, 2H), 7.27 (td, 
J = 9.2, 2.5 Hz, 1H), 7.21 – 7.06 (m, 1H); 13C NMR (75 MHz, DMSO-d6): δ (ppm) 180.89, 158.50 (d, J = 
239.2 Hz), 157.48, 139.25, 128.48, 124.52, 123.21, 114.37 (d, J = 24.6 Hz), 108.97 (d, J = 27.2 Hz); ESI-
MS: m/z 304 [M+H]+ (calc. for C14H10FN3S2: 303.03); EA: calc. C, 55.43; H, 3.32; N, 13.85; S, 21.14. 
Found: C, 55.13; H, 3.14; N, 14.10; S, 20.80. 
 
Compound 53 
The crude product was recrystallized from petroleum ether/heptan. 
1-(6-fluorobenzo[d]thiazol-2-yl)-3-phenylguanidine 
M.p. 166–168 °C. Yield 32 %. 1H NMR (500 MHz, CD3OD): δ (ppm) 7.51 (dd, J = 8.8, 4.8 Hz, 1H), 7.44 – 
7.33 (m, 5H), 7.15 (tt, J = 7.4, 1.3 Hz, 1H), 7.03 (td, J = 9.1, 2.7 Hz, 1H). 13C NMR (126 MHz, CD3OD): δ 
(ppm) 174.60, 160.27 (d, J = 239.6 Hz), 156.54, 149.69, 139.25, 133.70 (d, J = 10.7 Hz), 130.28, 
125.78, 123.96, 121.04 (d, J = 8.9 Hz), 114.00 (d, J = 24.3 Hz), 108.14 (d, J = 27.0 Hz). ESI-HRMS: m/z 




M.p. 314–316 °C. Yield 59 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.12 (br s, 1H), 9.23 (br s, 1H), 
8.56 (d, J = 0.8 Hz, 1H), 7.97 (dd, J = 8.5, 1.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 7.7 Hz, 2H), 
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7.34 (t, J = 7.9 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR 
(126 MHz, DMSO-d6): δ (ppm) 165.49, 162.76, 151.89, 138.25, 131.45, 128.93, 127.06, 124.17, 
123.41, 123.13, 119.08, 118.88, 60.64, 14.23. ESI-HRMS: m/z 342.09009 [M+H]+ (calc. for 




M.p. 207.5–208.8 °C. Yield 88 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.61 (s, 1H), 8.48 (s, 1H), 
7.99 (dd, J = 8.4, 1.6 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.60 (s, 1H), 7.37 (t, J = 6.9 Hz, 2H), 7.16 (s, 1H), 
4.33 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 181.89, 165.35, 
156.99, 139.18, 128.55, 128.48, 127.74, 124.73, 124.01, 123.41, 112.48, 60.79, 14.27. ESI-MS: m/z 
358 [M+H]+ (calc. for C17H15N3O2S2: 357.06). EA: calc. C, 57.12; H, 4.23; N, 11.76; S, 17.94. Found: C, 
56.85; H, 3.92; N, 11.60; 17.52. 
 
Compound 56 
The crude product was recrystallized from petroleum ether/heptan. 
ethyl 2-(3-phenylguanidino)benzo[d]thiazole-6-carboxylate 
M.p. 134–136 °C. Yield 28 % 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.31 (br s, 1H), 8.36 (s, 1H), 8.14 
(br s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 7.1 Hz, 2H), 7.36 (t, J = 7.7 Hz, 
2H), 7.10 (t, J = 7.1 Hz, 1H), 4.31 (dd, J = 14.0, 6.9 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 176.24, 165.56, 155.35, 154.57, 138.31, 130.74, 128.93, 126.78, 123.54, 122.58, 





M.p. 316–318 °C. Yield 87 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.59 (br s, 1H), 8.94 (br s, 1H), 
7.55 (d, J = 8.7 Hz, 1H), 7.50 (d, J = 2.3 Hz, 1H), 7.41 (d, J = 8.7 Hz, 2H), 6.98 (dd, J = 8.7, 2.2 Hz, 1H), 
6.91 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.73 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 157.57, 
155.64, 155.20, 151.87, 142.77, 132.48, 131.38, 120.70, 120.16, 114.30, 114.09, 104.92, 55.59, 55.20. 
ESI-MS: m/z 330 [M+H]+ (calc. for C16H15N3O3S: 329.08); EA: calc. C, 58.35; H, 4.59; N, 12.76; S, 9.73. 






M.p. 202.2–202.7 °C. Yield 90 %. 1H NMR (500 MHz, DMSO-d6): δ 12.33 (br s, 1H), 11.04 (br s, 1H), 
7.60 – 7.40 (m, 4H), 7.01 (dd, J = 8.8, 2.6 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.76 (s, 3H). 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 179.76, 160.68, 156.49, 156.06, 138.31, 132.03, 129.52, 125.22, 
118.05, 114.61, 113.63, 105.76, 55.66, 55.24. ESI-MS: m/z 346 [M+H]+ (calc. for C16H15N3O2S2: 




M.p. 160.5–161.7 °C. Yield 72 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.96 (br s, 1H), 7.82 (s, 1H), 
7.43 (d, J = 8.8 Hz, 1H), 7.37 – 7.29 (m, 3H), 6.96 – 6.91 (m, 2H), 6.89 (dd, J = 8.8, 2.6 Hz, 1H), 3.76 (s, 
3H), 3.74 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 171.74, 155.71, 155.14, 154.33, 145.77, 
131.66, 131.35, 123.57, 119.28, 114.15, 113.37, 104.97, 55.51, 55.22. ESI-MS: m/z 329 [M+H]+ (calc. 
for C16H16N4O2S: 328.10).; EA: calc. C, 58.52; H, 4.91; N, 17.06; S, 9.76. Found: C, 58.15; H, 4.60; N, 




M.p. 295 °C decomp. Yield 96 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.52 (br s, 1H), 8.75 (br s, 
1H), 7.94 – 7.89 (m, 2H), 7.67 – 7.61 (m, 2H), 7.57 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 2.6 Hz, 1H), 7.00 (dd, 
J = 8.8, 2.6 Hz, 1H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.96, 157.31, 155.83, 
152.10, 142.98, 141.94, 132.38, 130.65, 124.57, 120.06, 117.58, 114.56, 104.99, 55.67. ESI-MS: m/z 
344 [M+H]+ (calc. for C16H13N3O4S: 343.06). EA: calc. C, 55.97; H, 3.82; N, 12.24; S, 9.34. Found: C, 




M.p. 278 °C decomp. Yield 95 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.67 (br s, 1H), 10.70 (br s, 
1H), 7.91 (m, 4H), 7.49 (d, J = 2.4 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.04 (dd, J = 8.8, 2.5 Hz, 1H), 3.80 (s, 
3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 182.47, 167.17, 156.08, 143.81, 132.24, 129.89, 128.53, 
125.15, 120.84, 115.32, 114.89, 106.10, 55.70. ESI-MS: m/z 360 [M+H]+ (calc. for C16H13N3O3S2: 
359.04). EA: calc. C, 53.47; H, 3.65; N, 11.69; S, 17.84. Found: C, 53.10; H, 3.73; N, 11.94; S, 17.98. 
 
Compound 62 




M.p. 275–277 °C. Yield 17 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.61 (br s, 1H), 9.38 (br s, 1H), 
8.12 (br s, 2H), 7.91 – 7.87 (m, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 2.6 Hz, 
1H), 6.93 (dd, J = 8.8, 2.6 Hz, 1H), 3.78 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 171.03, 167.10, 
155.47, 153.07, 145.49, 143.47, 132.04, 130.34, 124.30, 119.86, 118.95, 113.76, 104.94, 55.55. ESI-




M.p. 317.5–319 °C. Yield 40 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.97 (s, 1H), 9.98 (s, 1H), 9.01 
(s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.70 (s, 1H), 7.59 (d, J = 2.5 Hz, 1H), 7.27 (dd, J = 8.4, 2.0 Hz, 1H), 7.18 
(dd, J = 8.7, 2.4 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 161.45, 
151.87, 149.93, 149.15, 130.68, 130.53, 130.17, 123.03, 122.84, 121.03, 119.70, 119.40, 119.09, 




M.p. 272–274 °C. Yield 52 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.54 (s, 1H), 7.69 – 7.53 (m, 2H), 
7.41 (t, J = 7.9 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.19 (dd, J = 8.7, 2.2 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H). 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 159.38, 152.20, 149.29, 149.05, 130.63, 130.58, 127.39, 125.23, 
122.50, 120.65, 119.38, 119.30, 118.20, 116.72. ESI-HRMS: m/z 353.98566 [M+H]+ (calc. for 




M.p. 37–39 °C. Yield 82%. 1H NMR (300 MHz, CDCl3): δ (ppm) 8.97 (s, 1H), 8.04 (d, J = 8.7 Hz, 1H), 
7.93 (d, J = 2.1 Hz, 1H), 7.48 (dd, J = 8.7, 2.1 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ (ppm) 154.43, 





M.p. 223–224 °C. Yield 77 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.48 (s, 1H), 9.88 (s, 1H), 8.98 
(s, 1H), 7.60 (d, J = 2.6 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 7.16 (dd, J = 8.7, 2.6 Hz, 1H), 6.97 (d, J = 2.2 Hz, 
1H), 6.92 (d, J = 8.7 Hz, 1H), 6.66 (dd, J = 8.5, 2.2 Hz, 1H), 5.07 (br s, 2H). 13C NMR (126 MHz, DMSO-
d6): δ (ppm) 155.24, 152.15, 148.75, 145.19, 139.03, 132.30, 130.98, 120.62, 119.61, 119.33, 119.28, 
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M.p. 249–250 °C. Yield 85%. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.57 (s, 1H), 9.91 (s, 1H), 9.44 (s, 
1H), 8.98 (s, 1H), 7.59 (d, J = 2.5 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.22 (d, J = 2.3 Hz, 1H), 7.17 (dd, J = 
8.8, 2.5 Hz, 1H), 6.92 (d, J = 8.7 Hz, 1H), 6.83 (dd, J = 8.7, 2.5 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ 
(ppm) 156.96, 153.68, 152.29, 148.86, 141.49, 132.31, 130.88, 120.71, 120.02, 119.38, 119.33, 





M.p. 238–240 °C. Yield 66 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.75 (s, 1H), 7.90 (d, J = 1.9 Hz, 
1H), 7.60 (d, J = 2.6 Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.43 (dd, J = 8.5, 2.0 Hz, 1H), 7.18 (dd, J = 8.8, 2.6 
Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 1.32 (s, 9H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.43, 152.17, 
148.89, 145.88, 145.02, 130.87, 130.77, 123.74, 120.40, 119.36, 119.08, 118.41, 117.78, 116.74, 




M.p. 271–273 °C. Yield 58 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.86 (br s, 1H), 9.94 (s, 1H), 9.01 
(s, 1H), 8.30 (s, 1H), 7.66 (dd, J = 8.4, 1.6 Hz, 1H), 7.59 (d, J = 2.2 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 7.18 
(dd, J = 8.6, 1.8 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.16, 
151.89, 149.04, 134.50, 133.90, 130.59, 129.67, 120.90, 119.56, 119.33, 116.65, 86.22. ESI-HRMS: 




M.p. 256–258 °C. Yield 28 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.98 (s, 1H), 9.94 (s, 1H), 9.34 
(s, 1H), 7.69 (d, J = 2.5 Hz, 1H), 7.40 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.18 (dd, J = 8.8, 2.5 Hz, 
1H), 7.07 (dd, J = 8.4, 2.0 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 
152.91, 149.27, 148.69, 136.85, 134.35, 131.21, 125.03, 120.78, 120.64, 119.32, 119.19, 116.66, 






M.p. 190.5–191.5 °C. Yield 59 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.33 (s, 1H), 10.22 (s, 1H), 
9.94 (s, 1H), 7.70 (d, J = 1.5 Hz, 1H), 7.60 – 7.47 (m, 2H), 7.33 – 7.18 (m, 3H), 6.95 (d, J = 8.7 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6): δ (ppm) 156.78, 149.75, 149.39, 147.01, 140.03, 130.11, 124.62, 
123.09, 121.47, 120.07, 119.34, 117.45, 116.63, 109.90. ESI-HRMS: m/z 304.04807 [M+H]+ (calc. for 
C14H10ClN3O3: 304.04835 [M+H]+). 
 
Compound 90 
The crude product was purified using column chromatography. 
1-(3-chloro-4-hydroxyphenyl)-3-(6-chlorobenzo[d]oxazol-2-yl)urea 
M.p. 188.5–190.5 °C. Yield 35 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.46 (s, 1H), 10.21 (s, 1H), 
10.00 (s, 1H), 7.77 (d, J = 1.7 Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.34 (dd, J = 8.4, 
2.0 Hz, 1H), 7.26 (dd, J = 8.8, 2.6 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ 
(ppm) 157.70, 152.28, 149.23, 146.84, 138.05, 130.53, 126.96, 124.83, 121.26, 119.88, 119.34, 




M.p. 224–226 °C. Yield 24 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.77 (s, 1H), 9.20 (s, 1H), 8.89 (s, 
1H), 8.60 (s, 1H), 8.35 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 2.6 Hz, 1H), 7.47 (dd, J = 
8.8, 2.2 Hz, 1H), 7.11 (dd, J = 8.7, 2.6 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ 
(ppm) 153.69, 152.69, 148.26, 148.17, 137.64, 134.46, 131.92, 122.92, 120.22, 119.26, 118.82, 




M.p. 220–222 °C. Yield 74 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.83 (s, 1H), 9.81 (s, 1H), 7.56 (d, 
J = 2.6 Hz, 1H), 7.47 (dd, J = 3.9, 1.6 Hz, 1H), 7.20 (dd, J = 3.8, 1.5 Hz, 1H), 7.15 (dd, J = 8.8, 2.6 Hz, 1H), 
6.95 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.49, 151.25, 149.00, 133.59, 
130.64, 120.41, 119.39, 119.08, 116.78, 113.06. ESI-HRMS: m/z 270.0099 [M+H]+ (calc. for 





The crude product was recrystallized from Et2O. 
1-(3-chloro-4-hydroxyphenyl)-3-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)urea 
M.p. 258–260 °C. Yield 58 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.91 (br s, 1H), 7.55 (d, J = 2.4 Hz, 
1H), 7.14 (dd, J = 8.7, 2.4 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 2.59 (s, 2H), 2.54 (s, 2H), 1.75 (s, 4H). 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 158.38, 151.01, 149.02, 138.46, 130.54, 120.47, 120.31, 119.38, 




The crude product was recrystallized from Et2O. 
1-(3-Chloro-4-hydroxyphenyl)-3-(4-(4-chlorophenyl)thiazol-2-yl)urea 
M.p. 206–208 °C. Yield 71 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.69 (s, 1H), 9.91 (s, 1H), 8.76 
(s, 1H), 7.92 – 7.87 (m, 2H), 7.60 – 7.57 (m, 2H), 7.50 – 7.45 (m, 2H), 7.14 (dd, J = 8.7, 2.6 Hz, 1H), 6.93 
(d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.31, 151.59, 148.87, 147.41, 133.16, 
132.07, 130.69, 128.67, 127.26, 120.67, 119.34, 116.66, 107.89. ESI-HRMS: m/z 380.00168 [M+H]+ 




M.p. 203–205 °C. Yield 21%. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.59 (br s, 1H), 8.14 (br s, 1H), 
7.52 (d, J = 2.6 Hz, 1H), 7.29 – 7.19 (m, 2H), 7.19 – 7.10 (m, 2H), 6.97 (dd, J = 8.7, 2.6 Hz, 1H), 6.83 (d, 
J = 8.7 Hz, 1H), 6.36 (d, J = 7.3 Hz, 1H), 4.48 – 4.31 (m, 1H), 3.25 – 3.09 (m, 2H), 2.84 – 2.67 (m, 2H). 
13C NMR (126 MHz, DMSO-d6): δ (ppm) 155.00, 147.38, 141.23, 132.93, 126.40, 124.56, 119.34, 





M.p. 161.5–163.5 °C. Yield 21 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.58 (br s, 1H), 8.29 (br s, 
1H), 7.52 (d, J = 2.5 Hz, 1H), 7.14 (d, J = 8.5 Hz, 2H), 6.97 (dd, J = 8.7, 2.5 Hz, 1H), 6.89 – 6.84 (m, 2H), 
6.82 (d, J = 8.7 Hz, 1H), 5.98 (t, J = 5.5 Hz, 1H), 3.72 (s, 3H), 3.33 – 3.19 (m, 2H), 2.66 (t, J = 7.2 Hz, 2H). 
13C NMR (126 MHz, DMSO-d6): δ (ppm) 157.65, 155.20, 147.32, 133.06, 131.35, 129.58, 119.37, 
119.14, 117.90, 116.54, 113.78, 54.97, 40.87, 34.96. ESI-HRMS: m/z 321.09967 [M+H]+ (calc. for 






M.p. 254.5–256.5 °C. Yield 94 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.71 (br s, 2H), 8.43 (br s, 
2H), 7.54 (d, J = 2.6 Hz, 2H), 7.06 (dd, J = 8.8, 2.6 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H). 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 152.77, 147.99, 132.14, 120.11, 119.22, 118.71, 116.59. ESI-HRMS: m/z 




M.p. 232.5–234 °C. Yield 80 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.60 (s, 1H), 10.67 (s, 1H), 
10.15 (s, 1H), 8.00 (s, 1H), 7.75 – 7.27 (m, 4H), 6.95 (d, J = 8.7 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ 
(ppm) 150.68, 131.10, 127.32, 126.75, 125.22, 124.04, 121.93, 118.86, 116.10, 114.96. ESI-HRMS: 
m/z 369.96365 [M+H]+ (calc. for C14H9Cl2N3OS2: 369.96368 [M+H]+). 
 
Compound 100 
The crude product was recrystallized from water. 
1-(3-chloro-4-hydroxyphenyl)-3-(6-chlorobenzo[d]thiazol-2-yl)guanidine 
M.p. 274–275 °C. Yield 38 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.58 (s, 1H), 8.68 (s, 1H), 8.09 
(d, J = 2.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.52 – 7.40 (m, 2H), 7.18 (dd, J = 8.7, 2.5 Hz, 1H), 7.11 (d, J = 
8.7 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 164.14, 155.06, 152.54, 130.55, 128.14, 127.02, 





M.p. 213–214.5 °C. Yield 30 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.49 (br s, 1H), 9.92 (br s, 1H), 
7.94 – 7.85 (m, 2H), 7.54 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.8, 2.6 Hz, 1H), 7.31 (dd, J = 8.6, 2.2 Hz, 1H), 
6.98 (d, J = 8.8 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 162.53, 150.83, 148.56, 132.94, 
131.53, 126.01, 125.88, 120.74, 119.86, 119.74, 119.43, 118.46, 116.87. ESI-HRMS: m/z 310.98016 






M.p. 301.5–302.5 °C. Yield 69 %. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.51 (br s, 1H), 11.25 (br s, 
1H), 8.21 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.66 (d, J = 8.9 Hz, 1H), 7.59 (s, 1H), 7.17 – 6.96 (m, 2H), 3.82 
(s, 3H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 164.08, 157.27, 156.85, 156.21, 142.57, 132.85, 130.34, 
128.93, 123.50, 120.96, 119.89, 116.34, 115.00, 104.66, 55.64. ESI-HRMS: m/z 335.02466 [M+H]+ 




M.p. 260–261.5 °C. Yield 58 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.94 (br s, 1H), 10.09 (br s, 
1H), 8.06 (d, J = 8.4 Hz, 1H), 7.94 (s, 1H), 7.80 (s, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.23 (d, J = 8.1 Hz, 1H), 
6.97 (d, J = 8.2 Hz, 1H), 3.88 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 161.76, 158.62, 157.88, 
149.87, 147.05, 138.22, 130.34, 124.71, 122.22, 120.81, 119.09, 117.30, 116.36, 104.79, 55.84. ESI-
HRMS: m/z 335.02466 [M+H]+ (calc. for C15H11ClN2O3S: 335.02517 [M+H]+). 
 
Compound 104 
The crude product was purified using column chromatography. 
1-(3-chloro-4-hydroxybenzyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea 
M.p. 249–251 °C. Yield 20 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.60 (br s, 1H), 10.08 (br s, 1H), 
7.51 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H), 7.29 (d, J = 2.1 Hz, 1H), 7.13 (t, J = 5.3 Hz, 1H), 7.10 
(dd, J = 8.3, 2.1 Hz, 1H), 6.98 – 6.90 (m, 2H), 4.25 (d, J = 5.9 Hz, 2H), 3.78 (s, 3H). 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 157.80, 155.52, 153.84, 152.01, 143.16, 132.59, 131.25, 128.80, 127.18, 120.19, 
119.37, 116.54, 114.15, 104.81, 55.57, 42.01. ESI-HRMS: m/z 364.05115 [M+H]+ (calc. for 
C16H14ClN3O3S: 364.05172 [M+H]+). 
 
Compound 105 
After the reaction was completed (monitored by TLC), 1M aq. HCl was poured to the reaction 
mixture and the product was extracted to DCM. The organic layer was concentrated and the crude 
product was recrystallized from MeCN. 
1-(3,4-dihydroxybenzyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea 
M.p. 141.5–142 °C. Yield 50 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.51 (d, J = 8.8 Hz, 1H), 7.48 (d, 
J = 2.6 Hz, 1H), 7.15 (br s, 1H), 6.95 (dd, J = 8.8, 2.6 Hz, 1H), 6.71 (d, J = 2.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 
1H), 6.56 (dd, J = 8.0, 2.0 Hz, 1H), 4.18 (d, J = 5.5 Hz, 2H), 3.78 (s, 3H). 13C NMR (126 MHz, DMSO-d6): 
δ (ppm) 158.51, 155.74, 153.64, 145.23, 144.41, 141.36, 131.95, 129.93, 119.61, 118.26, 115.49, 







M.p. 171–172 °C. Yield 83 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.02 (s, 1H), 9.47 (s, 1H), 7.94 – 
7.84 (m, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 2.6 Hz, 1H), 7.45 – 7.35 (m, 1H), 7.31 (dd, J = 8.8, 2.6 
Hz, 1H), 7.28 – 7.19 (m, 1H), 6.96 (d, J = 8.7 Hz, 1H), 3.75 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ 
(ppm) 161.45, 153.45, 149.66, 148.45, 132.76, 130.50, 125.80, 123.42, 123.09, 121.95, 121.12, 
120.29, 119.01, 116.29, 34.55 (d, J = 3.0 Hz). ESI-HRMS: m/z 334.04080 [M+H]+ (calc. for 
C15H12ClN3O2S: 334.04115 [M+H]+). 
 
Compound 107 
The crude product was dissolved in Et2O and filtered. To the filtrate was added PE and the solution 
was left to crystallize in freezer. Filtration gave the desired pure product. 
3-(benzo[d]thiazol-2-yl)-1-(3-chloro-4-hydroxyphenyl)-1-methylurea 
M.p. 139–141 °C. Yield 53 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.28 (br s, 1H), 7.81 (d, J = 7.5 
Hz, 1H), 7.45 (br s, 1H), 7.38 – 7.30 (m, 2H), 7.19 (t, J = 7.9 Hz, 1H), 7.11 (dd, J = 8.6, 2.5 Hz, 1H), 6.99 
(d, J = 8.6 Hz, 1H), 3.26 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 151.90, 135.11, 128.70, 
126.89, 125.94, 122.65, 121.62, 119.46, 116.66, 37.93. ESI-HRMS: m/z 334.0414 [M+H]+ (calc. for 
C15H12ClN3O2S: 334.0412 [M+H]+). 
 
Compound 108 
The crude product was purified using column chromatography. 
1-(3-chloro-4-hydroxyphenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)-1-methylurea 
M.p. 220 °C decomp. Yield 50 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.28 (br s, 1H), 7.45 (d, J = 
2.2 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 2.5 Hz, 1H), 7.11 (dd, J = 8.6, 2.5 Hz, 1H), 6.98 (d, J = 
8.6 Hz, 1H), 6.94 (dd, J = 8.8, 2.6 Hz, 1H), 3.77 (s, 3H), 3.25 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ 
(ppm) 155.57, 151.97, 134.94, 131.53, 128.78, 126.95, 119.52, 118.40, 116.70, 114.18, 105.12, 55.60, 




M.p. 227–228.5 °C. Yield 43 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.09 (s, 1H), 7.74 (d, J = 7.7 
Hz, 1H), 7.47 – 7.37 (m, 2H), 7.36 (d, J = 2.4 Hz, 1H), 7.23 (t, J = 7.9 Hz, 1H), 7.13 (dd, J = 8.6, 2.2 Hz, 
1H), 6.95 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 165.20, 160.92, 150.53, 137.50, 
102 
 
136.58, 127.60, 126.56, 125.93, 125.38, 123.01, 122.40, 118.67, 115.86, 111.35, 37.16, 31.51. ESI-





M.p. 165–167 °C. Yield 22 %. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 10.60 (br s, 1H, NH indole), 8.76 
(s, 1H, OH), 7.25 (t, J = 6.3 Hz, 1H, NH-allyl), 6.91 (d, J = 8.4 Hz, 1H, H-7), 6.51 (d, J = 2.3 Hz, 1H, H-4), 
6.36 (dd, J = 8.4, 2.3 Hz, 1H, H-6), 6.00 – 5.81 (m, 1H, H-10), 5.26 – 5.19 (m, 1H, trans-H-11), 5.15 – 
5.10 (m, 1H, cis-H-11), 3.93 – 3.87 (m, 2H, H-9). 13C NMR (101 MHz, DMSO-d6): δ (ppm) 153.27 (C-2), 
152.23 (C-5), 135.28 (C-10), 129.53 (C-3a), 125.68 (C-7a), 118.27 (C-8), 115.50 (C-11), 110.57 (C-7), 
107.92 (C-6), 101.05 (C-4), 61.04 (C-3), 44.89 (C-9). IR (KBr) ν 3400, 3270, 2190, 1600, 1477, 1328, 






M.p. 198–199 °C. Yield 10 %. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 10.88 (br s, 1H, NH indole), 8.82 
(s, 1H, OH), 7.43 (t, J = 6.5 Hz, 1H, NH-propargyl), 6.97 (d, J = 8.4 Hz, 1H, H-7), 6.55 (d, J = 2.3 Hz, 1H, 
H-4), 6.40 (dd, J = 8.4, 2.3 Hz, 1H, H-6), 4.06 (dd, J = 6.5, 2.3 Hz, 3H, H-9), 3.22 (t, J = 2.3 Hz, 1H, H-11). 
13C NMR (101 MHz, DMSO-d6): δ (ppm) 152.55 (C-2), 152.36 (C-5), 129.25 (C-3a), 125.74 (C-7a), 
117.83 (C-8), 110.90 (C-7), 108.41 (C-6), 101.17 (C-4), 81.29 (C-10), 73.98 (C-11), 62.29 (C-3), 32.40 
(C-9). IR (KBr) ν 3376, 3294, 2196, 1586, 1476, 1352, 1205, 1097, 793, 685 cm-1. ESI-HRMS: m/z 







M.p. 155–170 °C. Yield 14 %. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 9.01 (s, 1H, OH), 6.95 (d, J = 8.2 
Hz, 1H, H-7), 6.85 (br s, 2H, NH2), 6.69 (d, J = 2.1 Hz, 1H, H-4), 6.55 (dd, J = 8.2, 2.1 Hz, 1H, H-6), 4.85 
(d, J = 2.5 Hz, 2H, H-9), 3.31 (t, J = 2.4 Hz, 1H, H-11). 13C NMR (101 MHz, DMSO-d6): δ (ppm) 152.44 
(C-2), 152.22 (C-5), 133.22 (C-3a), 119.33 (C-7a), 117.84 (C-8), 115.84 (C-7), 109.93 (C-6), 96.79 (C-4), 
78.29 (C-10), 74.99 (C-11), 45.57 (C-3), 31.09 (C-9). IR (KBr) ν 3435, 3361, 3278, 2200, 1650, 1490, 





M.p. 252–254°C. Yield 48 %. 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.84 (br s, 1H, NH indole), 7.11 
(d, J = 8.3 Hz, 1H, H-7), 7.08 (d, J = 1.7 Hz, 1H, H-4), 6.93 (br s, 2H, NH2), 6.89 (dd, J = 8.3, 1.9 Hz, 1H, 
H-6). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 154.63 (C-2), 130.82 (C-7a), 129.90 (C-3a), 125.06 (C-5), 
119.19 (C-6), 117.06 (C-8), 114.21 (C-4), 111.42 (C-7), 61.67 (C-3). ESI-HRMS: m/z 192.03227 [M+H]+ 
(calc. for C9H6ClN3: 192.03230 [M+H]+). Anal. calc. for C9H6ClN3: C 56.41, H 3.16, N 21.93, found: C 







M.p. 335 °C decomp. . Yield 25 %. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 11.04 (s, 1H, NH), 8.23 (d, J 
= 7.8 Hz, 1H, H-10), 7.31 (d, J = 8.0 Hz, 1H, H-7), 7.24 (t, J = 7.6 Hz, 1H, H-8), 7.08 (t, J = 7.5 Hz, 1H, H-
9), 5.96 (br s, 2H, NH2), 2.78 (t, J = 5.9 Hz, 2H, H-4), 2.55 (t, J = 5.9 Hz, 2H, H-1), 1.70 – 1.90 (m, 4H, H-
2,3). 13C NMR (101 MHz, DMSO-d6): δ (ppm) 153.18 (C-4a), 151.45 (C-5a), 147.39 (C-11), 137.24 (C-
6a), 123.33 (C-8), 121.06 (C-10a), 120.91 (C-10), 118.30 (C-9), 109.87 (C-7), 106.69 (C-11a), 98.50 (C-
10b), 33.20 (C-4), 22.97 (C-1), 22.87 (2C, C-2,3). IR (KBr) ν 3454, 3363, 3053, 2939, 2849, 1627, 1457, 





M.p. 305–307 °C. Yield 16 %. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 10.80 (s, 1H, NH), 7.80 (d, J = 2.4 
Hz, 1H, H-10), 7.20 (d, J = 8.6 Hz, 1H, H-7), 6.87 (dd, J = 8.7, 2.4 Hz, 1H, H-8), 5.98 (br s, 2H, NH2), 2.76 
(t, J = 6.0 Hz, 2H, H-4), 2.54 (t, J = 6.0 Hz, 2H, H-1), 1.90 – 1.70 (m, 4H, H-2,3). 13C NMR (101 MHz, 
DMSO-d6): δ (ppm) 153.17 (C-4a), 153.01 (C-9), 152.03 (C-5a), 147.42 (C-11), 131.94 (C-6a), 121.47 
(C-10a), 111.60 (C-8), 110.22 (C-7), 106.16 (C-11a), 105.37 (C-10), 98.79 (C-10b), 55.96 (OCH3), 33.21 
(C-4), 23.02 (C-1), 22.88 (2C, C-2,3). IR (KBr) ν 3343, 3133, 3044, 2936, 1620, 1471, 1215, 1036, 793, 





M.p. 199–200 °C. Yield 54 %. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.83 (d, J = 7.6 Hz, 1H, H-10), 7.40 – 
7.10 (m, 8H, ArH), 5.65 (s, 2H, N-CH2-Ph), 4.72 (br s, 2H, NH2), 3.00 (t, J = 6.0 Hz, 2H, H-4), 2.63 (t, J = 
6.1 Hz, 2H, H-1), 2.03 – 1.84 (m, 4H, H-2,3). 13C NMR (101 MHz, CDCl3): δ (ppm) 154.65 (C-4a), 151.20 
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(C-5a), 147.02 (C-11), 138.48 (C-6a), 137.98 (C-1‘), 128.60 (2C, C-3‘,5‘), 127.16 (2C, C-2‘,6‘), 124.26 (C-
8), 120.95 (C-10a), 120.22 (C-10), 119.56 (C-4‘), 109.71 (C-7), 108.31 (C-11a), 99.63 (C-10b), 44.84 (N-
CH2-Ph), 33.83 (C-4), 23.26, 23.18, 23.09. IR (KBr) ν 3436, 3550, 3031, 2929, 1622, 1461, 1343, 1177, 




4.3 Biological evaluation 
4.3.1 ABAD enzymatic activity assay 
(performed at University of St Andrews, prof. Frank Gunn-Moore group) 
4.3.1.1 Enzyme kinetics 
Purification of ABAD was performed according the described conditions [118]. The kinetic 
parameters of the ABAD mediated reduction of acetoacetyl-CoA were measured using recombinant 
ABAD enzyme (0.02 μg/mL, 740 pM), NADH (250 μM) and a range of acetoacetyl-CoA concentrations 
(0 – 140 μM). Solutions were prepared in assay buffer (10 mM HEPES buffer, ± 0.5 % (w/v) gelatin 
(porcine skin), pH 7.4 at 37 °C). Reaction progression was measured via a decrease in NADH 
absorbance at 340 nm using a SpectraMAX 250 spectrophotometer. A reaction time of 800 s was 
employed yielding steady state conditions (R2 > 0.9). Non-linear regression analysis was performed 
using GraphPad Prism, utilising the Michaelis-Menten equation. 
The kinetic parameters of the ABAD mediated reduction of acetoacetyl-CoA were assessed 
with respect to the co-factor, NADH, using recombinant ABAD enzyme (0.02 μg/mL, 740 pM), 120 
μM acetoacetyl-CoA and a range of NADH concentrations (0 – 600 μM). Experiments were performed 
as described for acetoacetyl-CoA above.  
A Vmax value of 10.64 ± 0.42 μmol min-1 mg-1 and a Km value of 11.79 ± 1.86 μM were 
calculated with respect to acetoacetyl-CoA (Fig. 25). A concentration of 120 μM acetoacetyl-CoA was 
selected for subsequent experiments. 
 
 
Figure 25. ABAD enzyme activity in the presence of the indicated concentrations of acetoacetyl-CoA. 
A Vmax value of 10.64 ± 0.42 μM min-1 mg-1 and a Km value of 11.79 ± 1.86 μM were calculated with 
respect to acetoacetyl-CoA. Values shown are an average of two independent experiments each with 
two technical repeats ± SEM. 
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A Vmax value of 15.54 ± 0.95 μmol min-1 mg-1 and a Km value of 99.84 ± 21.34 μM were 




Figure 26. ABAD enzyme activity in the presence of the indicated concentrations of NADH. A Vmax 
value of 15.54 ± 0.95 μmol min-1 mg-1 and a Km value of 99.84 ± 21.34 μM were calculated with 
respect to NADH. Values shown are an average of two independent experiments each with two 
technical repeats ± SEM. 
 
4.3.1.2 Compound screening 
Activity assay conditions consisted of ABAD enzyme (0.5 μg/mL), NADH (250 μM), 
acetoacetyl-CoA (120 μM) and a single compound of interest (25 μM, 1% DMSO (v/v)). Solutions 
were prepared in assay buffer (10 mM HEPES buffer, 0.5% (w/v)), pH 7.4 at 37°C). Each compound 
was weighted in milligrams with maximal 0.1 mg deviation to prepare a 10 mM stock solution in 
DMSO. The DMSO stock solution was further diluted by 10 mM HEPES buffer solution to give a final 
assay concentration 25 μM 1% DMSO (v/v). Control solutions containing an equivalent concentration 
of DMSO (1% (v/v)) were also prepared and run concurrently. Reaction progression was measured 
via a decrease in NADH absorbance at 340 nm using a SpectraMAX M2e spectrophotometer. The 
reaction period was gated to yield steady state conditions (R2 > 0.9). Calculated IC50 values are an 




4.3.2 ElogP and ElogD experimental determination 
(performed at University of Hradec Kralove, assoc. prof. Kamil Musílek group) 
The method of measurement and calculation of ElogP was adapted from Technical guide 
OECD No. 117 [119]. Based on this method, the ElogD was determined accordingly. All chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Seven standard stock solutions were 
prepared by dissolving nitrobenzene (ReagentPlus, 99%), chlorobenzene (puriss. p.a., ACS reagent, 
≥99.5%), thymol (≥99.0%), biphenyl (ReagentPlus, 99.5%), butylbenzene (≥99%), fluoranthene (98%) 
and 4,4′-DDT (98%) in HPLC grade methanol and stored in the refrigerator at temperature of 4 °C. 
Mixed standard solution was prepared prior analysis by adding each of the stock standard solutions 
(100 µL) to 1.5 ml glass vial and addition of HPLC grade methanol (300 µL). Standard solution for 
dead time measurement was prepared by dissolving of citric acid (1 mg) in 70% solution of HPLC 
grade methanol and 30% distilled water (1 mL). The TRIS-HCl buffer for mobile phase was prepared 
from 0.05 M tris(hydroxymethyl)aminomethane solution by adjusting with 1 M HCl to pH 7.4. The pH 
measurement was carried out by a multimeter inoLab Multi 9430 IDS (WTW, Weilheim, DEU) with an 
attached electrode SenTix Mic (WTW, Weilheim, DEU), DuraCal pH buffers (Hamilton, Bonduz, CHE) 
were used for calibration of pH electrode. All used water was prepared by an Ultrapore Simplicity 
Water Purification System type 1 (Merck Millipore, Billerica, MA, USA). 
The synthesized sample (1 mg) was dissolved in solution of 70% HPLC grade methanol and 
30% distilled water (1 mL). Sample solutions were centrifuged by Eppendorf Centrifuge 5418 
(Eppendorf, Hamburg, Germany) for 10 minutes at 14000 revolutions per minute and 0.9 mL of 
centrifuged supernatants was transferred to 1.5 mL glass vials. The analysis was performed by HPLC 
system Infinity 1260 (Agilent Technologies, Santa Clara, CA, USA) with Infinity 1290 auto sampler 
(G4226A), Infinity 1260 Quaternary LC pump (G1311B), Infinity 1260 Thermostatted Column 
Compartment (G1316A), and Infinity 1260 Diode-Array Detector (G4212B). Used LC column was 
Kinetex® 5 µm C18 100 Å, 100 x 4.6 mm (Phenomenex, Torrance, CA, USA) with an attached 
SecurityGuard™ system for C18 HPLC column (Phenomenex, Torrance, CA, USA). Duration of the 
analysis was set to 60 min in a flow rate of mobile phases 1 mL/min and at a temperature of 20°C 
within the column. Dosage of sample and standard solution from autosampler was set to 10 μL. 
There was isocratic flow of mobile phases with 70% HPLC grade methanol and 30% distilled water for 
ElogP measurement and 70% HPLC grade methanol and 30% 0.05 M TRIS-HCl buffer with pH 7.4 for 
ElogD measurement respectively. Both, analyses of standard solution and sample solutions were 
performed in triplicate. 
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   (Eq. 2) 
k = capacity factor; t0 = dead time (retention time of citric acid); tr = retention time of sample 
 
The ElogP values were calculated (Eq. 3). Linear regression coefficients were obtained from 
linear regression of ElogP of standard solutions against the log of their capacity factors. The ElogD 
values were calculated from measurement with 0.05 M Tris-HCl buffer (pH 7.4) as mobile phase B, 
using the same standard solutions and equations. 
Elog𝑃 = 𝑎 + 𝑏 × log 𝑘  (Eq. 3) 
P = octanol/water partition coefficient; a, b = linear regression coefficients; k = capacity factor 
 
4.3.3 Inhibition of monoamine oxidase 
(performed at University of St Andrews, prof. Rona R. Ramsay group) 
The activity for membrane-bound MAO (Sigma-Aldrich, UK) was determined from the 
production of hydrogen peroxide, coupled to a dye [Ampliflu Red (Sigma-Aldrich, UK) at a final 
concentration of 50 µM] via horseradish peroxidase (2.5 U/mL) producing the fluorescent resorufin 
that was measured in a fluorescence plate-reader (Molecular Devices FilterMax F5) at 30°C [120–
122]. Under the conditions used, the Km for tyramine with MAO A was 0.4 mM and for MAO B was 
0.16 mM. 
The compounds were screened for quenching of the fluorescence of the product, resorufin, 
by addition of 50 µM compound to 1 and 10 µM resorufin; no quenching was observed. The 
compounds were also examined for inhibition of HRP used in the assay. Inhibition of horseradish 
peroxidase (0.025 U/mL) by 50 µM compound was measured in triplicate using H2O2 at a 
concentration of 2×Km (4 µM since Km=2.0 ± 0.5 µM) and Ampliflu Red at 200 µM. Inhibition was 
significant especially for 4b (Table 18), so the concentration of HRP in the MAO assay was increased 




Table 18. Inhibition of horseradish peroxidase (0.025 U/mL) by 50 µM compound (displayed as % 
inhibition). 








Having adjusted the conditions to minimize artefacts, the IC50 values for membrane-bound 
MAO A and B were determined without and with pre-incubation with the compound (>10 
concentrations in duplicate) for 30 min. IC50 values were determined from the rates with varied 
inhibitor concentrations in the presence of 2×Km substrate concentration with the enzyme added last 
for time 0, or with the substrate and dye mix added last after pre-incubation of enzyme and inhibitor 
for 30 min. IC50 values after 30 min pre-incubation lower than without pre-incubation would indicate 
slow binding or inactivation. Data are expressed as a value ± standard deviation, obtained by fitting 
the data (usually for 10 concentrations in triplicate) to the appropriate three-parameter equation 
using GraphPad PRISM 4. At least two separate determinations were made for each value reported. 
Apparent Ki values were derived from a Dixon plot when the enzyme is not pre-incubated with the 
inhibitor. 
 
4.3.4 Inhibition of cholinesterases 
(performed at University of Defence, assoc. prof. Daniel Jun group) 
The acetylcholinesterase (AChE; EC 3.1.1.7) and butyrylcholinesterase (BChE; EC 3.1.1.8) 
inhibitory activity of the tested drugs was determined using modified Ellman´s method [123] and is 
expressed as IC50, i.e. concentration that reduces the cholinesterase activity by 50%. Human 
recombinant AChE, human plasma BChE, 5,5´-dithiobis(2-nitrobenzoic acid) (Ellman´s reagent, 
DTNB), phosphate buffer (PB), acetylthiocholine iodide (ATCI), and butyrylthiocholine iodide (BTCI), 
were purchased from Sigma-Aldrich. Cholinestrase activity was measured in polystyrene Nunc 
96-well microplates with flat bottom shape (ThermoFisher Scientific, USA). All the assays were 
carried out in PB (0.1 M KH2PO4/K2HPO4, pH 7.4). Enzyme solutions were prepared in 2 mL aliquots 
with activity 2.0 U/mL. The assay medium (100 µL) consisted of 40 µL of 0.1 M PB, 20 µL of 0.01 M 
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DTNB, 10 µL of enzyme, and 20 µL of 0.01 M substrate (ATCI for AChE, BTCI for BChE). Assay solutions 
with inhibitor (concentration range 10-3 – 10-9 M) were preincubated for 5 min. The reaction was 
started by immediate addition of 20 µL of substrate. The activity was determined by measuring the 
increase in absorbance at 412 nm at 37°C at 2 min intervals using a Multi-mode microplate reader 
Synergy 2 (Vermont, USA). Each concentration was assayed in triplicate. Software GraphPad Prism 5 
(San Diego, USA) was used for the statistical data evaluation. 
 
4.3.5 Antioxidant activity 
(performed at University of Defence, assoc. prof. Daniel Jun group) 
The DPPH (diphenyl-1-picrylhydrazyl stabile free radical) test is a simple method to 
determine the antioxidant activity, which is expressed as EC50, i.e. concentration of the substrate 
causing 50% loss of the DPPH activity. DPPH, methanol, N-acetylcystein and trolox (last two as the 
refence standards), were purchased from Sigma-Aldrich. For measuring purposes – polystyrene Nunc 
96-well microplates with flat bottom shape (ThermoFisher Scientific, USA) were utilized. All the 
assays were carried out in methanol. DPPH solution was prepared at 0.2 mM concentration. The 
assay medium (200 µL) consisted of 100 µL DPPH solution, 100 µL of assay solutions with inhibitor 
(10-3 – 10-6 M). The reaction time was 30 min. The activity was determined by measuring the increase 
in absorbance at 517 nm at laboratory temperature using a Multi-mode microplate reader Synergy 2 
(Vermont, USA). Each concentration was assayed in triplicate. Software GraphPad Prism 5 (San 
Diego, USA) was used for the statistical data evaluation [124, 125]. 
 
4.3.6 Cell viability 
4.3.6.1 Combined MTT and LDH assay 
(performed at University Hospital Hradec Králové, dr. Ondřej Soukup group) 
The effect of compounds on the cell viability was examined using methodology combining 
LDH and MTT assay into one experimental setup. Such an assay has been chosen due to the fact, that 
widely used MTT test is partially dependent on the mitochondrial oxidoreductases [126], whose 
activity might be influenced by the tested compounds targeted to mitochondria. The protocol for this 
assay has been described previously [127]. Briefly CHO cell line (Chinese hamster ovary, CHO-K1WT2, 
CRL-1984 ECACC, Salisbury, UK) were cultured according to ECACC recommended conditions and 
seeded in a density of 8 000 cells per well as was described earlier [128]. Tested compounds were 
dissolved in DMSO and subsequently in the growth medium (F-12) supplemented with 1% 
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PEN/STREP without FBS so that the final concentration of DMSO did not exceed 0.5% (v/v). Cells 
were exposed to a tested compound in the medium (100 µL) for 24 hours. Then 10 μL of MTT (2.5 
mg/mL) was added and 50 μL of the culture supernatant was transferred to a new plate yet 
containing 50 μL of LDH substrate mixture consisting of lactate (2.5 mg/mL), NAD (2.5 mg/mL), 
phenazine methansulphate (100 µM) and Triton X-100 (0.1%) in Tris–HCl buffer (pH 8.2). LDH 
reaction mixture was incubated at 37 °C for 15-30 min until the difference between negative (no 
treatment) and positive control (0.1% Triton X-100) was obvious. Cellular fraction containing MTT 
was allowed to produce formazan for another approximately 3 h at 37 °C. Thereafter, medium with 
MTT was removed and crystals of formazan were dissolved in DMSO (100 µL). Absorbance was 
measured at 570 nm with 650 nm reference wavelength on Synergy HT reader (BioTek, USA) for both 
LDH and MTT fraction. IC50 was then calculated from the control - subtracted triplicates using non-
linear regression (four parameters) of GraphPad Prism 5 software. Final IC50 and SEM value was 
obtained as a mean of at least 3 independent measurements. 
4.3.6.2 LDH assay 
(performed at University of St Andrews, prof. Frank Gunn-Moore group) 
HEK293 and SHSY5Y cells were seeded into clear 96 well plates at a density of 10 000 cells 
per well and incubated for 24h at 37 °C and 5% CO2. Following incubation, culture media was gently 
aspirated and replaced with fresh media containing a titration of selected compounds (10 μM – 100 
μM), an appropriate volume of DMSO was added to additional wells as a vehicle control. The plates 
were incubated for a further 24 h at 37 °C and 5% CO2. Following incubation 0.1% Triton-X 100 was 
added to three additional control wells as a positive control and incubated for 15 minutes. A measure 
of cell death was then made using a Sigma Aldrich lactate dehydrogenase kit (#MAK066) as per 
manufacturer’s instructions. The reported values are an average of three independent experiments 
each with three technical repeats ± SEM (Figure 8). 
 
4.3.7 Hepatotoxicity 
(performed at University of Defence, assoc. prof. Daniel Jun group) 
The hepatotoxicity of tested compounds was evaluated using the cell line HepG2 originally 
from human liver hepatocellular carcinoma (ATCC, Virginia USA). These cells were plated in 96-well 
plate at density 17×103 per well in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, USA) with 
10% FBS (Gibco, USA) and was leaf attached overnight. The incubation was performed under 
condition 37°C, 5% CO2 and 80 – 95% air humidity. Stock solutions of tested compounds were 
prepared in dimethyl sulfoxide (DMSO) (Sigma –Aldrich) and then diluted in DMEM medium. The 
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stock solutions in medium were serially diluted and added to cells in 96-well culture plates. The final 
concentration of DMSO was less than 0.25%. The cell viability was detected using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [114] after 24 h incubation with 
tested compounds. After 24 h was the medium aspirated and 100 µl MTT solution (0.5 mg/mL) in 
serum free DMEM medium was added to cells. The cells were then incubated for 1 h. The medium 
was then aspirated and purple crystals of MTT formazan were dissolved in 100 μL DMSO under 
shaking. The absorbance was measured with a microplate reader (Beckman Coulter, Inc., California 
USA) at a test wavelength of 570 nm. The IC50 value was calculated using four parametric nonlinear 
regression with statistic software GraphPad Prism (version 5.04 Prism 5 for Windows, GraphPad 
Software Inc., USA). The data were obtained from three independent experiments. The IC50 value 
was expressed as mean ± SEM. 
 
4.3.8 PAMPA assay 
(performed at University Hospital Hradec Králové, dr. Ondřej Soukup group) 
Penetration across the BBB is an essential property for compounds targeting the CNS. In 
order to predict passive blood-brain penetration of novel compounds modification of the parallel 
artificial membrane permeation assay (PAMPA) has been used based on reported protocol [116]. The 
filter membrane of the donor plate was coated with PBL (Polar Brain Lipid, Avanti, USA) in dodecane 
(4 µL of 20 mg/mL PBL in dodecane) and the acceptor well was filled with 300 µL of PBS pH 7.4 buffer 
(VD). Tested compound were dissolved first in DMSO and that diluted with PBS pH 7.4 to reach the 
final concentration 100 µM in the donor well. Concentration of DMSO did not exceed 0.5% (V/V) in 
the donor solution. 300 µL of the donor solution was added to the donor wells (VA) and the donor 
filter plate was carefully put on the acceptor plate so that coated membrane was “in touch” with 
both donor solution and acceptor buffer. Test compound diffused from the donor well through the 
lipid membrane (Area = 0.28 cm2) to the acceptor well. The concentration of the drug in both donor 
and the acceptor wells was assessed after 3, 4, 5 and 6 hours of incubation in quadruplicate using the 
UV plate reader Synergy HT (Biotek, USA) at the maximum absorption wavelength of each 
compound. Concentration of the compounds was calculated from the standard curve and expressed 
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6 Summary in English 
 
Alzheimer’s disease (AD) is the most common cause of senile dementia worldwide. Despite 
being subject to intensive research, the pathogenic mechanisms of AD are still not fully understood 
and consequently an effective treatment is yet to be developed. Although the aetiology of AD is still 
unknown, a build-up of amyloid-beta peptide (Aβ) is considered to play an important role in disease 
progression. The original amyloid cascade hypothesis proposed that insoluble extracellular plaques 
were responsible for the majority of Aβ toxicity. This hypothesis has since been refined, as recent 
data indicates that soluble intracellular oligomers are now responsible for the majority of Aβ induced 
toxic effects. The mitochondrial dysfunction also plays an important role in the pathophysiology of 
AD. Aβ was detected inside mitochondria and several mitochondrial proteins were found to interact 
directly with Aβ. Such interactions can affect a protein’s function and cause damage to the 
mitochondria, which finally results in progression of AD. 
The background for the experimental part of this dissertation thesis was literature review 
summarizing current knowledge on mitochondrial proteins directly interacting with Aβ in order to 
identify potential drug targets for AD treatment. A deeper look was taken on mitochondrial enzyme 
Aβ binding alcohol dehydrogenase (ABAD), which appeared to be the most promising drug target. 
The aim of the experimental work was design, synthesis and evaluation of novel compounds 
targeting the mitochondrial enzymes connected to AD pathophysiology (e.g. ABAD or monoamine 
oxidase). For this purpose were employed two different paradigms: the classical ‘‘one-target one-
compound’’ and the innovative ‘‘multitarget-directed ligand’’ (MTDL) strategy. Compounds designed 
according to MTDL approach should be able to intervene simultaneously in the different pathological 
events underlying the aetiology of AD. 
Together, more than one hundred potential ABAD inhibitors and seven MTDLs targeting 
monoamine oxidase and cholinesterases were designed and synthesized. Several of these 
compounds showed promising in vitro activity and as such present structural leads for further anti-




7 Shrnutí v českém jazyce 
 
Alzheimerova nemoc (AD) je celosvětově nejběžnější příčinou stařecké demence. Přes 
intenzivní výzkum se zatím nepodařilo odhalit mechanismus vzniku tohoto onemocnění, a proto pro 
něj neexistuje kauzální léčba. Přestože je etiologie AD neznámá, víme, že peptid beta-amyloid (Aβ) 
hraje důležitou role v jejím rozvoji. Původní teorie amyloidní kaskády předpokládala, že extracelulární 
amyloidní plaky jsou zodpovědné za toxické působní Aβ. Tato teorie byla později upravena na základě 
nových poznatků, která naznačují, že za toxicitu jsou zodpovědné zejména rozpustné oligomerní 
formy Aβ a jejich působení uvnitř buněk. Důležitou roli v patofyziologie AD má také poškození 
mitochondrií. Aβ byl detekován uvnitř mitochondrií, kde přímo interaguje s několika 
mitochondriálními proteiny. Interakce s Aβ ovlivňuje funkci těchto enzymů, což poškozuje 
mitochondrie a v konečném důsledku může vést k rozvoji AD. 
Základem pro experimentální část této práce bylo sepsání literární rešerše, shrnující současné 
poznatky o mitochondriálních enzymech interagujících s Aβ, za účelem nalézt potenciální cíle pro 
terapii AD. Následně byla věnována pozornost zejména mitochondriálnímu enzymu ABAD, který se 
jevil jako velmi vhodný cíl pro farmakoterapii. 
Cílem experimentální práce byl design, syntéza a testování nových sloučenin ovlivňujících 
mitochondriální enzymy, které se účastní rozvoje AD (např. ABAD nebo monoaminooxidasa). Za tímto 
účelem byly využity dva různé přístupy k designu nových sloučenin: klasický ‘‘jedna molekula – jeden 
cíl’’ a novější ‘‘multitarget-directed ligand’’ (MTDL) strategie. Sloučeniny navržené systémem MTDL 
by měly současně ovlivňovat více patologických procesů podílejících se na rozvoji AD. 
Celkem bylo v rámci této práce připraveno více jak sto nových potenciálních inhibitorů ABAD 
a sedm MTDL sloučenin inhibujících současně cholinesterasy a monoaminooxidasu. Několik sloučenin 
vykázalo při in vitro testování slibnou aktivitu a mohou tak posloužit jako strukturní základ pro další 
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